id	sid	tid	token	lemma	pos
bjp-23953	1	1	introduction	introduction	NOUN
bjp-23953	1	2	the	the	DET
bjp-23953	1	3	incidence	incidence	NOUN
bjp-23953	1	4	of	of	ADP
bjp-23953	1	5	small	small	ADJ
bjp-23953	1	6	-	-	PUNCT
bjp-23953	1	7	cell	cell	NOUN
bjp-23953	1	8	lung	lung	NOUN
bjp-23953	1	9	cancer	cancer	NOUN
bjp-23953	1	10	rises	rise	VERB
bjp-23953	1	11	sharply	sharply	ADV
bjp-23953	1	12	in	in	ADP
bjp-23953	1	13	malignant	malignant	ADJ
bjp-23953	1	14	lung	lung	NOUN
bjp-23953	1	15	cancer	cancer	NOUN
bjp-23953	1	16	and	and	CCONJ
bjp-23953	1	17	usually	usually	ADV
bjp-23953	1	18	found	find	VERB
bjp-23953	1	19	at	at	ADP
bjp-23953	1	20	a	a	DET
bjp-23953	1	21	late	late	ADJ
bjp-23953	1	22	stage	stage	NOUN
bjp-23953	1	23	or	or	CCONJ
bjp-23953	1	24	with	with	ADP
bjp-23953	1	25	metastasis	metastasis	NOUN
bjp-23953	1	26	(	(	PUNCT
bjp-23953	1	27	cheng	cheng	PROPN
bjp-23953	1	28	and	and	CCONJ
bjp-23953	1	29	su	su	PROPN
bjp-23953	1	30	,	,	PUNCT
bjp-23953	1	31	2010	2010	NUM
bjp-23953	1	32	)	)	PUNCT
bjp-23953	1	33	.	.	PUNCT
bjp-23953	2	1	amrubicin	amrubicin	PROPN
bjp-23953	2	2	is	be	AUX
bjp-23953	2	3	a	a	DET
bjp-23953	2	4	third	third	ADJ
bjp-23953	2	5	-	-	PUNCT
bjp-23953	2	6	generation	generation	NOUN
bjp-23953	2	7	synthetic	synthetic	ADJ
bjp-23953	2	8	anthracycline	anthracycline	NOUN
bjp-23953	2	9	analogue	analogue	NOUN
bjp-23953	2	10	,	,	PUNCT
bjp-23953	2	11	of	of	ADP
bjp-23953	2	12	which	which	PRON
bjp-23953	2	13	the	the	DET
bjp-23953	2	14	pharmacological	pharmacological	ADJ
bjp-23953	2	15	mechanism	mechanism	NOUN
bjp-23953	2	16	is	be	AUX
bjp-23953	2	17	to	to	PART
bjp-23953	2	18	eventually	eventually	ADV
bjp-23953	2	19	lead	lead	VERB
bjp-23953	2	20	to	to	ADP
bjp-23953	2	21	dna	dna	PROPN
bjp-23953	2	22	breaks	break	NOUN
bjp-23953	2	23	and	and	CCONJ
bjp-23953	2	24	inhibition	inhibition	NOUN
bjp-23953	2	25	of	of	ADP
bjp-23953	2	26	tumor	tumor	NOUN
bjp-23953	2	27	cell	cell	NOUN
bjp-23953	2	28	proliferation	proliferation	NOUN
bjp-23953	2	29	by	by	ADP
bjp-23953	2	30	inhibiting	inhibit	VERB
bjp-23953	2	31	the	the	DET
bjp-23953	2	32	activity	activity	NOUN
bjp-23953	2	33	of	of	ADP
bjp-23953	2	34	topoii	topoii	NOUN
bjp-23953	2	35	,	,	PUNCT
bjp-23953	2	36	which	which	PRON
bjp-23953	2	37	has	have	VERB
bjp-23953	2	38	good	good	ADJ
bjp-23953	2	39	effect	effect	NOUN
bjp-23953	2	40	on	on	ADP
bjp-23953	2	41	the	the	DET
bjp-23953	2	42	treatment	treatment	NOUN
bjp-23953	2	43	of	of	ADP
bjp-23953	2	44	advanced	advanced	ADJ
bjp-23953	2	45	sclc	sclc	PROPN
bjp-23953	2	46	,	,	PUNCT
bjp-23953	2	47	but	but	CCONJ
bjp-23953	2	48	with	with	ADP
bjp-23953	2	49	some	some	DET
bjp-23953	2	50	adverse	adverse	ADJ
bjp-23953	2	51	reactions	reaction	NOUN
bjp-23953	2	52	(	(	PUNCT
bjp-23953	2	53	bosch	bosch	PROPN
bjp-23953	2	54	,	,	PUNCT
bjp-23953	2	55	2007	2007	NUM
bjp-23953	2	56	;	;	PUNCT
bjp-23953	2	57	ding	ding	NOUN
bjp-23953	2	58	and	and	CCONJ
bjp-23953	2	59	zhan	zhan	NOUN
bjp-23953	2	60	,	,	PUNCT
bjp-23953	2	61	2013	2013	NUM
bjp-23953	2	62	;	;	PUNCT
bjp-23953	2	63	sekine	sekine	PROPN
bjp-23953	2	64	et	et	PROPN
bjp-23953	2	65	al	al	PROPN
bjp-23953	2	66	.	.	PROPN
bjp-23953	2	67	,	,	PUNCT
bjp-23953	2	68	2014	2014	NUM
bjp-23953	2	69	)	)	PUNCT
bjp-23953	2	70	.	.	PUNCT
bjp-23953	3	1	as	as	ADP
bjp-23953	3	2	a	a	DET
bjp-23953	3	3	drug	drug	NOUN
bjp-23953	3	4	of	of	ADP
bjp-23953	3	5	anthracycline	anthracycline	NOUN
bjp-23953	3	6	,	,	PUNCT
bjp-23953	3	7	through	through	ADP
bjp-23953	3	8	inhibiting	inhibit	VERB
bjp-23953	3	9	the	the	DET
bjp-23953	3	10	activity	activity	NOUN
bjp-23953	3	11	of	of	ADP
bjp-23953	3	12	topoii	topoii	NOUN
bjp-23953	3	13	,	,	PUNCT
bjp-23953	3	14	dna	dna	PROPN
bjp-23953	3	15	is	be	AUX
bjp-23953	3	16	fractured	fractured	ADJ
bjp-23953	3	17	and	and	CCONJ
bjp-23953	3	18	amrubicin	amrubicin	NOUN
bjp-23953	3	19	blocks	block	VERB
bjp-23953	3	20	tumor	tumor	NOUN
bjp-23953	3	21	cells	cell	NOUN
bjp-23953	3	22	proliferation	proliferation	NOUN
bjp-23953	3	23	(	(	PUNCT
bjp-23953	3	24	wang	wang	PROPN
bjp-23953	3	25	et	et	PROPN
bjp-23953	3	26	al	al	PROPN
bjp-23953	3	27	.	.	PROPN
bjp-23953	3	28	,	,	PUNCT
bjp-23953	3	29	2015	2015	NUM
bjp-23953	3	30	)	)	PUNCT
bjp-23953	3	31	.	.	PUNCT
bjp-23953	4	1	the	the	DET
bjp-23953	4	2	mechanism	mechanism	NOUN
bjp-23953	4	3	of	of	ADP
bjp-23953	4	4	action	action	NOUN
bjp-23953	4	5	for	for	ADP
bjp-23953	4	6	amrubicin	amrubicin	NOUN
bjp-23953	4	7	is	be	AUX
bjp-23953	4	8	distinct	distinct	ADJ
bjp-23953	4	9	with	with	ADP
bjp-23953	4	10	that	that	PRON
bjp-23953	4	11	of	of	ADP
bjp-23953	4	12	adriamycin	adriamycin	NOUN
bjp-23953	4	13	(	(	PUNCT
bjp-23953	4	14	chotenimitkhun	chotenimitkhun	PROPN
bjp-23953	4	15	et	et	PROPN
bjp-23953	4	16	al	al	PROPN
bjp-23953	4	17	.	.	PROPN
bjp-23953	4	18	,	,	PUNCT
bjp-23953	4	19	2015	2015	NUM
bjp-23953	4	20	)	)	PUNCT
bjp-23953	4	21	.	.	PUNCT
bjp-23953	5	1	with	with	ADP
bjp-23953	5	2	favorable	favorable	ADJ
bjp-23953	5	3	cardiac	cardiac	ADJ
bjp-23953	5	4	safety	safety	NOUN
bjp-23953	5	5	and	and	CCONJ
bjp-23953	5	6	great	great	ADJ
bjp-23953	5	7	tolerance	tolerance	NOUN
bjp-23953	5	8	of	of	ADP
bjp-23953	5	9	patients	patient	NOUN
bjp-23953	5	10	,	,	PUNCT
bjp-23953	5	11	amrubicin	amrubicin	PROPN
bjp-23953	5	12	is	be	AUX
bjp-23953	5	13	better	well	ADJ
bjp-23953	5	14	than	than	ADP
bjp-23953	5	15	other	other	ADJ
bjp-23953	5	16	anthracycline	anthracycline	NOUN
bjp-23953	5	17	compounds	compound	NOUN
bjp-23953	5	18	.	.	PUNCT
bjp-23953	6	1	amrubicin	amrubicin	PROPN
bjp-23953	6	2	is	be	AUX
bjp-23953	6	3	considered	consider	VERB
bjp-23953	6	4	as	as	ADP
bjp-23953	6	5	an	an	DET
bjp-23953	6	6	anti	anti	ADJ
bjp-23953	6	7	-	-	ADJ
bjp-23953	6	8	lung	lung	ADJ
bjp-23953	6	9	cancer	cancer	NOUN
bjp-23953	6	10	chemotherapeutic	chemotherapeutic	ADJ
bjp-23953	6	11	drug	drug	NOUN
bjp-23953	6	12	with	with	ADP
bjp-23953	6	13	high	high	ADJ
bjp-23953	6	14	efficiency	efficiency	NOUN
bjp-23953	6	15	and	and	CCONJ
bjp-23953	6	16	huge	huge	ADJ
bjp-23953	6	17	developmental	developmental	ADJ
bjp-23953	6	18	potential	potential	NOUN
bjp-23953	6	19	(	(	PUNCT
bjp-23953	6	20	ikeda	ikeda	PROPN
bjp-23953	6	21	et	et	PROPN
bjp-23953	6	22	al	al	PROPN
bjp-23953	6	23	.	.	PROPN
bjp-23953	6	24	,	,	PUNCT
bjp-23953	6	25	2014	2014	NUM
bjp-23953	6	26	)	)	PUNCT
bjp-23953	6	27	.	.	PUNCT
bjp-23953	7	1	clinical	clinical	ADJ
bjp-23953	7	2	studies	study	NOUN
bjp-23953	7	3	based	base	VERB
bjp-23953	7	4	on	on	ADP
bjp-23953	7	5	the	the	DET
bjp-23953	7	6	combined	combined	ADJ
bjp-23953	7	7	chemotherapy	chemotherapy	NOUN
bjp-23953	7	8	of	of	ADP
bjp-23953	7	9	amrubicin	amrubicin	NOUN
bjp-23953	7	10	are	be	AUX
bjp-23953	7	11	being	be	AUX
bjp-23953	7	12	conducted	conduct	VERB
bjp-23953	7	13	both	both	CCONJ
bjp-23953	7	14	at	at	ADP
bjp-23953	7	15	home	home	NOUN
bjp-23953	7	16	and	and	CCONJ
bjp-23953	7	17	abroad	abroad	ADV
bjp-23953	7	18	.	.	PUNCT
bjp-23953	8	1	in	in	ADP
bjp-23953	8	2	2002	2002	NUM
bjp-23953	8	3	,	,	PUNCT
bjp-23953	8	4	amrubicin	amrubicin	NOUN
bjp-23953	8	5	appeared	appear	VERB
bjp-23953	8	6	on	on	ADP
bjp-23953	8	7	japan	japan	PROPN
bjp-23953	8	8	market	market	NOUN
bjp-23953	8	9	to	to	PART
bjp-23953	8	10	cure	cure	VERB
bjp-23953	8	11	non	non	ADJ
bjp-23953	8	12	-	-	ADJ
bjp-23953	8	13	small	small	ADJ
bjp-23953	8	14	cell	cell	NOUN
bjp-23953	8	15	lung	lung	NOUN
bjp-23953	8	16	cancer	cancer	NOUN
bjp-23953	8	17	and	and	CCONJ
bjp-23953	8	18	small	small	ADJ
bjp-23953	8	19	cell	cell	NOUN
bjp-23953	8	20	lung	lung	NOUN
bjp-23953	8	21	cancer	cancer	NOUN
bjp-23953	8	22	(	(	PUNCT
bjp-23953	8	23	gervais	gervais	PROPN
bjp-23953	8	24	et	et	PROPN
bjp-23953	8	25	al	al	PROPN
bjp-23953	8	26	.	.	PROPN
bjp-23953	8	27	,	,	PUNCT
bjp-23953	8	28	2015	2015	NUM
bjp-23953	8	29	)	)	PUNCT
bjp-23953	8	30	.	.	PUNCT
bjp-23953	9	1	75	75	NUM
bjp-23953	9	2	%	%	NOUN
bjp-23953	9	3	of	of	ADP
bjp-23953	9	4	patients	patient	NOUN
bjp-23953	9	5	with	with	ADP
bjp-23953	9	6	small	small	ADJ
bjp-23953	9	7	cell	cell	NOUN
bjp-23953	9	8	lung	lung	NOUN
bjp-23953	9	9	cancers	cancer	NOUN
bjp-23953	9	10	and	and	CCONJ
bjp-23953	9	11	20	20	NUM
bjp-23953	9	12	%	%	NOUN
bjp-23953	9	13	of	of	ADP
bjp-23953	9	14	patients	patient	NOUN
bjp-23953	9	15	with	with	ADP
bjp-23953	9	16	non	non	ADJ
bjp-23953	9	17	-	-	ADJ
bjp-23953	9	18	small	small	ADJ
bjp-23953	9	19	cell	cell	NOUN
bjp-23953	9	20	lung	lung	NOUN
bjp-23953	9	21	cancer	cancer	NOUN
bjp-23953	9	22	showed	show	VERB
bjp-23953	9	23	good	good	ADJ
bjp-23953	9	24	curative	curative	ADJ
bjp-23953	9	25	effects	effect	NOUN
bjp-23953	9	26	(	(	PUNCT
bjp-23953	9	27	ikeda	ikeda	PROPN
bjp-23953	9	28	et	et	PROPN
bjp-23953	9	29	al	al	PROPN
bjp-23953	9	30	.	.	PROPN
bjp-23953	9	31	,	,	PUNCT
bjp-23953	9	32	2014	2014	NUM
bjp-23953	9	33	)	)	PUNCT
bjp-23953	9	34	.	.	PUNCT
bjp-23953	10	1	compared	compare	VERB
bjp-23953	10	2	with	with	ADP
bjp-23953	10	3	other	other	ADJ
bjp-23953	10	4	anthracycline	anthracycline	NOUN
bjp-23953	10	5	drugs	drug	NOUN
bjp-23953	10	6	,	,	PUNCT
bjp-23953	10	7	it	it	PRON
bjp-23953	10	8	has	have	VERB
bjp-23953	10	9	better	well	ADJ
bjp-23953	10	10	clinical	clinical	ADJ
bjp-23953	10	11	tolerance	tolerance	NOUN
bjp-23953	10	12	.	.	PUNCT
bjp-23953	11	1	amrubicin	amrubicin	PROPN
bjp-23953	11	2	has	have	VERB
bjp-23953	11	3	good	good	ADJ
bjp-23953	11	4	efficacy	efficacy	NOUN
bjp-23953	11	5	in	in	ADP
bjp-23953	11	6	second	second	ADJ
bjp-23953	11	7	-	-	PUNCT
bjp-23953	11	8	line	line	NOUN
bjp-23953	11	9	treatment	treatment	NOUN
bjp-23953	11	10	of	of	ADP
bjp-23953	11	11	small	small	ADJ
bjp-23953	11	12	-	-	PUNCT
bjp-23953	11	13	cell	cell	NOUN
bjp-23953	11	14	lung	lung	NOUN
bjp-23953	11	15	cancer	cancer	NOUN
bjp-23953	11	16	,	,	PUNCT
bjp-23953	11	17	and	and	CCONJ
bjp-23953	11	18	its	its	PRON
bjp-23953	11	19	efficacy	efficacy	NOUN
bjp-23953	11	20	is	be	AUX
bjp-23953	11	21	superior	superior	ADJ
bjp-23953	11	22	to	to	ADP
bjp-23953	11	23	topotecan	topotecan	NOUN
bjp-23953	11	24	(	(	PUNCT
bjp-23953	11	25	yamaoka	yamaoka	PROPN
bjp-23953	11	26	et	et	PROPN
bjp-23953	11	27	al	al	PROPN
bjp-23953	11	28	.	.	PROPN
bjp-23953	11	29	,	,	PUNCT
bjp-23953	11	30	1999	1999	NUM
bjp-23953	11	31	)	)	PUNCT
bjp-23953	11	32	.	.	PUNCT
bjp-23953	12	1	it	it	PRON
bjp-23953	12	2	was	be	AUX
bjp-23953	12	3	effective	effective	ADJ
bjp-23953	12	4	for	for	ADP
bjp-23953	12	5	the	the	DET
bjp-23953	12	6	elderly	elderly	ADJ
bjp-23953	12	7	patients	patient	NOUN
bjp-23953	12	8	with	with	ADP
bjp-23953	12	9	refractory	refractory	NOUN
bjp-23953	12	10	relapsed	relapse	VERB
bjp-23953	12	11	small	small	ADJ
bjp-23953	12	12	cell	cell	NOUN
bjp-23953	12	13	lung	lung	NOUN
bjp-23953	12	14	cancer	cancer	NOUN
bjp-23953	12	15	as	as	ADP
bjp-23953	12	16	third	third	ADJ
bjp-23953	12	17	-	-	PUNCT
bjp-23953	12	18	line	line	NOUN
bjp-23953	12	19	chemotherapy	chemotherapy	NOUN
bjp-23953	12	20	(	(	PUNCT
bjp-23953	12	21	asai	asai	PROPN
bjp-23953	12	22	et	et	PROPN
bjp-23953	12	23	al	al	PROPN
bjp-23953	12	24	.	.	PROPN
bjp-23953	12	25	,	,	PUNCT
bjp-23953	12	26	2012	2012	NUM
bjp-23953	12	27	)	)	PUNCT
bjp-23953	12	28	.	.	PUNCT
bjp-23953	13	1	the	the	DET
bjp-23953	13	2	present	present	ADJ
bjp-23953	13	3	study	study	NOUN
bjp-23953	13	4	investigated	investigate	VERB
bjp-23953	13	5	whether	whether	SCONJ
bjp-23953	13	6	the	the	DET
bjp-23953	13	7	effect	effect	NOUN
bjp-23953	13	8	of	of	ADP
bjp-23953	13	9	amrubicin	amrubicin	NOUN
bjp-23953	13	10	therapy	therapy	NOUN
bjp-23953	13	11	improved	improve	VERB
bjp-23953	13	12	patients	patient	NOUN
bjp-23953	13	13	with	with	ADP
bjp-23953	13	14	refractory	refractory	NOUN
bjp-23953	13	15	small	small	ADJ
bjp-23953	13	16	-	-	PUNCT
bjp-23953	13	17	cell	cell	NOUN
bjp-23953	13	18	lung	lung	NOUN
bjp-23953	13	19	cancer	cancer	NOUN
bjp-23953	13	20	in	in	ADP
bjp-23953	13	21	chinese	chinese	ADJ
bjp-23953	13	22	clinical	clinical	ADJ
bjp-23953	13	23	study	study	NOUN
bjp-23953	13	24	.	.	PUNCT
bjp-23953	14	1	materials	material	NOUN
bjp-23953	14	2	and	and	CCONJ
bjp-23953	14	3	methods	method	NOUN
bjp-23953	14	4	study	study	NOUN
bjp-23953	14	5	design	design	NOUN
bjp-23953	15	1	this	this	DET
bjp-23953	15	2	study	study	NOUN
bjp-23953	15	3	was	be	AUX
bjp-23953	15	4	an	an	DET
bjp-23953	15	5	open	open	ADJ
bjp-23953	15	6	-	-	PUNCT
bjp-23953	15	7	label	label	NOUN
bjp-23953	15	8	,	,	PUNCT
bjp-23953	15	9	multicenter	multicenter	NOUN
bjp-23953	15	10	,	,	PUNCT
bjp-23953	15	11	single	single	ADJ
bjp-23953	15	12	-	-	PUNCT
bjp-23953	15	13	arm	arm	NOUN
bjp-23953	15	14	confirmatory	confirmatory	NOUN
bjp-23953	15	15	research	research	NOUN
bjp-23953	15	16	involving	involve	VERB
bjp-23953	15	17	25	25	NUM
bjp-23953	15	18	institutions	institution	NOUN
bjp-23953	15	19	in	in	ADP
bjp-23953	15	20	a	a	DET
bjp-23953	15	21	journal	journal	NOUN
bjp-23953	15	22	of	of	ADP
bjp-23953	15	23	the	the	DET
bjp-23953	15	24	bangladesh	bangladesh	NOUN
bjp-23953	15	25	pharmacological	pharmacological	ADJ
bjp-23953	15	26	society	society	NOUN
bjp-23953	15	27	(	(	PUNCT
bjp-23953	15	28	bdps	bdps	NOUN
bjp-23953	15	29	)	)	PUNCT
bjp-23953	15	30	bangladesh	bangladesh	PROPN
bjp-23953	15	31	j	j	PROPN
bjp-23953	15	32	pharmacol	pharmacol	PROPN
bjp-23953	15	33	2016	2016	NUM
bjp-23953	15	34	;	;	PUNCT
bjp-23953	15	35	11	11	NUM
bjp-23953	15	36	:	:	SYM
bjp-23953	15	37	564	564	NUM
bjp-23953	15	38	-	-	SYM
bjp-23953	15	39	569	569	NUM
bjp-23953	15	40	journal	journal	NOUN
bjp-23953	15	41	homepage	homepage	NOUN
bjp-23953	15	42	:	:	PUNCT
bjp-23953	15	43	www.banglajol.info	www.banglajol.info	PROPN
bjp-23953	15	44	abstracted	abstract	VERB
bjp-23953	15	45	/	/	SYM
bjp-23953	15	46	indexed	index	VERB
bjp-23953	15	47	in	in	ADP
bjp-23953	15	48	academic	academic	ADJ
bjp-23953	15	49	search	search	NOUN
bjp-23953	15	50	complete	complete	ADJ
bjp-23953	15	51	,	,	PUNCT
bjp-23953	15	52	asia	asia	PROPN
bjp-23953	15	53	journals	journal	NOUN
bjp-23953	15	54	online	online	ADV
bjp-23953	15	55	,	,	PUNCT
bjp-23953	15	56	bangladesh	bangladesh	NOUN
bjp-23953	15	57	journals	journal	NOUN
bjp-23953	15	58	online	online	ADV
bjp-23953	15	59	,	,	PUNCT
bjp-23953	15	60	biological	biological	ADJ
bjp-23953	15	61	abstracts	abstract	NOUN
bjp-23953	15	62	,	,	PUNCT
bjp-23953	15	63	biosis	biosis	NOUN
bjp-23953	15	64	previews	preview	NOUN
bjp-23953	15	65	,	,	PUNCT
bjp-23953	15	66	cab	cab	NOUN
bjp-23953	15	67	abstracts	abstract	NOUN
bjp-23953	15	68	,	,	PUNCT
bjp-23953	15	69	current	current	ADJ
bjp-23953	15	70	abstracts	abstract	NOUN
bjp-23953	15	71	,	,	PUNCT
bjp-23953	15	72	directory	directory	NOUN
bjp-23953	15	73	of	of	ADP
bjp-23953	15	74	open	open	ADJ
bjp-23953	15	75	access	access	NOUN
bjp-23953	15	76	journals	journal	NOUN
bjp-23953	15	77	,	,	PUNCT
bjp-23953	15	78	embase	embase	NOUN
bjp-23953	15	79	/	/	SYM
bjp-23953	15	80	excerpta	excerpta	NOUN
bjp-23953	15	81	medica	medica	NOUN
bjp-23953	15	82	,	,	PUNCT
bjp-23953	15	83	google	google	PROPN
bjp-23953	15	84	scholar	scholar	NOUN
bjp-23953	15	85	,	,	PUNCT
bjp-23953	15	86	hinari	hinari	X
bjp-23953	15	87	(	(	PUNCT
bjp-23953	15	88	who	who	PRON
bjp-23953	15	89	)	)	PUNCT
bjp-23953	15	90	,	,	PUNCT
bjp-23953	15	91	international	international	ADJ
bjp-23953	15	92	pharmaceutical	pharmaceutical	ADJ
bjp-23953	15	93	abstracts	abstract	NOUN
bjp-23953	15	94	,	,	PUNCT
bjp-23953	15	95	open	open	ADJ
bjp-23953	15	96	j	j	PROPN
bjp-23953	15	97	-	-	PUNCT
bjp-23953	15	98	gate	gate	NOUN
bjp-23953	15	99	,	,	PUNCT
bjp-23953	15	100	science	science	NOUN
bjp-23953	15	101	citation	citation	NOUN
bjp-23953	15	102	index	index	NOUN
bjp-23953	15	103	expanded	expand	VERB
bjp-23953	15	104	,	,	PUNCT
bjp-23953	15	105	scopus	scopus	NOUN
bjp-23953	15	106	and	and	CCONJ
bjp-23953	15	107	social	social	ADJ
bjp-23953	15	108	sciences	sciences	PROPN
bjp-23953	15	109	citation	citation	NOUN
bjp-23953	15	110	index	index	NOUN
bjp-23953	15	111	;	;	PUNCT
bjp-23953	15	112	issn	issn	PROPN
bjp-23953	15	113	:	:	PUNCT
bjp-23953	15	114	1991	1991	NUM
bjp-23953	15	115	-	-	SYM
bjp-23953	15	116	0088	0088	NUM
bjp-23953	15	117	abstract	abstract	NOUN
bjp-23953	15	118	our	our	PRON
bjp-23953	15	119	objective	objective	NOUN
bjp-23953	15	120	was	be	AUX
bjp-23953	15	121	to	to	PART
bjp-23953	15	122	evaluate	evaluate	VERB
bjp-23953	15	123	an	an	DET
bjp-23953	15	124	open	open	ADJ
bjp-23953	15	125	-	-	PUNCT
bjp-23953	15	126	label	label	NOUN
bjp-23953	15	127	,	,	PUNCT
bjp-23953	15	128	multicenter	multicenter	NOUN
bjp-23953	15	129	,	,	PUNCT
bjp-23953	15	130	single	single	ADJ
bjp-23953	15	131	-	-	PUNCT
bjp-23953	15	132	arm	arm	NOUN
bjp-23953	15	133	study	study	NOUN
bjp-23953	15	134	to	to	PART
bjp-23953	15	135	appraise	appraise	VERB
bjp-23953	15	136	whether	whether	SCONJ
bjp-23953	15	137	amrubicin	amrubicin	NOUN
bjp-23953	15	138	therapy	therapy	NOUN
bjp-23953	15	139	improves	improve	VERB
bjp-23953	15	140	patients	patient	NOUN
bjp-23953	15	141	with	with	ADP
bjp-23953	15	142	refractory	refractory	NOUN
bjp-23953	15	143	smallcell	smallcell	VERB
bjp-23953	15	144	lung	lung	NOUN
bjp-23953	15	145	cancer	cancer	NOUN
bjp-23953	15	146	in	in	ADP
bjp-23953	15	147	chinese	chinese	ADJ
bjp-23953	15	148	clinical	clinical	ADJ
bjp-23953	15	149	study	study	NOUN
bjp-23953	15	150	.	.	PUNCT
bjp-23953	16	1	patients	patient	NOUN
bjp-23953	16	2	(	(	PUNCT
bjp-23953	16	3	n=95	n=95	NOUN
bjp-23953	16	4	)	)	PUNCT
bjp-23953	16	5	with	with	ADP
bjp-23953	16	6	refractory	refractory	NOUN
bjp-23953	16	7	small	small	ADJ
bjp-23953	16	8	-	-	PUNCT
bjp-23953	16	9	cell	cell	NOUN
bjp-23953	16	10	lung	lung	NOUN
bjp-23953	16	11	cancer	cancer	NOUN
bjp-23953	16	12	received	receive	VERB
bjp-23953	16	13	3	3	NUM
bjp-23953	16	14	consecutive	consecutive	ADJ
bjp-23953	16	15	days	day	NOUN
bjp-23953	16	16	amrubicin	amrubicin	NOUN
bjp-23953	16	17	therapy	therapy	NOUN
bjp-23953	16	18	for	for	ADP
bjp-23953	16	19	21	21	NUM
bjp-23953	16	20	days	day	NOUN
bjp-23953	16	21	.	.	PUNCT
bjp-23953	17	1	overall	overall	ADJ
bjp-23953	17	2	response	response	NOUN
bjp-23953	17	3	rate	rate	NOUN
bjp-23953	17	4	of	of	ADP
bjp-23953	17	5	response	response	NOUN
bjp-23953	17	6	to	to	ADP
bjp-23953	17	7	amrubicin	amrubicin	NOUN
bjp-23953	17	8	was	be	AUX
bjp-23953	17	9	39	39	NUM
bjp-23953	17	10	%	%	NOUN
bjp-23953	17	11	.	.	PUNCT
bjp-23953	18	1	anemia	anemia	NOUN
bjp-23953	18	2	,	,	PUNCT
bjp-23953	18	3	febrile	febrile	NOUN
bjp-23953	18	4	neutropenia	neutropenia	NOUN
bjp-23953	18	5	,	,	PUNCT
bjp-23953	18	6	thrombocytopenia	thrombocytopenia	PROPN
bjp-23953	18	7	,	,	PUNCT
bjp-23953	18	8	hyperglycemia	hyperglycemia	NOUN
bjp-23953	18	9	,	,	PUNCT
bjp-23953	18	10	hyponatremia	hyponatremia	NOUN
bjp-23953	18	11	,	,	PUNCT
bjp-23953	18	12	infection	infection	NOUN
bjp-23953	18	13	,	,	PUNCT
bjp-23953	18	14	elevated	elevated	ADJ
bjp-23953	18	15	serum	serum	NOUN
bjp-23953	18	16	transaminases	transaminase	NOUN
bjp-23953	18	17	levels	level	NOUN
bjp-23953	18	18	were	be	AUX
bjp-23953	18	19	appeared	appear	VERB
bjp-23953	18	20	,	,	PUNCT
bjp-23953	18	21	but	but	CCONJ
bjp-23953	18	22	the	the	DET
bjp-23953	18	23	incidences	incidence	NOUN
bjp-23953	18	24	of	of	ADP
bjp-23953	18	25	adverse	adverse	ADJ
bjp-23953	18	26	events	event	NOUN
bjp-23953	18	27	were	be	AUX
bjp-23953	18	28	very	very	ADV
bjp-23953	18	29	few	few	ADJ
bjp-23953	18	30	.	.	PUNCT
bjp-23953	19	1	our	our	PRON
bjp-23953	19	2	results	result	NOUN
bjp-23953	19	3	suggest	suggest	VERB
bjp-23953	19	4	amrubicin	amrubicin	NOUN
bjp-23953	19	5	therapy	therapy	NOUN
bjp-23953	19	6	can	can	AUX
bjp-23953	19	7	improve	improve	VERB
bjp-23953	19	8	patients	patient	NOUN
bjp-23953	19	9	with	with	ADP
bjp-23953	19	10	refractory	refractory	NOUN
bjp-23953	19	11	small	small	ADJ
bjp-23953	19	12	-	-	PUNCT
bjp-23953	19	13	cell	cell	NOUN
bjp-23953	19	14	lung	lung	NOUN
bjp-23953	19	15	cancer	cancer	NOUN
bjp-23953	19	16	and	and	CCONJ
bjp-23953	19	17	may	may	AUX
bjp-23953	19	18	be	be	AUX
bjp-23953	19	19	an	an	DET
bjp-23953	19	20	effective	effective	ADJ
bjp-23953	19	21	and	and	CCONJ
bjp-23953	19	22	safe	safe	ADJ
bjp-23953	19	23	treatment	treatment	NOUN
bjp-23953	19	24	option	option	NOUN
bjp-23953	19	25	.	.	PUNCT
bjp-23953	20	1	article	article	NOUN
bjp-23953	20	2	info	info	NOUN
bjp-23953	20	3	received	receive	VERB
bjp-23953	20	4	:	:	PUNCT
bjp-23953	20	5	30	30	NUM
bjp-23953	20	6	june	june	PROPN
bjp-23953	20	7	2015	2015	NUM
bjp-23953	20	8	accepted	accept	VERB
bjp-23953	20	9	:	:	PUNCT
bjp-23953	20	10	5	5	NUM
bjp-23953	20	11	january	january	PROPN
bjp-23953	20	12	2016	2016	NUM
bjp-23953	20	13	available	available	ADJ
bjp-23953	20	14	online	online	ADV
bjp-23953	20	15	:	:	PUNCT
bjp-23953	20	16	1	1	NUM
bjp-23953	20	17	june	june	PROPN
bjp-23953	20	18	2016	2016	NUM
bjp-23953	20	19	doi	doi	NOUN
bjp-23953	20	20	:	:	PUNCT
bjp-23953	20	21	10.3329	10.3329	NUM
bjp-23953	20	22	/	/	SYM
bjp-23953	20	23	bjp.v11i3.23953	bjp.v11i3.23953	PROPN
bjp-23953	20	24	cite	cite	VERB
bjp-23953	20	25	this	this	DET
bjp-23953	20	26	article	article	NOUN
bjp-23953	20	27	:	:	PUNCT
bjp-23953	20	28	zheng	zheng	PROPN
bjp-23953	20	29	m	m	PROPN
bjp-23953	20	30	,	,	PUNCT
bjp-23953	20	31	zhou	zhou	PROPN
bjp-23953	20	32	n	n	PROPN
bjp-23953	20	33	,	,	PUNCT
bjp-23953	20	34	ma	ma	PROPN
bjp-23953	20	35	l	l	PROPN
bjp-23953	20	36	,	,	PUNCT
bjp-23953	20	37	jin	jin	PROPN
bjp-23953	20	38	w.	w.	PROPN
bjp-23953	20	39	amrubicin	amrubicin	PROPN
bjp-23953	20	40	therapy	therapy	NOUN
bjp-23953	20	41	improves	improve	VERB
bjp-23953	20	42	patients	patient	NOUN
bjp-23953	20	43	with	with	ADP
bjp-23953	20	44	refractory	refractory	NOUN
bjp-23953	20	45	small	small	ADJ
bjp-23953	20	46	-	-	PUNCT
bjp-23953	20	47	cell	cell	NOUN
bjp-23953	20	48	lung	lung	NOUN
bjp-23953	20	49	cancer	cancer	NOUN
bjp-23953	20	50	:	:	PUNCT
bjp-23953	20	51	a	a	DET
bjp-23953	20	52	single	single	ADJ
bjp-23953	20	53	-	-	PUNCT
bjp-23953	20	54	arm	arm	NOUN
bjp-23953	20	55	confirmatory	confirmatory	NOUN
bjp-23953	20	56	chinese	chinese	ADJ
bjp-23953	20	57	cl	cl	PROPN
bjp-23953	20	58	inical	inical	ADJ
bjp-23953	20	59	study	study	NOUN
bjp-23953	20	60	.	.	PUNCT
bjp-23953	21	1	bangladesh	bangladesh	PROPN
bjp-23953	21	2	j	j	PROPN
bjp-23953	21	3	pharmacol	pharmacol	PROPN
bjp-23953	21	4	.	.	PROPN
bjp-23953	22	1	2016	2016	NUM
bjp-23953	22	2	;	;	PUNCT
bjp-23953	22	3	11	11	NUM
bjp-23953	22	4	:	:	SYM
bjp-23953	22	5	564	564	NUM
bjp-23953	22	6	-	-	SYM
bjp-23953	22	7	69	69	NUM
bjp-23953	22	8	.	.	PUNCT
bjp-23953	23	1	amrubicin	amrubicin	NOUN
bjp-23953	23	2	therapy	therapy	NOUN
bjp-23953	23	3	improves	improve	VERB
bjp-23953	23	4	patients	patient	NOUN
bjp-23953	23	5	with	with	ADP
bjp-23953	23	6	refractory	refractory	NOUN
bjp-23953	23	7	small	small	ADJ
bjp-23953	23	8	-	-	PUNCT
bjp-23953	23	9	cell	cell	NOUN
bjp-23953	23	10	lung	lung	NOUN
bjp-23953	23	11	cancer	cancer	NOUN
bjp-23953	23	12	:	:	PUNCT
bjp-23953	23	13	a	a	DET
bjp-23953	23	14	single	single	ADJ
bjp-23953	23	15	-	-	PUNCT
bjp-23953	23	16	arm	arm	NOUN
bjp-23953	23	17	confirmatory	confirmatory	NOUN
bjp-23953	23	18	chinese	chinese	ADJ
bjp-23953	23	19	clinical	clinical	ADJ
bjp-23953	23	20	study	study	NOUN
bjp-23953	23	21	mengli	mengli	PROPN
bjp-23953	23	22	zheng	zheng	PROPN
bjp-23953	23	23	,	,	PUNCT
bjp-23953	23	24	naikang	naikang	PROPN
bjp-23953	23	25	zhou	zhou	PROPN
bjp-23953	23	26	,	,	PUNCT
bjp-23953	23	27	lianjun	lianjun	PROPN
bjp-23953	23	28	ma	ma	PROPN
bjp-23953	23	29	and	and	CCONJ
bjp-23953	23	30	wenbo	wenbo	PROPN
bjp-23953	23	31	jin	jin	PROPN
bjp-23953	23	32	department	department	PROPN
bjp-23953	23	33	of	of	ADP
bjp-23953	23	34	general	general	ADJ
bjp-23953	23	35	thoracic	thoracic	NOUN
bjp-23953	23	36	surgery	surgery	NOUN
bjp-23953	23	37	,	,	PUNCT
bjp-23953	23	38	the	the	DET
bjp-23953	23	39	309th	309th	ADJ
bjp-23953	23	40	hospital	hospital	NOUN
bjp-23953	23	41	of	of	ADP
bjp-23953	23	42	chinese	chinese	ADJ
bjp-23953	23	43	pla	pla	PROPN
bjp-23953	23	44	,	,	PUNCT
bjp-23953	23	45	beijing	beijing	PROPN
bjp-23953	23	46	100	100	NUM
bjp-23953	23	47	-	-	SYM
bjp-23953	23	48	091	091	NUM
bjp-23953	23	49	,	,	PUNCT
bjp-23953	23	50	china	china	PROPN
bjp-23953	23	51	.	.	PUNCT
bjp-23953	24	1	c	c	PROPN
bjp-23953	24	2	lin	lin	PROPN
bjp-23953	24	3	ic	ic	PROPN
bjp-23953	24	4	al	al	PROPN
bjp-23953	24	5	t	t	PROPN
bjp-23953	24	6	ria	ria	PROPN
bjp-23953	24	7	l	l	PROPN
bjp-23953	24	8	http://www.bioxbio.com/if/html/bangl-j-pharmacol.html	http://www.bioxbio.com/if/html/bangl-j-pharmacol.html	PROPN
bjp-23953	24	9	china	china	PROPN
bjp-23953	24	10	.	.	PUNCT
bjp-23953	25	1	the	the	DET
bjp-23953	25	2	study	study	NOUN
bjp-23953	25	3	protocol	protocol	NOUN
bjp-23953	25	4	was	be	AUX
bjp-23953	25	5	approved	approve	VERB
bjp-23953	25	6	by	by	ADP
bjp-23953	25	7	the	the	DET
bjp-23953	25	8	china	china	PROPN
bjp-23953	25	9	clinical	clinical	ADJ
bjp-23953	25	10	oncology	oncology	NOUN
bjp-23953	25	11	group	group	NOUN
bjp-23953	25	12	(	(	PUNCT
bjp-23953	25	13	jcog	jcog	PROPN
bjp-23953	25	14	)	)	PUNCT
bjp-23953	25	15	protocol	protocol	PROPN
bjp-23953	25	16	review	review	NOUN
bjp-23953	25	17	committee	committee	NOUN
bjp-23953	25	18	and	and	CCONJ
bjp-23953	25	19	the	the	DET
bjp-23953	25	20	institutional	institutional	ADJ
bjp-23953	25	21	review	review	NOUN
bjp-23953	25	22	board	board	NOUN
bjp-23953	25	23	of	of	ADP
bjp-23953	25	24	each	each	DET
bjp-23953	25	25	participating	participate	VERB
bjp-23953	25	26	institution	institution	NOUN
bjp-23953	25	27	.	.	PUNCT
bjp-23953	26	1	eligibility	eligibility	NOUN
bjp-23953	26	2	criteria	criterion	NOUN
bjp-23953	26	3	patients	patient	NOUN
bjp-23953	26	4	who	who	PRON
bjp-23953	26	5	were	be	AUX
bjp-23953	26	6	chosen	choose	VERB
bjp-23953	26	7	were	be	AUX
bjp-23953	26	8	known	know	VERB
bjp-23953	26	9	to	to	PART
bjp-23953	26	10	be	be	AUX
bjp-23953	26	11	ones	one	NOUN
bjp-23953	26	12	of	of	ADP
bjp-23953	26	13	small	small	ADJ
bjp-23953	26	14	-	-	PUNCT
bjp-23953	26	15	cell	cell	NOUN
bjp-23953	26	16	lung	lung	NOUN
bjp-23953	26	17	cancer	cancer	NOUN
bjp-23953	26	18	by	by	ADP
bjp-23953	26	19	histological	histological	ADJ
bjp-23953	26	20	or	or	CCONJ
bjp-23953	26	21	cytological	cytological	ADJ
bjp-23953	26	22	means	mean	NOUN
bjp-23953	26	23	,	,	PUNCT
bjp-23953	26	24	and	and	CCONJ
bjp-23953	26	25	they	they	PRON
bjp-23953	26	26	were	be	AUX
bjp-23953	26	27	resistant	resistant	ADJ
bjp-23953	26	28	to	to	ADP
bjp-23953	26	29	one	one	NUM
bjp-23953	26	30	or	or	CCONJ
bjp-23953	26	31	two	two	NUM
bjp-23953	26	32	treatments	treatment	NOUN
bjp-23953	26	33	of	of	ADP
bjp-23953	26	34	making	make	VERB
bjp-23953	26	35	use	use	NOUN
bjp-23953	26	36	of	of	ADP
bjp-23953	26	37	chemical	chemical	ADJ
bjp-23953	26	38	substances	substance	NOUN
bjp-23953	26	39	,	,	PUNCT
bjp-23953	26	40	with	with	ADP
bjp-23953	26	41	at	at	ADV
bjp-23953	26	42	least	least	ADV
bjp-23953	26	43	one	one	NUM
bjp-23953	26	44	platinum	platinum	NOUN
bjp-23953	26	45	-	-	PUNCT
bjp-23953	26	46	based	base	VERB
bjp-23953	26	47	treatment	treatment	NOUN
bjp-23953	26	48	.	.	PUNCT
bjp-23953	27	1	a	a	DET
bjp-23953	27	2	refractory	refractory	NOUN
bjp-23953	27	3	disease	disease	NOUN
bjp-23953	27	4	was	be	AUX
bjp-23953	27	5	interpreted	interpret	VERB
bjp-23953	27	6	as	as	ADP
bjp-23953	27	7	one	one	NUM
bjp-23953	27	8	failing	fail	VERB
bjp-23953	27	9	to	to	PART
bjp-23953	27	10	respond	respond	VERB
bjp-23953	27	11	to	to	ADP
bjp-23953	27	12	prior	prior	ADJ
bjp-23953	27	13	chemotherapy	chemotherapy	NOUN
bjp-23953	27	14	,	,	PUNCT
bjp-23953	27	15	disease	disease	NOUN
bjp-23953	27	16	continuation	continuation	NOUN
bjp-23953	27	17	on	on	ADP
bjp-23953	27	18	chemotherapy	chemotherapy	NOUN
bjp-23953	27	19	,	,	PUNCT
bjp-23953	27	20	or	or	CCONJ
bjp-23953	27	21	disease	disease	NOUN
bjp-23953	27	22	continuance	continuance	NOUN
bjp-23953	27	23	<	<	X
bjp-23953	27	24	90	90	NUM
bjp-23953	27	25	days	day	NOUN
bjp-23953	27	26	of	of	ADP
bjp-23953	27	27	concluding	conclude	VERB
bjp-23953	27	28	prior	prior	ADJ
bjp-23953	27	29	chemotherapy	chemotherapy	NOUN
bjp-23953	27	30	after	after	ADP
bjp-23953	27	31	corroborating	corroborate	VERB
bjp-23953	27	32	a	a	DET
bjp-23953	27	33	complete	complete	ADJ
bjp-23953	27	34	response	response	NOUN
bjp-23953	27	35	(	(	PUNCT
bjp-23953	27	36	cr	cr	NOUN
bjp-23953	27	37	)	)	PUNCT
bjp-23953	27	38	or	or	CCONJ
bjp-23953	27	39	partial	partial	ADJ
bjp-23953	27	40	response	response	NOUN
bjp-23953	27	41	(	(	PUNCT
bjp-23953	27	42	pr	pr	NOUN
bjp-23953	27	43	)	)	PUNCT
bjp-23953	27	44	.	.	PUNCT
bjp-23953	28	1	additional	additional	ADJ
bjp-23953	28	2	criteria	criterion	NOUN
bjp-23953	28	3	for	for	ADP
bjp-23953	28	4	inclusion	inclusion	NOUN
bjp-23953	28	5	consisted	consist	VERB
bjp-23953	28	6	of	of	ADP
bjp-23953	28	7	persons	person	NOUN
bjp-23953	28	8	aged	age	VERB
bjp-23953	28	9	from	from	ADP
bjp-23953	28	10	20	20	NUM
bjp-23953	28	11	to	to	ADP
bjp-23953	28	12	74	74	NUM
bjp-23953	28	13	,	,	PUNCT
bjp-23953	28	14	with	with	ADP
bjp-23953	28	15	eastern	eastern	ADJ
bjp-23953	28	16	cooperative	cooperative	ADJ
bjp-23953	28	17	oncology	oncology	NOUN
bjp-23953	28	18	group	group	NOUN
bjp-23953	28	19	performance	performance	NOUN
bjp-23953	28	20	status	status	NOUN
bjp-23953	28	21	of	of	ADP
bjp-23953	28	22	0	0	NUM
bjp-23953	28	23	1	1	NUM
bjp-23953	28	24	,	,	PUNCT
bjp-23953	28	25	measurable	measurable	ADJ
bjp-23953	28	26	disease	disease	NOUN
bjp-23953	28	27	,	,	PUNCT
bjp-23953	28	28	no	no	DET
bjp-23953	28	29	history	history	NOUN
bjp-23953	28	30	of	of	ADP
bjp-23953	28	31	chemotherapy	chemotherapy	NOUN
bjp-23953	28	32	with	with	ADP
bjp-23953	28	33	amr	amr	NOUN
bjp-23953	28	34	,	,	PUNCT
bjp-23953	28	35	no	no	DET
bjp-23953	28	36	history	history	NOUN
bjp-23953	28	37	of	of	ADP
bjp-23953	28	38	surgery	surgery	NOUN
bjp-23953	28	39	for	for	ADP
bjp-23953	28	40	small	small	ADJ
bjp-23953	28	41	-	-	PUNCT
bjp-23953	28	42	cell	cell	NOUN
bjp-23953	28	43	lung	lung	NOUN
bjp-23953	28	44	cancer	cancer	NOUN
bjp-23953	28	45	,	,	PUNCT
bjp-23953	28	46	no	no	DET
bjp-23953	28	47	thoracic	thoracic	NOUN
bjp-23953	28	48	radiation	radiation	NOUN
bjp-23953	28	49	therapy	therapy	NOUN
bjp-23953	28	50	≤4	≤4	ADJ
bjp-23953	28	51	weeks	week	NOUN
bjp-23953	28	52	prior	prior	ADV
bjp-23953	28	53	to	to	ADP
bjp-23953	28	54	registration	registration	NOUN
bjp-23953	28	55	,	,	PUNCT
bjp-23953	28	56	satisfactory	satisfactory	ADJ
bjp-23953	28	57	baseline	baseline	NOUN
bjp-23953	28	58	organ	organ	NOUN
bjp-23953	28	59	function	function	NOUN
bjp-23953	29	1	[	[	X
bjp-23953	29	2	leukocyte	leukocyte	NOUN
bjp-23953	29	3	count	count	NOUN
bjp-23953	29	4	≥	≥	NOUN
bjp-23953	29	5	3000	3000	NUM
bjp-23953	29	6	/	/	SYM
bjp-23953	29	7	mm3	mm3	PROPN
bjp-23953	29	8	,	,	PUNCT
bjp-23953	29	9	absolute	absolute	ADJ
bjp-23953	29	10	neutrophil	neutrophil	ADJ
bjp-23953	29	11	count	count	NOUN
bjp-23953	29	12	≥1500	≥1500	NOUN
bjp-23953	29	13	/	/	SYM
bjp-23953	29	14	mm3	mm3	PROPN
bjp-23953	29	15	,	,	PUNCT
bjp-23953	29	16	hemoglobin	hemoglobin	NOUN
bjp-23953	29	17	≥9.0	≥9.0	ADJ
bjp-23953	29	18	g	g	PROPN
bjp-23953	29	19	/	/	SYM
bjp-23953	29	20	dl	dl	PROPN
bjp-23953	29	21	,	,	PUNCT
bjp-23953	29	22	platelet	platelet	NOUN
bjp-23953	29	23	count	count	NOUN
bjp-23953	29	24	≥100,000	≥100,000	PROPN
bjp-23953	29	25	/	/	SYM
bjp-23953	29	26	mm3	mm3	ADJ
bjp-23953	29	27	,	,	PUNCT
bjp-23953	29	28	total	total	ADJ
bjp-23953	29	29	bilirubin	bilirubin	NOUN
bjp-23953	29	30	≤2.0	≤2.0	PUNCT
bjp-23953	29	31	mg	mg	PROPN
bjp-23953	29	32	/	/	SYM
bjp-23953	29	33	dl	dl	PROPN
bjp-23953	29	34	,	,	PUNCT
bjp-23953	29	35	aspartate	aspartate	NOUN
bjp-23953	29	36	aminotransferase	aminotransferase	NOUN
bjp-23953	29	37	(	(	PUNCT
bjp-23953	29	38	ast	ast	NOUN
bjp-23953	29	39	)	)	PUNCT
bjp-23953	29	40	and	and	CCONJ
bjp-23953	29	41	alanine	alanine	NOUN
bjp-23953	29	42	aminotransferase	aminotransferase	PROPN
bjp-23953	29	43	(	(	PUNCT
bjp-23953	29	44	alt	alt	NOUN
bjp-23953	29	45	)	)	PUNCT
bjp-23953	29	46	levels	level	NOUN
bjp-23953	29	47	≤	≤	ADV
bjp-23953	29	48	100	100	NUM
bjp-23953	29	49	iu	iu	PROPN
bjp-23953	29	50	/	/	SYM
bjp-23953	29	51	l	l	NOUN
bjp-23953	29	52	,	,	PUNCT
bjp-23953	29	53	serum	serum	NOUN
bjp-23953	29	54	creatinine	creatinine	NOUN
bjp-23953	29	55	level	level	NOUN
bjp-23953	29	56	≤2.0	≤2.0	PUNCT
bjp-23953	29	57	mg	mg	PROPN
bjp-23953	29	58	/	/	SYM
bjp-23953	29	59	dl	dl	PROPN
bjp-23953	29	60	,	,	PUNCT
bjp-23953	29	61	pao2	pao2	PROPN
bjp-23953	29	62	under	under	ADP
bjp-23953	29	63	room	room	NOUN
bjp-23953	29	64	air	air	NOUN
bjp-23953	29	65	≥60	≥60	PROPN
bjp-23953	29	66	mmhg	mmhg	NOUN
bjp-23953	29	67	,	,	PUNCT
bjp-23953	29	68	and	and	CCONJ
bjp-23953	29	69	electrocardiographic	electrocardiographic	ADJ
bjp-23953	29	70	findings	finding	NOUN
bjp-23953	29	71	within	within	ADP
bjp-23953	29	72	normal	normal	ADJ
bjp-23953	29	73	range	range	NOUN
bjp-23953	29	74	]	]	PUNCT
bjp-23953	29	75	.	.	PUNCT
bjp-23953	30	1	informed	informed	ADJ
bjp-23953	30	2	consent	consent	NOUN
bjp-23953	30	3	in	in	ADP
bjp-23953	30	4	written	write	VERB
bjp-23953	30	5	form	form	NOUN
bjp-23953	30	6	was	be	AUX
bjp-23953	30	7	received	receive	VERB
bjp-23953	30	8	from	from	ADP
bjp-23953	30	9	all	all	DET
bjp-23953	30	10	participants	participant	NOUN
bjp-23953	30	11	.	.	PUNCT
bjp-23953	31	1	patients	patient	NOUN
bjp-23953	31	2	were	be	AUX
bjp-23953	31	3	deemed	deem	VERB
bjp-23953	31	4	not	not	PART
bjp-23953	31	5	qualified	qualified	ADJ
bjp-23953	31	6	providing	provide	VERB
bjp-23953	31	7	they	they	PRON
bjp-23953	31	8	suffered	suffer	VERB
bjp-23953	31	9	from	from	ADP
bjp-23953	31	10	active	active	ADJ
bjp-23953	31	11	concomitant	concomitant	ADJ
bjp-23953	31	12	malignancy	malignancy	NOUN
bjp-23953	31	13	,	,	PUNCT
bjp-23953	31	14	massive	massive	ADJ
bjp-23953	31	15	pleural	pleural	ADJ
bjp-23953	31	16	or	or	CCONJ
bjp-23953	31	17	pericardial	pericardial	ADJ
bjp-23953	31	18	effusion	effusion	NOUN
bjp-23953	31	19	,	,	PUNCT
bjp-23953	31	20	symptomatic	symptomatic	ADJ
bjp-23953	31	21	brain	brain	NOUN
bjp-23953	31	22	metastasis	metastasis	NOUN
bjp-23953	31	23	,	,	PUNCT
bjp-23953	31	24	or	or	CCONJ
bjp-23953	31	25	severe	severe	ADJ
bjp-23953	31	26	comorbidities	comorbiditie	NOUN
bjp-23953	31	27	such	such	ADJ
bjp-23953	31	28	as	as	ADP
bjp-23953	31	29	active	active	ADJ
bjp-23953	31	30	infections	infection	NOUN
bjp-23953	31	31	,	,	PUNCT
bjp-23953	31	32	uncontrolled	uncontrolled	ADJ
bjp-23953	31	33	hypertension	hypertension	NOUN
bjp-23953	31	34	,	,	PUNCT
bjp-23953	31	35	severe	severe	ADJ
bjp-23953	31	36	heart	heart	NOUN
bjp-23953	31	37	disease	disease	NOUN
bjp-23953	31	38	,	,	PUNCT
bjp-23953	31	39	uncontrolled	uncontrolled	ADJ
bjp-23953	31	40	diabetes	diabetes	NOUN
bjp-23953	31	41	mellitus	mellitus	NOUN
bjp-23953	31	42	,	,	PUNCT
bjp-23953	31	43	bowel	bowel	NOUN
bjp-23953	31	44	obstruction	obstruction	NOUN
bjp-23953	31	45	,	,	PUNCT
bjp-23953	31	46	psychiatric	psychiatric	ADJ
bjp-23953	31	47	disease	disease	NOUN
bjp-23953	31	48	,	,	PUNCT
bjp-23953	31	49	severe	severe	ADJ
bjp-23953	31	50	emphysema	emphysema	NOUN
bjp-23953	31	51	,	,	PUNCT
bjp-23953	31	52	interstitial	interstitial	ADJ
bjp-23953	31	53	pneumonia	pneumonia	NOUN
bjp-23953	31	54	,	,	PUNCT
bjp-23953	31	55	or	or	CCONJ
bjp-23953	31	56	pulmonary	pulmonary	ADJ
bjp-23953	31	57	fibrosis	fibrosis	NOUN
bjp-23953	31	58	.	.	PUNCT
bjp-23953	32	1	patients	patient	NOUN
bjp-23953	32	2	who	who	PRON
bjp-23953	32	3	took	take	VERB
bjp-23953	32	4	some	some	DET
bjp-23953	32	5	medication	medication	NOUN
bjp-23953	32	6	for	for	ADP
bjp-23953	32	7	systemic	systemic	ADJ
bjp-23953	32	8	steroid	steroid	NOUN
bjp-23953	32	9	and	and	CCONJ
bjp-23953	32	10	who	who	PRON
bjp-23953	32	11	were	be	AUX
bjp-23953	32	12	pregnant	pregnant	ADJ
bjp-23953	32	13	or	or	CCONJ
bjp-23953	32	14	breastfeeding	breastfeeding	NOUN
bjp-23953	32	15	were	be	AUX
bjp-23953	32	16	not	not	PART
bjp-23953	32	17	included	include	VERB
bjp-23953	32	18	.	.	PUNCT
bjp-23953	33	1	treatment	treatment	NOUN
bjp-23953	33	2	treatment	treatment	NOUN
bjp-23953	33	3	began	begin	VERB
bjp-23953	33	4	within	within	ADP
bjp-23953	33	5	the	the	DET
bjp-23953	33	6	first	first	ADJ
bjp-23953	33	7	week	week	NOUN
bjp-23953	33	8	following	follow	VERB
bjp-23953	33	9	confirmed	confirm	VERB
bjp-23953	33	10	participation	participation	NOUN
bjp-23953	33	11	in	in	ADP
bjp-23953	33	12	the	the	DET
bjp-23953	33	13	study	study	NOUN
bjp-23953	33	14	.	.	PUNCT
bjp-23953	34	1	at	at	ADP
bjp-23953	34	2	an	an	DET
bjp-23953	34	3	interval	interval	NOUN
bjp-23953	34	4	of	of	ADP
bjp-23953	34	5	21	21	NUM
bjp-23953	34	6	days	day	NOUN
bjp-23953	34	7	,	,	PUNCT
bjp-23953	34	8	patients	patient	NOUN
bjp-23953	34	9	received	receive	VERB
bjp-23953	34	10	amrubicin	amrubicin	NOUN
bjp-23953	34	11	at	at	ADP
bjp-23953	34	12	40	40	NUM
bjp-23953	34	13	mg	mg	PROPN
bjp-23953	34	14	/	/	SYM
bjp-23953	34	15	m2	m2	PROPN
bjp-23953	34	16	/	/	SYM
bjp-23953	34	17	day	day	NOUN
bjp-23953	34	18	for	for	ADP
bjp-23953	34	19	three	three	NUM
bjp-23953	34	20	days	day	NOUN
bjp-23953	34	21	in	in	ADP
bjp-23953	34	22	succession	succession	NOUN
bjp-23953	34	23	.	.	PUNCT
bjp-23953	35	1	such	such	ADJ
bjp-23953	35	2	treatment	treatment	NOUN
bjp-23953	35	3	went	go	VERB
bjp-23953	35	4	on	on	ADP
bjp-23953	35	5	if	if	SCONJ
bjp-23953	35	6	without	without	ADP
bjp-23953	35	7	worsening	worsen	VERB
bjp-23953	35	8	of	of	ADP
bjp-23953	35	9	the	the	DET
bjp-23953	35	10	disease	disease	NOUN
bjp-23953	35	11	,	,	PUNCT
bjp-23953	35	12	unbearable	unbearable	ADJ
bjp-23953	35	13	toxicity	toxicity	NOUN
bjp-23953	35	14	,	,	PUNCT
bjp-23953	35	15	or	or	CCONJ
bjp-23953	35	16	refusal	refusal	NOUN
bjp-23953	35	17	on	on	ADP
bjp-23953	35	18	the	the	DET
bjp-23953	35	19	part	part	NOUN
bjp-23953	35	20	of	of	ADP
bjp-23953	35	21	the	the	DET
bjp-23953	35	22	patient	patient	NOUN
bjp-23953	35	23	in	in	ADP
bjp-23953	35	24	question	question	NOUN
bjp-23953	35	25	.	.	PUNCT
bjp-23953	36	1	the	the	DET
bjp-23953	36	2	dosage	dosage	NOUN
bjp-23953	36	3	of	of	ADP
bjp-23953	36	4	amrubicin	amrubicin	NOUN
bjp-23953	36	5	was	be	AUX
bjp-23953	36	6	reduced	reduce	VERB
bjp-23953	36	7	to	to	ADP
bjp-23953	36	8	35	35	NUM
bjp-23953	36	9	mg	mg	PROPN
bjp-23953	36	10	/	/	SYM
bjp-23953	36	11	m2	m2	PROPN
bjp-23953	36	12	/	/	SYM
bjp-23953	36	13	day	day	NOUN
bjp-23953	36	14	assuming	assume	VERB
bjp-23953	36	15	that	that	SCONJ
bjp-23953	36	16	any	any	DET
bjp-23953	36	17	one	one	NUM
bjp-23953	36	18	of	of	ADP
bjp-23953	36	19	the	the	DET
bjp-23953	36	20	items	item	NOUN
bjp-23953	36	21	listed	list	VERB
bjp-23953	36	22	below	below	ADV
bjp-23953	36	23	was	be	AUX
bjp-23953	36	24	noticed	notice	VERB
bjp-23953	36	25	in	in	ADP
bjp-23953	36	26	the	the	DET
bjp-23953	36	27	process	process	NOUN
bjp-23953	36	28	of	of	ADP
bjp-23953	36	29	the	the	DET
bjp-23953	36	30	previous	previous	ADJ
bjp-23953	36	31	course	course	NOUN
bjp-23953	36	32	:	:	PUNCT
bjp-23953	36	33	leukocyte	leukocyte	NOUN
bjp-23953	36	34	count	count	NOUN
bjp-23953	36	35	<	<	X
bjp-23953	36	36	1000	1000	NUM
bjp-23953	36	37	/	/	SYM
bjp-23953	36	38	mm3	mm3	ADJ
bjp-23953	36	39	,	,	PUNCT
bjp-23953	36	40	platelet	platelet	NOUN
bjp-23953	36	41	count	count	NOUN
bjp-23953	36	42	<	<	PROPN
bjp-23953	36	43	20,000	20,000	NUM
bjp-23953	36	44	/	/	SYM
bjp-23953	36	45	mm3	mm3	ADJ
bjp-23953	36	46	,	,	PUNCT
bjp-23953	36	47	grade	grade	NOUN
bjp-23953	36	48	3	3	NUM
bjp-23953	36	49	febrile	febrile	NOUN
bjp-23953	36	50	neutropenia	neutropenia	NOUN
bjp-23953	36	51	,	,	PUNCT
bjp-23953	36	52	or	or	CCONJ
bjp-23953	36	53	grade	grade	NOUN
bjp-23953	36	54	3	3	NUM
bjp-23953	36	55	non	non	ADJ
bjp-23953	36	56	-	-	ADJ
bjp-23953	36	57	hematological	hematological	ADJ
bjp-23953	36	58	toxicity	toxicity	NOUN
bjp-23953	36	59	(	(	PUNCT
bjp-23953	36	60	except	except	SCONJ
bjp-23953	36	61	nausea	nausea	NOUN
bjp-23953	36	62	,	,	PUNCT
bjp-23953	36	63	anorexia	anorexia	PROPN
bjp-23953	36	64	,	,	PUNCT
bjp-23953	36	65	weight	weight	NOUN
bjp-23953	36	66	loss	loss	NOUN
bjp-23953	36	67	,	,	PUNCT
bjp-23953	36	68	creatinine	creatinine	NOUN
bjp-23953	36	69	,	,	PUNCT
bjp-23953	36	70	hyponatremia	hyponatremia	PROPN
bjp-23953	36	71	,	,	PUNCT
bjp-23953	36	72	hyperglycemia	hyperglycemia	NOUN
bjp-23953	36	73	or	or	CCONJ
bjp-23953	36	74	alopecia	alopecia	NOUN
bjp-23953	36	75	)	)	PUNCT
bjp-23953	36	76	.	.	PUNCT
bjp-23953	37	1	the	the	DET
bjp-23953	37	2	dosage	dosage	NOUN
bjp-23953	37	3	was	be	AUX
bjp-23953	37	4	decreased	decrease	VERB
bjp-23953	37	5	to	to	ADP
bjp-23953	37	6	30	30	NUM
bjp-23953	37	7	mg	mg	PROPN
bjp-23953	37	8	/	/	SYM
bjp-23953	37	9	m2	m2	PROPN
bjp-23953	37	10	/	/	SYM
bjp-23953	37	11	day	day	NOUN
bjp-23953	37	12	for	for	ADP
bjp-23953	37	13	the	the	DET
bjp-23953	37	14	second	second	ADJ
bjp-23953	37	15	time	time	NOUN
bjp-23953	37	16	in	in	ADP
bjp-23953	37	17	cycles	cycle	NOUN
bjp-23953	37	18	that	that	PRON
bjp-23953	37	19	followed	follow	VERB
bjp-23953	37	20	in	in	ADP
bjp-23953	37	21	accordance	accordance	NOUN
bjp-23953	37	22	with	with	ADP
bjp-23953	37	23	the	the	DET
bjp-23953	37	24	same	same	ADJ
bjp-23953	37	25	criteria	criterion	NOUN
bjp-23953	37	26	.	.	PUNCT
bjp-23953	38	1	in	in	ADP
bjp-23953	38	2	the	the	DET
bjp-23953	38	3	case	case	NOUN
bjp-23953	38	4	of	of	ADP
bjp-23953	38	5	grade	grade	NOUN
bjp-23953	38	6	4	4	NUM
bjp-23953	38	7	nonhematological	nonhematological	ADJ
bjp-23953	38	8	toxicity	toxicity	NOUN
bjp-23953	38	9	or	or	CCONJ
bjp-23953	38	10	continued	continue	VERB
bjp-23953	38	11	toxicity	toxicity	NOUN
bjp-23953	38	12	that	that	PRON
bjp-23953	38	13	might	might	AUX
bjp-23953	38	14	have	have	AUX
bjp-23953	38	15	necessitated	necessitate	VERB
bjp-23953	38	16	a	a	DET
bjp-23953	38	17	reduction	reduction	NOUN
bjp-23953	38	18	of	of	ADP
bjp-23953	38	19	dosage	dosage	NOUN
bjp-23953	38	20	for	for	ADP
bjp-23953	38	21	the	the	DET
bjp-23953	38	22	third	third	ADJ
bjp-23953	38	23	time	time	NOUN
bjp-23953	38	24	,	,	PUNCT
bjp-23953	38	25	the	the	DET
bjp-23953	38	26	protocol	protocol	NOUN
bjp-23953	38	27	of	of	ADP
bjp-23953	38	28	the	the	DET
bjp-23953	38	29	treatment	treatment	NOUN
bjp-23953	38	30	was	be	AUX
bjp-23953	38	31	discontinued	discontinue	VERB
bjp-23953	38	32	.	.	PUNCT
bjp-23953	39	1	evaluation	evaluation	NOUN
bjp-23953	39	2	the	the	DET
bjp-23953	39	3	response	response	NOUN
bjp-23953	39	4	evaluation	evaluation	NOUN
bjp-23953	39	5	criteria	criterion	NOUN
bjp-23953	39	6	in	in	ADP
bjp-23953	39	7	solid	solid	ADJ
bjp-23953	39	8	tumors	tumor	NOUN
bjp-23953	39	9	guidelines	guideline	NOUN
bjp-23953	39	10	(	(	PUNCT
bjp-23953	39	11	ver	ver	NOUN
bjp-23953	39	12	.	.	PROPN
bjp-23953	39	13	1.0	1.0	NUM
bjp-23953	39	14	)	)	PUNCT
bjp-23953	39	15	wre	wre	PRON
bjp-23953	39	16	made	make	VERB
bjp-23953	39	17	use	use	NOUN
bjp-23953	39	18	of	of	ADP
bjp-23953	39	19	in	in	ADP
bjp-23953	39	20	order	order	NOUN
bjp-23953	39	21	to	to	PART
bjp-23953	39	22	make	make	VERB
bjp-23953	39	23	an	an	DET
bjp-23953	39	24	evaluation	evaluation	NOUN
bjp-23953	39	25	of	of	ADP
bjp-23953	39	26	any	any	DET
bjp-23953	39	27	tumor	tumor	NOUN
bjp-23953	39	28	response	response	NOUN
bjp-23953	39	29	.	.	PUNCT
bjp-23953	40	1	calculated	calculate	VERB
bjp-23953	40	2	tomography	tomography	NOUN
bjp-23953	40	3	was	be	AUX
bjp-23953	40	4	employed	employ	VERB
bjp-23953	40	5	at	at	ADP
bjp-23953	40	6	baseline	baseline	NOUN
bjp-23953	40	7	in	in	ADP
bjp-23953	40	8	at	at	ADP
bjp-23953	40	9	least	least	ADJ
bjp-23953	40	10	every	every	DET
bjp-23953	40	11	two	two	NUM
bjp-23953	40	12	cycles	cycle	NOUN
bjp-23953	40	13	.	.	PUNCT
bjp-23953	41	1	verification	verification	NOUN
bjp-23953	41	2	of	of	ADP
bjp-23953	41	3	a	a	DET
bjp-23953	41	4	cr	cr	NOUN
bjp-23953	41	5	or	or	CCONJ
bjp-23953	41	6	pr	pr	NOUN
bjp-23953	41	7	was	be	AUX
bjp-23953	41	8	obligatory	obligatory	ADJ
bjp-23953	41	9	at	at	ADV
bjp-23953	41	10	least	least	ADV
bjp-23953	41	11	four	four	NUM
bjp-23953	41	12	weeks	week	NOUN
bjp-23953	41	13	subsequent	subsequent	ADJ
bjp-23953	41	14	to	to	ADP
bjp-23953	41	15	the	the	DET
bjp-23953	41	16	first	first	ADJ
bjp-23953	41	17	corroboration	corroboration	NOUN
bjp-23953	41	18	of	of	ADP
bjp-23953	41	19	a	a	DET
bjp-23953	41	20	response	response	NOUN
bjp-23953	41	21	.	.	PUNCT
bjp-23953	42	1	for	for	ADP
bjp-23953	42	2	those	those	DET
bjp-23953	42	3	patients	patient	NOUN
bjp-23953	42	4	whose	whose	DET
bjp-23953	42	5	tumor	tumor	NOUN
bjp-23953	42	6	was	be	AUX
bjp-23953	42	7	found	find	VERB
bjp-23953	42	8	to	to	PART
bjp-23953	42	9	shrink	shrink	VERB
bjp-23953	42	10	to	to	ADP
bjp-23953	42	11	a	a	DET
bjp-23953	42	12	more	more	ADV
bjp-23953	42	13	or	or	CCONJ
bjp-23953	42	14	less	less	ADJ
bjp-23953	42	15	extent	extent	NOUN
bjp-23953	42	16	,	,	PUNCT
bjp-23953	42	17	an	an	DET
bjp-23953	42	18	independent	independent	ADJ
bjp-23953	42	19	review	review	NOUN
bjp-23953	42	20	of	of	ADP
bjp-23953	42	21	any	any	DET
bjp-23953	42	22	response	response	NOUN
bjp-23953	42	23	of	of	ADP
bjp-23953	42	24	the	the	DET
bjp-23953	42	25	tumor	tumor	NOUN
bjp-23953	42	26	by	by	ADP
bjp-23953	42	27	an	an	DET
bjp-23953	42	28	independent	independent	ADJ
bjp-23953	42	29	panel	panel	NOUN
bjp-23953	42	30	,	,	PUNCT
bjp-23953	42	31	consisting	consist	VERB
bjp-23953	42	32	of	of	ADP
bjp-23953	42	33	at	at	ADV
bjp-23953	42	34	least	least	ADJ
bjp-23953	42	35	a	a	DET
bjp-23953	42	36	diagnostic	diagnostic	ADJ
bjp-23953	42	37	radiologist	radiologist	NOUN
bjp-23953	42	38	,	,	PUNCT
bjp-23953	42	39	was	be	AUX
bjp-23953	42	40	later	later	ADV
bjp-23953	42	41	conducted	conduct	VERB
bjp-23953	42	42	.	.	PUNCT
bjp-23953	43	1	any	any	DET
bjp-23953	43	2	detrimental	detrimental	ADJ
bjp-23953	43	3	effects	effect	NOUN
bjp-23953	43	4	were	be	AUX
bjp-23953	43	5	put	put	VERB
bjp-23953	43	6	down	down	ADP
bjp-23953	43	7	in	in	ADP
bjp-23953	43	8	writing	writing	NOUN
bjp-23953	43	9	by	by	ADP
bjp-23953	43	10	means	mean	NOUN
bjp-23953	43	11	of	of	ADP
bjp-23953	43	12	the	the	DET
bjp-23953	43	13	common	common	ADJ
bjp-23953	43	14	terminology	terminology	NOUN
bjp-23953	43	15	criteria	criterion	NOUN
bjp-23953	43	16	for	for	ADP
bjp-23953	43	17	adverse	adverse	ADJ
bjp-23953	43	18	events	event	NOUN
bjp-23953	43	19	(	(	PUNCT
bjp-23953	43	20	ver	ver	NOUN
bjp-23953	43	21	.	.	PROPN
bjp-23953	43	22	3.0	3.0	NUM
bjp-23953	43	23	)	)	PUNCT
bjp-23953	43	24	.	.	PUNCT
bjp-23953	44	1	an	an	DET
bjp-23953	44	2	assessment	assessment	NOUN
bjp-23953	44	3	of	of	ADP
bjp-23953	44	4	cardiotoxicity	cardiotoxicity	NOUN
bjp-23953	44	5	was	be	AUX
bjp-23953	44	6	carried	carry	VERB
bjp-23953	44	7	out	out	ADP
bjp-23953	44	8	as	as	SCONJ
bjp-23953	44	9	planned	plan	VERB
bjp-23953	44	10	according	accord	VERB
bjp-23953	44	11	to	to	ADP
bjp-23953	44	12	the	the	DET
bjp-23953	44	13	judgment	judgment	NOUN
bjp-23953	44	14	of	of	ADP
bjp-23953	44	15	the	the	DET
bjp-23953	44	16	physician	physician	NOUN
bjp-23953	44	17	.	.	PUNCT
bjp-23953	45	1	patients	patient	NOUN
bjp-23953	45	2	were	be	AUX
bjp-23953	45	3	provided	provide	VERB
bjp-23953	45	4	with	with	ADP
bjp-23953	45	5	full	full	ADJ
bjp-23953	45	6	supportive	supportive	ADJ
bjp-23953	45	7	care	care	NOUN
bjp-23953	45	8	as	as	SCONJ
bjp-23953	45	9	needed	need	VERB
bjp-23953	45	10	,	,	PUNCT
bjp-23953	45	11	consisting	consist	VERB
bjp-23953	45	12	of	of	ADP
bjp-23953	45	13	blood	blood	NOUN
bjp-23953	45	14	transfusion	transfusion	NOUN
bjp-23953	45	15	.	.	PUNCT
bjp-23953	46	1	the	the	DET
bjp-23953	46	2	plan	plan	NOUN
bjp-23953	46	3	for	for	ADP
bjp-23953	46	4	treatment	treatment	NOUN
bjp-23953	46	5	specified	specify	VERB
bjp-23953	46	6	that	that	SCONJ
bjp-23953	46	7	granulocyte	granulocyte	ADJ
bjp-23953	46	8	colony	colony	NOUN
bjp-23953	46	9	-	-	PUNCT
bjp-23953	46	10	stimulating	stimulate	VERB
bjp-23953	46	11	factor	factor	NOUN
bjp-23953	46	12	(	(	PUNCT
bjp-23953	46	13	g	g	NOUN
bjp-23953	46	14	-	-	PUNCT
bjp-23953	46	15	csf	csf	NOUN
bjp-23953	46	16	)	)	PUNCT
bjp-23953	46	17	ought	ought	AUX
bjp-23953	46	18	to	to	PART
bjp-23953	46	19	be	be	AUX
bjp-23953	46	20	made	make	VERB
bjp-23953	46	21	use	use	NOUN
bjp-23953	46	22	of	of	ADP
bjp-23953	46	23	in	in	ADP
bjp-23953	46	24	compliance	compliance	NOUN
bjp-23953	46	25	with	with	ADP
bjp-23953	46	26	the	the	DET
bjp-23953	46	27	national	national	PROPN
bjp-23953	46	28	health	health	PROPN
bjp-23953	46	29	insurance	insurance	NOUN
bjp-23953	46	30	coverage	coverage	NOUN
bjp-23953	46	31	of	of	ADP
bjp-23953	46	32	china	china	PROPN
bjp-23953	46	33	.	.	PUNCT
bjp-23953	47	1	furthermore	furthermore	ADV
bjp-23953	47	2	,	,	PUNCT
bjp-23953	47	3	indications	indication	NOUN
bjp-23953	47	4	for	for	ADP
bjp-23953	47	5	g	g	NOUN
bjp-23953	47	6	-	-	PUNCT
bjp-23953	47	7	csf	csf	ADJ
bjp-23953	47	8	administration	administration	NOUN
bjp-23953	47	9	were	be	AUX
bjp-23953	47	10	stated	state	VERB
bjp-23953	47	11	as	as	SCONJ
bjp-23953	47	12	follows	follow	VERB
bjp-23953	47	13	:	:	PUNCT
bjp-23953	47	14	a	a	X
bjp-23953	47	15	)	)	PUNCT
bjp-23953	47	16	when	when	SCONJ
bjp-23953	47	17	fever	fever	NOUN
bjp-23953	47	18	(	(	PUNCT
bjp-23953	47	19	for	for	ADP
bjp-23953	47	20	the	the	DET
bjp-23953	47	21	most	most	ADJ
bjp-23953	47	22	part	part	NOUN
bjp-23953	47	23	more	more	ADJ
bjp-23953	47	24	than	than	ADP
bjp-23953	47	25	38	38	NUM
bjp-23953	47	26	°	°	NOUN
bjp-23953	47	27	c	c	NOUN
bjp-23953	47	28	)	)	PUNCT
bjp-23953	47	29	was	be	AUX
bjp-23953	47	30	noticed	notice	VERB
bjp-23953	47	31	with	with	ADP
bjp-23953	47	32	a	a	DET
bjp-23953	47	33	neutrophil	neutrophil	ADJ
bjp-23953	47	34	count	count	NOUN
bjp-23953	47	35	of	of	ADP
bjp-23953	47	36	≤1000	≤1000	NUM
bjp-23953	47	37	/	/	SYM
bjp-23953	47	38	mm3	mm3	ADJ
bjp-23953	47	39	;	;	PUNCT
bjp-23953	47	40	b	b	X
bjp-23953	47	41	)	)	PUNCT
bjp-23953	47	42	when	when	SCONJ
bjp-23953	47	43	a	a	DET
bjp-23953	47	44	neutrophil	neutrophil	ADJ
bjp-23953	47	45	count	count	NOUN
bjp-23953	47	46	of	of	ADP
bjp-23953	47	47	500	500	NUM
bjp-23953	47	48	/	/	SYM
bjp-23953	47	49	mm3	mm3	NOUN
bjp-23953	47	50	was	be	AUX
bjp-23953	47	51	observed	observe	VERB
bjp-23953	47	52	;	;	PUNCT
bjp-23953	48	1	c	c	X
bjp-23953	48	2	)	)	PUNCT
bjp-23953	48	3	during	during	ADP
bjp-23953	48	4	the	the	DET
bjp-23953	48	5	previous	previous	ADJ
bjp-23953	48	6	course	course	NOUN
bjp-23953	48	7	,	,	PUNCT
bjp-23953	48	8	if	if	SCONJ
bjp-23953	48	9	fever	fever	NOUN
bjp-23953	48	10	(	(	PUNCT
bjp-23953	48	11	for	for	ADP
bjp-23953	48	12	the	the	DET
bjp-23953	48	13	most	most	ADJ
bjp-23953	48	14	part	part	NOUN
bjp-23953	48	15	more	more	ADJ
bjp-23953	48	16	than	than	ADP
bjp-23953	48	17	38	38	NUM
bjp-23953	48	18	°	°	NOUN
bjp-23953	48	19	c	c	NOUN
bjp-23953	48	20	)	)	PUNCT
bjp-23953	48	21	with	with	ADP
bjp-23953	48	22	a	a	DET
bjp-23953	48	23	neutrophil	neutrophil	ADJ
bjp-23953	48	24	count	count	NOUN
bjp-23953	48	25	of	of	ADP
bjp-23953	48	26	≤1000	≤1000	NOUN
bjp-23953	48	27	/	/	SYM
bjp-23953	48	28	mm3	mm3	NOUN
bjp-23953	48	29	was	be	AUX
bjp-23953	48	30	observed	observe	VERB
bjp-23953	48	31	,	,	PUNCT
bjp-23953	48	32	or	or	CCONJ
bjp-23953	48	33	if	if	SCONJ
bjp-23953	48	34	a	a	DET
bjp-23953	48	35	neutrophil	neutrophil	ADJ
bjp-23953	48	36	count	count	NOUN
bjp-23953	48	37	of	of	ADP
bjp-23953	48	38	500	500	NUM
bjp-23953	48	39	/	/	SYM
bjp-23953	48	40	mm3	mm3	NOUN
bjp-23953	48	41	was	be	AUX
bjp-23953	48	42	observed	observe	VERB
bjp-23953	48	43	,	,	PUNCT
bjp-23953	48	44	then	then	ADV
bjp-23953	48	45	after	after	ADP
bjp-23953	48	46	concluding	conclude	VERB
bjp-23953	48	47	the	the	DET
bjp-23953	48	48	same	same	ADJ
bjp-23953	48	49	chemotherapy	chemotherapy	NOUN
bjp-23953	48	50	,	,	PUNCT
bjp-23953	48	51	if	if	SCONJ
bjp-23953	48	52	a	a	DET
bjp-23953	48	53	neutrophil	neutrophil	ADJ
bjp-23953	48	54	count	count	NOUN
bjp-23953	48	55	of	of	ADP
bjp-23953	48	56	≤	≤	NUM
bjp-23953	48	57	1000	1000	NUM
bjp-23953	48	58	/	/	SYM
bjp-23953	48	59	mm3	mm3	NOUN
bjp-23953	48	60	was	be	AUX
bjp-23953	48	61	observed	observe	VERB
bjp-23953	48	62	.	.	PUNCT
bjp-23953	49	1	no	no	DET
bjp-23953	49	2	more	more	ADJ
bjp-23953	49	3	restriction	restriction	NOUN
bjp-23953	49	4	whatever	whatever	PRON
bjp-23953	49	5	for	for	ADP
bjp-23953	49	6	the	the	DET
bjp-23953	49	7	purpose	purpose	NOUN
bjp-23953	49	8	of	of	ADP
bjp-23953	49	9	following	follow	VERB
bjp-23953	49	10	chemotherapy	chemotherapy	NOUN
bjp-23953	49	11	was	be	AUX
bjp-23953	49	12	necessary	necessary	ADJ
bjp-23953	49	13	after	after	ADP
bjp-23953	49	14	worsening	worsen	VERB
bjp-23953	49	15	of	of	ADP
bjp-23953	49	16	the	the	DET
bjp-23953	49	17	disease	disease	NOUN
bjp-23953	49	18	in	in	ADP
bjp-23953	49	19	this	this	DET
bjp-23953	49	20	study	study	NOUN
bjp-23953	49	21	.	.	PUNCT
bjp-23953	50	1	statistical	statistical	ADJ
bjp-23953	50	2	analysis	analysis	NOUN
bjp-23953	50	3	data	datum	NOUN
bjp-23953	50	4	are	be	AUX
bjp-23953	50	5	presented	present	VERB
bjp-23953	50	6	using	use	VERB
bjp-23953	50	7	spss	spss	PROPN
bjp-23953	50	8	version	version	NOUN
bjp-23953	50	9	17.0	17.0	NUM
bjp-23953	50	10	as	as	SCONJ
bjp-23953	50	11	means	mean	VERB
bjp-23953	50	12	±	±	NUM
bjp-23953	50	13	standard	standard	ADJ
bjp-23953	50	14	deviation	deviation	NOUN
bjp-23953	50	15	.	.	PUNCT
bjp-23953	51	1	statistical	statistical	ADJ
bjp-23953	51	2	significances	significance	NOUN
bjp-23953	51	3	of	of	ADP
bjp-23953	51	4	differences	difference	NOUN
bjp-23953	51	5	were	be	AUX
bjp-23953	51	6	determined	determine	VERB
bjp-23953	51	7	using	use	VERB
bjp-23953	51	8	student	student	NOUN
bjp-23953	51	9	t	t	PROPN
bjp-23953	51	10	-	-	PUNCT
bjp-23953	51	11	test	test	NOUN
bjp-23953	51	12	.	.	PUNCT
bjp-23953	52	1	a	a	DET
bjp-23953	52	2	value	value	NOUN
bjp-23953	52	3	of	of	ADP
bjp-23953	52	4	p<0.05	p<0.05	NOUN
bjp-23953	52	5	was	be	AUX
bjp-23953	52	6	considered	consider	VERB
bjp-23953	52	7	statistically	statistically	ADV
bjp-23953	52	8	significant	significant	ADJ
bjp-23953	52	9	.	.	PUNCT
bjp-23953	53	1	results	result	NOUN
bjp-23953	53	2	patient	patient	ADJ
bjp-23953	53	3	characteristics	characteristic	NOUN
bjp-23953	53	4	a	a	DET
bjp-23953	53	5	total	total	NOUN
bjp-23953	53	6	of	of	ADP
bjp-23953	53	7	95	95	NUM
bjp-23953	53	8	patients	patient	NOUN
bjp-23953	53	9	(	(	PUNCT
bjp-23953	53	10	11	11	NUM
bjp-23953	53	11	women	woman	NOUN
bjp-23953	53	12	and	and	CCONJ
bjp-23953	53	13	84	84	NUM
bjp-23953	53	14	men	man	NOUN
bjp-23953	53	15	;	;	PUNCT
bjp-23953	53	16	median	median	ADJ
bjp-23953	53	17	age	age	NOUN
bjp-23953	53	18	,	,	PUNCT
bjp-23953	53	19	63	63	NUM
bjp-23953	53	20	years	year	NOUN
bjp-23953	53	21	)	)	PUNCT
bjp-23953	53	22	from	from	ADP
bjp-23953	53	23	the	the	DET
bjp-23953	53	24	309th	309th	ADJ
bjp-23953	53	25	hospital	hospital	NOUN
bjp-23953	53	26	of	of	ADP
bjp-23953	53	27	chinese	chinese	ADJ
bjp-23953	53	28	pla	pla	PROPN
bjp-23953	53	29	were	be	AUX
bjp-23953	53	30	enrolled	enrol	VERB
bjp-23953	53	31	in	in	ADP
bjp-23953	53	32	this	this	DET
bjp-23953	53	33	study	study	NOUN
bjp-23953	53	34	from	from	ADP
bjp-23953	53	35	september	september	PROPN
bjp-23953	53	36	2012	2012	NUM
bjp-23953	53	37	to	to	ADP
bjp-23953	53	38	december	december	PROPN
bjp-23953	53	39	2014	2014	NUM
bjp-23953	53	40	(	(	PUNCT
bjp-23953	53	41	table	table	NOUN
bjp-23953	53	42	i	i	NOUN
bjp-23953	53	43	)	)	PUNCT
bjp-23953	53	44	.	.	PUNCT
bjp-23953	54	1	patients	patient	NOUN
bjp-23953	54	2	were	be	AUX
bjp-23953	54	3	eligible	eligible	ADJ
bjp-23953	54	4	for	for	ADP
bjp-23953	54	5	analysis	analysis	NOUN
bjp-23953	54	6	of	of	ADP
bjp-23953	54	7	the	the	DET
bjp-23953	54	8	efficacy	efficacy	NOUN
bjp-23953	54	9	and	and	CCONJ
bjp-23953	54	10	safety	safety	NOUN
bjp-23953	54	11	of	of	ADP
bjp-23953	54	12	amrubicin	amrubicin	PROPN
bjp-23953	54	13	.	.	PUNCT
bjp-23953	55	1	all	all	DET
bjp-23953	55	2	enrolled	enrol	VERB
bjp-23953	55	3	patients	patient	NOUN
bjp-23953	55	4	received	receive	VERB
bjp-23953	55	5	prior	prior	ADV
bjp-23953	55	6	platinum	platinum	NOUN
bjp-23953	55	7	-	-	PUNCT
bjp-23953	55	8	based	base	VERB
bjp-23953	55	9	chemotherapy	chemotherapy	NOUN
bjp-23953	55	10	,	,	PUNCT
bjp-23953	55	11	including	include	VERB
bjp-23953	55	12	pretreatment	pretreatment	NOUN
bjp-23953	55	13	with	with	ADP
bjp-23953	55	14	cisplatincontaining	cisplatincontaine	VERB
bjp-23953	55	15	regimens	regimen	NOUN
bjp-23953	55	16	(	(	PUNCT
bjp-23953	55	17	n	n	NOUN
bjp-23953	55	18	=	=	SYM
bjp-23953	55	19	69	69	NUM
bjp-23953	55	20	;	;	PUNCT
bjp-23953	55	21	72.6	72.6	NUM
bjp-23953	55	22	%	%	NOUN
bjp-23953	55	23	)	)	PUNCT
bjp-23953	55	24	,	,	PUNCT
bjp-23953	55	25	carboplatin	carboplatin	NOUN
bjp-23953	55	26	-	-	PUNCT
bjp-23953	55	27	conbangladesh	conbangladesh	NOUN
bjp-23953	55	28	j	j	PROPN
bjp-23953	55	29	pharmacol	pharmacol	PROPN
bjp-23953	55	30	2016	2016	NUM
bjp-23953	55	31	;	;	PUNCT
bjp-23953	55	32	11	11	NUM
bjp-23953	55	33	:	:	SYM
bjp-23953	55	34	564	564	NUM
bjp-23953	55	35	-	-	SYM
bjp-23953	55	36	569	569	NUM
bjp-23953	55	37	565	565	NUM
bjp-23953	55	38	taining	taine	VERB
bjp-23953	55	39	regimens	regimen	NOUN
bjp-23953	55	40	(	(	PUNCT
bjp-23953	55	41	n	n	NOUN
bjp-23953	55	42	=	=	SYM
bjp-23953	55	43	19	19	NUM
bjp-23953	55	44	;	;	PUNCT
bjp-23953	55	45	20.0	20.0	NUM
bjp-23953	55	46	%	%	NOUN
bjp-23953	55	47	)	)	PUNCT
bjp-23953	55	48	,	,	PUNCT
bjp-23953	55	49	cisplatin	cisplatin	NOUN
bjp-23953	55	50	and	and	CCONJ
bjp-23953	55	51	carboplatin	carboplatin	NOUN
bjp-23953	55	52	-	-	PUNCT
bjp-23953	55	53	containing	contain	VERB
bjp-23953	55	54	regimens	regimen	NOUN
bjp-23953	55	55	(	(	PUNCT
bjp-23953	55	56	n	n	NOUN
bjp-23953	55	57	=	=	SYM
bjp-23953	55	58	7	7	NUM
bjp-23953	55	59	;	;	PUNCT
bjp-23953	55	60	77.4	77.4	NUM
bjp-23953	55	61	%	%	NOUN
bjp-23953	55	62	)	)	PUNCT
bjp-23953	55	63	,	,	PUNCT
bjp-23953	55	64	irinotecancontaining	irinotecancontaine	VERB
bjp-23953	55	65	chemotherapy	chemotherapy	NOUN
bjp-23953	55	66	regimens	regimen	NOUN
bjp-23953	55	67	(	(	PUNCT
bjp-23953	55	68	n	n	NOUN
bjp-23953	55	69	=	=	SYM
bjp-23953	55	70	50	50	NUM
bjp-23953	55	71	;	;	PUNCT
bjp-23953	55	72	52.6	52.6	NUM
bjp-23953	55	73	%	%	NOUN
bjp-23953	55	74	)	)	PUNCT
bjp-23953	55	75	,	,	PUNCT
bjp-23953	55	76	etoposide	etoposide	NOUN
bjp-23953	55	77	-	-	PUNCT
bjp-23953	55	78	containing	contain	VERB
bjp-23953	55	79	chemotherapy	chemotherapy	NOUN
bjp-23953	55	80	regimens	regimen	NOUN
bjp-23953	55	81	(	(	PUNCT
bjp-23953	55	82	n	n	NOUN
bjp-23953	55	83	=	=	SYM
bjp-23953	55	84	43	43	NUM
bjp-23953	55	85	;	;	PUNCT
bjp-23953	55	86	45.3	45.3	NUM
bjp-23953	55	87	%	%	NOUN
bjp-23953	55	88	)	)	PUNCT
bjp-23953	55	89	and	and	CCONJ
bjp-23953	55	90	topotecan	topotecan	NOUN
bjp-23953	55	91	-	-	PUNCT
bjp-23953	55	92	containing	contain	VERB
bjp-23953	55	93	regimens	regimen	NOUN
bjp-23953	55	94	(	(	PUNCT
bjp-23953	55	95	n	n	NOUN
bjp-23953	55	96	=	=	SYM
bjp-23953	55	97	2	2	NUM
bjp-23953	55	98	;	;	PUNCT
bjp-23953	55	99	2.1	2.1	NUM
bjp-23953	55	100	%	%	NOUN
bjp-23953	55	101	)	)	PUNCT
bjp-23953	55	102	.	.	PUNCT
bjp-23953	56	1	response	response	NOUN
bjp-23953	56	2	among	among	ADP
bjp-23953	56	3	the	the	DET
bjp-23953	56	4	total	total	ADJ
bjp-23953	56	5	study	study	NOUN
bjp-23953	56	6	population	population	NOUN
bjp-23953	56	7	,	,	PUNCT
bjp-23953	56	8	complete	complete	ADJ
bjp-23953	56	9	response	response	NOUN
bjp-23953	56	10	was	be	AUX
bjp-23953	56	11	achieved	achieve	VERB
bjp-23953	56	12	in	in	ADP
bjp-23953	56	13	5	5	NUM
bjp-23953	56	14	patients	patient	NOUN
bjp-23953	56	15	(	(	PUNCT
bjp-23953	56	16	5.3	5.3	NUM
bjp-23953	56	17	%	%	NOUN
bjp-23953	56	18	)	)	PUNCT
bjp-23953	56	19	,	,	PUNCT
bjp-23953	56	20	partial	partial	ADJ
bjp-23953	56	21	response	response	NOUN
bjp-23953	56	22	in	in	ADP
bjp-23953	56	23	32	32	NUM
bjp-23953	56	24	patients	patient	NOUN
bjp-23953	56	25	(	(	PUNCT
bjp-23953	56	26	33.9	33.9	NUM
bjp-23953	56	27	%	%	NOUN
bjp-23953	56	28	)	)	PUNCT
bjp-23953	56	29	,	,	PUNCT
bjp-23953	56	30	stable	stable	ADJ
bjp-23953	56	31	disease	disease	NOUN
bjp-23953	56	32	in	in	ADP
bjp-23953	56	33	41	41	NUM
bjp-23953	56	34	patients	patient	NOUN
bjp-23953	56	35	(	(	PUNCT
bjp-23953	56	36	43.2	43.2	NUM
bjp-23953	56	37	%	%	NOUN
bjp-23953	56	38	)	)	PUNCT
bjp-23953	56	39	,	,	PUNCT
bjp-23953	56	40	and	and	CCONJ
bjp-23953	56	41	progressive	progressive	ADJ
bjp-23953	56	42	disease	disease	NOUN
bjp-23953	56	43	in	in	ADP
bjp-23953	56	44	16	16	NUM
bjp-23953	56	45	patients	patient	NOUN
bjp-23953	56	46	(	(	PUNCT
bjp-23953	56	47	16.8	16.8	NUM
bjp-23953	56	48	%	%	NOUN
bjp-23953	56	49	)	)	PUNCT
bjp-23953	56	50	after	after	ADP
bjp-23953	56	51	treatment	treatment	NOUN
bjp-23953	56	52	with	with	ADP
bjp-23953	56	53	amrubicin	amrubicin	PROPN
bjp-23953	56	54	(	(	PUNCT
bjp-23953	56	55	table	table	NOUN
bjp-23953	56	56	ii	ii	PROPN
bjp-23953	56	57	)	)	PUNCT
bjp-23953	56	58	.	.	PUNCT
bjp-23953	57	1	thus	thus	ADV
bjp-23953	57	2	,	,	PUNCT
bjp-23953	57	3	for	for	ADP
bjp-23953	57	4	amrubicin	amrubicin	NOUN
bjp-23953	57	5	therapy	therapy	NOUN
bjp-23953	57	6	,	,	PUNCT
bjp-23953	57	7	an	an	DET
bjp-23953	57	8	overall	overall	ADJ
bjp-23953	57	9	response	response	NOUN
bjp-23953	57	10	rate	rate	NOUN
bjp-23953	57	11	of	of	ADP
bjp-23953	57	12	39.0	39.0	NUM
bjp-23953	57	13	%	%	NOUN
bjp-23953	57	14	was	be	AUX
bjp-23953	57	15	observed	observe	VERB
bjp-23953	57	16	.	.	PUNCT
bjp-23953	58	1	survival	survival	NOUN
bjp-23953	58	2	the	the	DET
bjp-23953	58	3	median	median	ADJ
bjp-23953	58	4	follow	follow	VERB
bjp-23953	58	5	-	-	PUNCT
bjp-23953	58	6	up	up	NOUN
bjp-23953	58	7	time	time	NOUN
bjp-23953	58	8	of	of	ADP
bjp-23953	58	9	all	all	DET
bjp-23953	58	10	registered	register	VERB
bjp-23953	58	11	patients	patient	NOUN
bjp-23953	58	12	was	be	AUX
bjp-23953	58	13	9.1	9.1	NUM
bjp-23953	58	14	months	month	NOUN
bjp-23953	58	15	(	(	PUNCT
bjp-23953	58	16	1.3	1.3	NUM
bjp-23953	58	17	-	-	SYM
bjp-23953	58	18	25.1	25.1	NUM
bjp-23953	58	19	months	month	NOUN
bjp-23953	58	20	)	)	PUNCT
bjp-23953	58	21	at	at	ADP
bjp-23953	58	22	the	the	DET
bjp-23953	58	23	cutoff	cutoff	NOUN
bjp-23953	58	24	date	date	NOUN
bjp-23953	58	25	for	for	ADP
bjp-23953	58	26	data	data	NOUN
bjp-23953	58	27	collection	collection	NOUN
bjp-23953	58	28	.	.	PUNCT
bjp-23953	59	1	of	of	ADP
bjp-23953	59	2	the	the	DET
bjp-23953	59	3	95	95	NUM
bjp-23953	59	4	patients	patient	NOUN
bjp-23953	59	5	,	,	PUNCT
bjp-23953	59	6	78	78	NUM
bjp-23953	59	7	patients	patient	NOUN
bjp-23953	59	8	(	(	PUNCT
bjp-23953	59	9	82.1	82.1	NUM
bjp-23953	59	10	%	%	NOUN
bjp-23953	59	11	)	)	PUNCT
bjp-23953	59	12	until	until	ADP
bjp-23953	59	13	death	death	NOUN
bjp-23953	59	14	,	,	PUNCT
bjp-23953	59	15	and	and	CCONJ
bjp-23953	59	16	94	94	NUM
bjp-23953	59	17	patients	patient	NOUN
bjp-23953	59	18	(	(	PUNCT
bjp-23953	59	19	99.0	99.0	NUM
bjp-23953	59	20	%	%	NOUN
bjp-23953	59	21	)	)	PUNCT
bjp-23953	59	22	were	be	AUX
bjp-23953	59	23	observed	observe	VERB
bjp-23953	59	24	until	until	ADP
bjp-23953	59	25	table	table	NOUN
bjp-23953	59	26	i	i	PRON
bjp-23953	59	27	patient	patient	ADJ
bjp-23953	60	1	characteristics	characteristic	NOUN
bjp-23953	60	2	patients	patient	NOUN
bjp-23953	60	3	(	(	PUNCT
bjp-23953	60	4	n	n	NOUN
bjp-23953	60	5	=	=	SYM
bjp-23953	60	6	95	95	NUM
bjp-23953	60	7	)	)	PUNCT
bjp-23953	60	8	characteristics	characteristic	NOUN
bjp-23953	60	9	n	n	PRON
bjp-23953	60	10	%	%	NOUN
bjp-23953	60	11	age	age	NOUN
bjp-23953	60	12	(	(	PUNCT
bjp-23953	60	13	years	year	NOUN
bjp-23953	60	14	)	)	PUNCT
bjp-23953	60	15	63	63	NUM
bjp-23953	60	16	gender	gender	NOUN
bjp-23953	60	17	female	female	ADJ
bjp-23953	60	18	11	11	NUM
bjp-23953	60	19	11.58	11.58	NUM
bjp-23953	60	20	male	male	NOUN
bjp-23953	60	21	84	84	NUM
bjp-23953	60	22	88.42	88.42	NUM
bjp-23953	60	23	eastern	eastern	ADJ
bjp-23953	60	24	cooperative	cooperative	ADJ
bjp-23953	60	25	oncology	oncology	NOUN
bjp-23953	60	26	group	group	NOUN
bjp-23953	60	27	performance	performance	NOUN
bjp-23953	60	28	status	status	NOUN
bjp-23953	60	29	0	0	NUM
bjp-23953	60	30	40	40	NUM
bjp-23953	60	31	42.11	42.11	NUM
bjp-23953	60	32	1	1	NUM
bjp-23953	60	33	55	55	NUM
bjp-23953	60	34	57.89	57.89	NUM
bjp-23953	60	35	disease	disease	NOUN
bjp-23953	60	36	extent	extent	NOUN
bjp-23953	60	37	at	at	ADP
bjp-23953	60	38	entry	entry	NOUN
bjp-23953	60	39	limited	limit	VERB
bjp-23953	60	40	disease	disease	NOUN
bjp-23953	60	41	5	5	NUM
bjp-23953	60	42	5.26	5.26	NUM
bjp-23953	60	43	extensive	extensive	ADJ
bjp-23953	60	44	disease	disease	NOUN
bjp-23953	60	45	90	90	NUM
bjp-23953	60	46	94.74	94.74	NUM
bjp-23953	60	47	no	no	NOUN
bjp-23953	60	48	.	.	PUNCT
bjp-23953	61	1	of	of	ADP
bjp-23953	61	2	prior	prior	ADJ
bjp-23953	61	3	chemotherapy	chemotherapy	NOUN
bjp-23953	61	4	regimens	regimen	NOUN
bjp-23953	61	5	1	1	NUM
bjp-23953	61	6	78	78	NUM
bjp-23953	61	7	82.11	82.11	NUM
bjp-23953	61	8	2	2	NUM
bjp-23953	61	9	17	17	NUM
bjp-23953	61	10	17.89	17.89	NUM
bjp-23953	61	11	prior	prior	ADJ
bjp-23953	61	12	chemotherapy	chemotherapy	NOUN
bjp-23953	61	13	regimen	regiman	NOUN
bjp-23953	61	14	(	(	PUNCT
bjp-23953	61	15	multiple	multiple	ADJ
bjp-23953	61	16	choices	choice	NOUN
bjp-23953	61	17	)	)	PUNCT
bjp-23953	61	18	cisplatin	cisplatin	NOUN
bjp-23953	61	19	-	-	PUNCT
bjp-23953	61	20	containing	contain	VERB
bjp-23953	61	21	69	69	NUM
bjp-23953	61	22	72.63	72.63	NUM
bjp-23953	61	23	carboplatin	carboplatin	NOUN
bjp-23953	61	24	-	-	PUNCT
bjp-23953	61	25	containing	contain	VERB
bjp-23953	61	26	19	19	NUM
bjp-23953	61	27	20.00	20.00	NUM
bjp-23953	61	28	cisplatin	cisplatin	NOUN
bjp-23953	61	29	and	and	CCONJ
bjp-23953	61	30	carboplatin	carboplatin	NOUN
bjp-23953	61	31	-	-	PUNCT
bjp-23953	61	32	containing	contain	VERB
bjp-23953	61	33	7	7	NUM
bjp-23953	61	34	7.37	7.37	NUM
bjp-23953	61	35	irinotecan	irinotecan	NOUN
bjp-23953	61	36	-	-	PUNCT
bjp-23953	61	37	containing	contain	VERB
bjp-23953	61	38	50	50	NUM
bjp-23953	61	39	52.63	52.63	NUM
bjp-23953	61	40	etoposide	etoposide	NOUN
bjp-23953	61	41	-	-	PUNCT
bjp-23953	61	42	containing	contain	VERB
bjp-23953	61	43	43	43	NUM
bjp-23953	61	44	45.26	45.26	NUM
bjp-23953	61	45	topotecan	topotecan	NOUN
bjp-23953	61	46	-	-	PUNCT
bjp-23953	61	47	containing	contain	VERB
bjp-23953	61	48	2	2	NUM
bjp-23953	61	49	2.11	2.11	NUM
bjp-23953	61	50	response	response	NOUN
bjp-23953	61	51	to	to	ADP
bjp-23953	61	52	prior	prior	ADJ
bjp-23953	61	53	chemotherapy	chemotherapy	NOUN
bjp-23953	61	54	complete	complete	ADJ
bjp-23953	61	55	response	response	NOUN
bjp-23953	61	56	5	5	NUM
bjp-23953	61	57	5.26	5.26	NUM
bjp-23953	61	58	partial	partial	ADJ
bjp-23953	61	59	response	response	NOUN
bjp-23953	61	60	65	65	NUM
bjp-23953	61	61	68.42	68.42	NUM
bjp-23953	61	62	stable	stable	ADJ
bjp-23953	61	63	disease	disease	NOUN
bjp-23953	61	64	7	7	NUM
bjp-23953	61	65	7.37	7.37	NUM
bjp-23953	61	66	progressive	progressive	ADJ
bjp-23953	61	67	disease	disease	NOUN
bjp-23953	61	68	18	18	NUM
bjp-23953	61	69	18.95	18.95	NUM
bjp-23953	61	70	history	history	NOUN
bjp-23953	61	71	of	of	ADP
bjp-23953	61	72	thoracic	thoracic	NOUN
bjp-23953	61	73	radiation	radiation	NOUN
bjp-23953	61	74	therapy	therapy	NOUN
bjp-23953	61	75	no	no	DET
bjp-23953	61	76	74	74	NUM
bjp-23953	61	77	77.89	77.89	NUM
bjp-23953	61	78	yes	yes	NOUN
bjp-23953	61	79	21	21	NUM
bjp-23953	61	80	22.11	22.11	NUM
bjp-23953	61	81	566	566	NUM
bjp-23953	61	82	bangladesh	bangladesh	NOUN
bjp-23953	61	83	j	j	PROPN
bjp-23953	61	84	pharmacol	pharmacol	PROPN
bjp-23953	61	85	2016	2016	NUM
bjp-23953	61	86	;	;	PUNCT
bjp-23953	61	87	11	11	NUM
bjp-23953	61	88	:	:	SYM
bjp-23953	61	89	564	564	NUM
bjp-23953	61	90	-	-	SYM
bjp-23953	61	91	569	569	NUM
bjp-23953	61	92	disease	disease	NOUN
bjp-23953	61	93	progression	progression	NOUN
bjp-23953	61	94	.	.	PUNCT
bjp-23953	62	1	the	the	DET
bjp-23953	62	2	median	median	ADJ
bjp-23953	62	3	overall	overall	ADJ
bjp-23953	62	4	survival	survival	NOUN
bjp-23953	62	5	of	of	ADP
bjp-23953	62	6	all	all	DET
bjp-23953	62	7	registered	register	VERB
bjp-23953	62	8	patients	patient	NOUN
bjp-23953	62	9	was	be	AUX
bjp-23953	62	10	9.2	9.2	NUM
bjp-23953	62	11	months	month	NOUN
bjp-23953	62	12	(	(	PUNCT
bjp-23953	62	13	95	95	NUM
bjp-23953	62	14	%	%	NOUN
bjp-23953	62	15	ci	ci	NOUN
bjp-23953	62	16	,	,	PUNCT
bjp-23953	62	17	7.4	7.4	NUM
bjp-23953	62	18	-	-	SYM
bjp-23953	62	19	11.8	11.8	NUM
bjp-23953	62	20	months	month	NOUN
bjp-23953	62	21	)	)	PUNCT
bjp-23953	62	22	.	.	PUNCT
bjp-23953	63	1	safety	safety	NOUN
bjp-23953	63	2	of	of	ADP
bjp-23953	63	3	the	the	DET
bjp-23953	63	4	95	95	NUM
bjp-23953	63	5	patients	patient	NOUN
bjp-23953	63	6	,	,	PUNCT
bjp-23953	63	7	53	53	NUM
bjp-23953	63	8	patients	patient	NOUN
bjp-23953	63	9	(	(	PUNCT
bjp-23953	63	10	55.8	55.8	NUM
bjp-23953	63	11	%	%	NOUN
bjp-23953	63	12	)	)	PUNCT
bjp-23953	63	13	were	be	AUX
bjp-23953	63	14	observed	observe	VERB
bjp-23953	63	15	grade	grade	NOUN
bjp-23953	63	16	3	3	NUM
bjp-23953	63	17	leukopenia	leukopenia	NOUN
bjp-23953	63	18	,	,	PUNCT
bjp-23953	63	19	24	24	NUM
bjp-23953	63	20	patients	patient	NOUN
bjp-23953	63	21	(	(	PUNCT
bjp-23953	63	22	25.3	25.3	NUM
bjp-23953	63	23	%	%	NOUN
bjp-23953	63	24	)	)	PUNCT
bjp-23953	63	25	were	be	AUX
bjp-23953	63	26	observed	observe	VERB
bjp-23953	63	27	grade	grade	NOUN
bjp-23953	63	28	4	4	NUM
bjp-23953	63	29	leukopenia	leukopenia	NOUN
bjp-23953	63	30	,	,	PUNCT
bjp-23953	63	31	and	and	CCONJ
bjp-23953	63	32	77	77	NUM
bjp-23953	63	33	patients	patient	NOUN
bjp-23953	63	34	(	(	PUNCT
bjp-23953	63	35	81.1	81.1	NUM
bjp-23953	63	36	%	%	NOUN
bjp-23953	63	37	)	)	PUNCT
bjp-23953	63	38	were	be	AUX
bjp-23953	63	39	observed	observe	VERB
bjp-23953	63	40	grade	grade	NOUN
bjp-23953	63	41	3	3	NUM
bjp-23953	63	42	+	+	SYM
bjp-23953	63	43	4	4	NUM
bjp-23953	63	44	leukopenia	leukopenia	NOUN
bjp-23953	63	45	.	.	PUNCT
bjp-23953	64	1	anemia	anemia	NOUN
bjp-23953	64	2	,	,	PUNCT
bjp-23953	64	3	febrile	febrile	NOUN
bjp-23953	64	4	neutronpenia	neutronpenia	NOUN
bjp-23953	64	5	,	,	PUNCT
bjp-23953	64	6	thrombocytopenia	thrombocytopenia	PROPN
bjp-23953	64	7	,	,	PUNCT
bjp-23953	64	8	hyperglycemia	hyperglycemia	NOUN
bjp-23953	64	9	,	,	PUNCT
bjp-23953	64	10	hyponatremia	hyponatremia	NOUN
bjp-23953	64	11	,	,	PUNCT
bjp-23953	64	12	infection	infection	NOUN
bjp-23953	64	13	,	,	PUNCT
bjp-23953	64	14	elevated	elevated	ADJ
bjp-23953	64	15	alt	alt	ADJ
bjp-23953	64	16	and	and	CCONJ
bjp-23953	64	17	ast	ast	NOUN
bjp-23953	64	18	level	level	NOUN
bjp-23953	64	19	were	be	AUX
bjp-23953	64	20	also	also	ADV
bjp-23953	64	21	appeared	appear	VERB
bjp-23953	64	22	,	,	PUNCT
bjp-23953	64	23	but	but	CCONJ
bjp-23953	64	24	quantity	quantity	NOUN
bjp-23953	64	25	of	of	ADP
bjp-23953	64	26	these	these	DET
bjp-23953	64	27	adverse	adverse	ADJ
bjp-23953	64	28	events	event	NOUN
bjp-23953	64	29	were	be	AUX
bjp-23953	64	30	very	very	ADV
bjp-23953	64	31	few	few	ADJ
bjp-23953	64	32	.	.	PUNCT
bjp-23953	65	1	however	however	ADV
bjp-23953	65	2	,	,	PUNCT
bjp-23953	65	3	21	21	NUM
bjp-23953	65	4	patients	patient	NOUN
bjp-23953	65	5	(	(	PUNCT
bjp-23953	65	6	22.1	22.1	NUM
bjp-23953	65	7	%	%	NOUN
bjp-23953	65	8	)	)	PUNCT
bjp-23953	65	9	were	be	AUX
bjp-23953	65	10	observed	observe	VERB
bjp-23953	65	11	grade	grade	NOUN
bjp-23953	65	12	3	3	NUM
bjp-23953	65	13	neutropenia	neutropenia	NOUN
bjp-23953	65	14	,	,	PUNCT
bjp-23953	65	15	64	64	NUM
bjp-23953	65	16	patients	patient	NOUN
bjp-23953	65	17	(	(	PUNCT
bjp-23953	65	18	67.4	67.4	NUM
bjp-23953	65	19	%	%	NOUN
bjp-23953	65	20	)	)	PUNCT
bjp-23953	65	21	were	be	AUX
bjp-23953	65	22	observed	observe	VERB
bjp-23953	65	23	grade	grade	NOUN
bjp-23953	65	24	4	4	NUM
bjp-23953	65	25	neutropenia	neutropenia	NOUN
bjp-23953	65	26	,	,	PUNCT
bjp-23953	65	27	and	and	CCONJ
bjp-23953	65	28	85	85	NUM
bjp-23953	65	29	patients	patient	NOUN
bjp-23953	65	30	(	(	PUNCT
bjp-23953	65	31	89.5	89.5	NUM
bjp-23953	65	32	%	%	NOUN
bjp-23953	65	33	)	)	PUNCT
bjp-23953	65	34	were	be	AUX
bjp-23953	65	35	observed	observe	VERB
bjp-23953	65	36	grade	grade	NOUN
bjp-23953	65	37	3	3	NUM
bjp-23953	65	38	+	+	SYM
bjp-23953	65	39	4	4	NUM
bjp-23953	65	40	neutropenia	neutropenia	NOUN
bjp-23953	65	41	(	(	PUNCT
bjp-23953	65	42	table	table	NOUN
bjp-23953	65	43	iii	iii	NOUN
bjp-23953	65	44	)	)	PUNCT
bjp-23953	65	45	.	.	PUNCT
bjp-23953	66	1	discussion	discussion	NOUN
bjp-23953	66	2	although	although	SCONJ
bjp-23953	66	3	small	small	ADJ
bjp-23953	66	4	-	-	PUNCT
bjp-23953	66	5	cell	cell	NOUN
bjp-23953	66	6	lung	lung	NOUN
bjp-23953	66	7	cancer	cancer	NOUN
bjp-23953	66	8	takes	take	VERB
bjp-23953	66	9	only	only	ADV
bjp-23953	66	10	about	about	ADV
bjp-23953	66	11	20	20	NUM
bjp-23953	66	12	%	%	NOUN
bjp-23953	66	13	of	of	ADP
bjp-23953	66	14	lung	lung	NOUN
bjp-23953	66	15	cancers	cancer	NOUN
bjp-23953	66	16	,	,	PUNCT
bjp-23953	66	17	but	but	CCONJ
bjp-23953	66	18	the	the	DET
bjp-23953	66	19	degree	degree	NOUN
bjp-23953	66	20	of	of	ADP
bjp-23953	66	21	malignancy	malignancy	NOUN
bjp-23953	66	22	is	be	AUX
bjp-23953	66	23	high	high	ADJ
bjp-23953	66	24	.	.	PUNCT
bjp-23953	67	1	compared	compare	VERB
bjp-23953	67	2	with	with	ADP
bjp-23953	67	3	non	non	ADJ
bjp-23953	67	4	-	-	ADJ
bjp-23953	67	5	small	small	ADJ
bjp-23953	67	6	-	-	PUNCT
bjp-23953	67	7	cell	cell	NOUN
bjp-23953	67	8	lung	lung	NOUN
bjp-23953	67	9	cancer	cancer	NOUN
bjp-23953	67	10	,	,	PUNCT
bjp-23953	67	11	it	it	PRON
bjp-23953	67	12	is	be	AUX
bjp-23953	67	13	more	more	ADV
bjp-23953	67	14	likely	likely	ADJ
bjp-23953	67	15	to	to	PART
bjp-23953	67	16	have	have	VERB
bjp-23953	67	17	distant	distant	ADJ
bjp-23953	67	18	metastasis	metastasis	NOUN
bjp-23953	67	19	,	,	PUNCT
bjp-23953	67	20	and	and	CCONJ
bjp-23953	67	21	most	most	ADJ
bjp-23953	67	22	patients	patient	NOUN
bjp-23953	67	23	have	have	VERB
bjp-23953	67	24	metastasis	metastasis	PRON
bjp-23953	67	25	when	when	SCONJ
bjp-23953	67	26	being	be	AUX
bjp-23953	67	27	treated	treat	VERB
bjp-23953	67	28	.	.	PUNCT
bjp-23953	68	1	the	the	DET
bjp-23953	68	2	median	median	ADJ
bjp-23953	68	3	survival	survival	NOUN
bjp-23953	68	4	is	be	AUX
bjp-23953	68	5	less	less	ADJ
bjp-23953	68	6	than	than	ADP
bjp-23953	68	7	1	1	NUM
bjp-23953	68	8	year	year	NOUN
bjp-23953	68	9	,	,	PUNCT
bjp-23953	68	10	and	and	CCONJ
bjp-23953	68	11	5	5	NUM
bjp-23953	68	12	-	-	PUNCT
bjp-23953	68	13	year	year	NOUN
bjp-23953	68	14	survival	survival	NOUN
bjp-23953	68	15	rate	rate	NOUN
bjp-23953	68	16	is	be	AUX
bjp-23953	68	17	less	less	ADJ
bjp-23953	68	18	than	than	ADP
bjp-23953	68	19	5	5	NUM
bjp-23953	68	20	%	%	NOUN
bjp-23953	68	21	(	(	PUNCT
bjp-23953	68	22	ding	ding	NOUN
bjp-23953	68	23	et	et	PROPN
bjp-23953	68	24	al	al	PROPN
bjp-23953	68	25	.	.	PROPN
bjp-23953	68	26	,	,	PUNCT
bjp-23953	68	27	2012	2012	NUM
bjp-23953	68	28	)	)	PUNCT
bjp-23953	68	29	.	.	PUNCT
bjp-23953	69	1	more	more	ADJ
bjp-23953	69	2	and	and	CCONJ
bjp-23953	69	3	more	more	ADJ
bjp-23953	69	4	studies	study	NOUN
bjp-23953	69	5	show	show	VERB
bjp-23953	69	6	that	that	SCONJ
bjp-23953	69	7	the	the	DET
bjp-23953	69	8	autocrine	autocrine	NOUN
bjp-23953	69	9	loop	loop	NOUN
bjp-23953	69	10	path	path	NOUN
bjp-23953	69	11	of	of	ADP
bjp-23953	69	12	body	body	NOUN
bjp-23953	69	13	,	,	PUNCT
bjp-23953	69	14	protooncogenes	protooncogene	NOUN
bjp-23953	69	15	and	and	CCONJ
bjp-23953	69	16	tumor	tumor	NOUN
bjp-23953	69	17	suppressor	suppressor	NOUN
bjp-23953	69	18	genes	gene	NOUN
bjp-23953	69	19	have	have	VERB
bjp-23953	69	20	an	an	DET
bjp-23953	69	21	important	important	ADJ
bjp-23953	69	22	position	position	NOUN
bjp-23953	69	23	in	in	ADP
bjp-23953	69	24	small	small	ADJ
bjp-23953	69	25	-	-	PUNCT
bjp-23953	69	26	cell	cell	NOUN
bjp-23953	69	27	lung	lung	NOUN
bjp-23953	69	28	cancer	cancer	NOUN
bjp-23953	69	29	occurrence	occurrence	NOUN
bjp-23953	69	30	and	and	CCONJ
bjp-23953	69	31	development	development	NOUN
bjp-23953	69	32	,	,	PUNCT
bjp-23953	69	33	and	and	CCONJ
bjp-23953	69	34	epigenetics	epigenetic	NOUN
bjp-23953	69	35	may	may	AUX
bjp-23953	69	36	affect	affect	VERB
bjp-23953	69	37	the	the	DET
bjp-23953	69	38	occurrence	occurrence	NOUN
bjp-23953	69	39	and	and	CCONJ
bjp-23953	69	40	development	development	NOUN
bjp-23953	69	41	of	of	ADP
bjp-23953	69	42	small	small	ADJ
bjp-23953	69	43	-	-	PUNCT
bjp-23953	69	44	cell	cell	NOUN
bjp-23953	69	45	lung	lung	NOUN
bjp-23953	69	46	cancer	cancer	NOUN
bjp-23953	69	47	by	by	ADP
bjp-23953	69	48	the	the	DET
bjp-23953	69	49	regulation	regulation	NOUN
bjp-23953	69	50	of	of	ADP
bjp-23953	69	51	these	these	DET
bjp-23953	69	52	factors	factor	NOUN
bjp-23953	69	53	(	(	PUNCT
bjp-23953	69	54	zhang	zhang	X
bjp-23953	69	55	et	et	PROPN
bjp-23953	69	56	al	al	PROPN
bjp-23953	69	57	.	.	PROPN
bjp-23953	69	58	,	,	PUNCT
bjp-23953	69	59	2013	2013	NUM
bjp-23953	69	60	)	)	PUNCT
bjp-23953	69	61	.	.	PUNCT
bjp-23953	70	1	we	we	PRON
bjp-23953	70	2	found	find	VERB
bjp-23953	70	3	that	that	SCONJ
bjp-23953	70	4	among	among	ADP
bjp-23953	70	5	the	the	DET
bjp-23953	70	6	total	total	ADJ
bjp-23953	70	7	study	study	NOUN
bjp-23953	70	8	population	population	NOUN
bjp-23953	70	9	,	,	PUNCT
bjp-23953	70	10	complete	complete	ADJ
bjp-23953	70	11	response	response	NOUN
bjp-23953	70	12	was	be	AUX
bjp-23953	70	13	achieved	achieve	VERB
bjp-23953	70	14	in	in	ADP
bjp-23953	70	15	5	5	NUM
bjp-23953	70	16	patients	patient	NOUN
bjp-23953	70	17	(	(	PUNCT
bjp-23953	70	18	5.3	5.3	NUM
bjp-23953	70	19	%	%	NOUN
bjp-23953	70	20	)	)	PUNCT
bjp-23953	70	21	,	,	PUNCT
bjp-23953	70	22	partial	partial	ADJ
bjp-23953	70	23	response	response	NOUN
bjp-23953	70	24	in	in	ADP
bjp-23953	70	25	32	32	NUM
bjp-23953	70	26	patients	patient	NOUN
bjp-23953	70	27	(	(	PUNCT
bjp-23953	70	28	33.9	33.9	NUM
bjp-23953	70	29	%	%	NOUN
bjp-23953	70	30	)	)	PUNCT
bjp-23953	70	31	,	,	PUNCT
bjp-23953	70	32	stable	stable	ADJ
bjp-23953	70	33	disease	disease	NOUN
bjp-23953	70	34	in	in	ADP
bjp-23953	70	35	41	41	NUM
bjp-23953	70	36	patients	patient	NOUN
bjp-23953	70	37	(	(	PUNCT
bjp-23953	70	38	43.2	43.2	NUM
bjp-23953	70	39	%	%	NOUN
bjp-23953	70	40	)	)	PUNCT
bjp-23953	70	41	,	,	PUNCT
bjp-23953	70	42	and	and	CCONJ
bjp-23953	70	43	progressive	progressive	ADJ
bjp-23953	70	44	disease	disease	NOUN
bjp-23953	70	45	in	in	ADP
bjp-23953	70	46	16	16	NUM
bjp-23953	70	47	patients	patient	NOUN
bjp-23953	70	48	(	(	PUNCT
bjp-23953	70	49	16.8	16.8	NUM
bjp-23953	70	50	%	%	NOUN
bjp-23953	70	51	)	)	PUNCT
bjp-23953	70	52	after	after	ADP
bjp-23953	70	53	treatment	treatment	NOUN
bjp-23953	70	54	with	with	ADP
bjp-23953	70	55	amrubicin	amrubicin	PROPN
bjp-23953	70	56	.	.	PUNCT
bjp-23953	71	1	phase	phase	NOUN
bjp-23953	71	2	iii	iii	NUM
bjp-23953	71	3	trials	trial	NOUN
bjp-23953	71	4	of	of	ADP
bjp-23953	71	5	small	small	ADJ
bjp-23953	71	6	-	-	PUNCT
bjp-23953	71	7	cell	cell	NOUN
bjp-23953	71	8	lung	lung	NOUN
bjp-23953	71	9	cancer	cancer	NOUN
bjp-23953	71	10	by	by	ADP
bjp-23953	71	11	second	second	ADJ
bjp-23953	71	12	-	-	PUNCT
bjp-23953	71	13	line	line	NOUN
bjp-23953	71	14	treatment	treatment	NOUN
bjp-23953	71	15	of	of	ADP
bjp-23953	71	16	amrubicin	amrubicin	NOUN
bjp-23953	71	17	is	be	AUX
bjp-23953	71	18	underway	underway	ADJ
bjp-23953	71	19	,	,	PUNCT
bjp-23953	71	20	and	and	CCONJ
bjp-23953	71	21	we	we	PRON
bjp-23953	71	22	will	will	AUX
bjp-23953	71	23	look	look	VERB
bjp-23953	71	24	forward	forward	ADV
bjp-23953	71	25	to	to	ADP
bjp-23953	71	26	the	the	DET
bjp-23953	71	27	final	final	ADJ
bjp-23953	71	28	release	release	NOUN
bjp-23953	71	29	of	of	ADP
bjp-23953	71	30	the	the	DET
bjp-23953	71	31	results	result	NOUN
bjp-23953	71	32	.	.	PUNCT
bjp-23953	72	1	in	in	ADP
bjp-23953	72	2	the	the	DET
bjp-23953	72	3	secondline	secondline	ADJ
bjp-23953	72	4	treatment	treatment	NOUN
bjp-23953	72	5	of	of	ADP
bjp-23953	72	6	small	small	ADJ
bjp-23953	72	7	-	-	PUNCT
bjp-23953	72	8	cell	cell	NOUN
bjp-23953	72	9	lung	lung	NOUN
bjp-23953	72	10	cancer	cancer	NOUN
bjp-23953	72	11	,	,	PUNCT
bjp-23953	72	12	the	the	DET
bjp-23953	72	13	appropriate	appropriate	ADJ
bjp-23953	72	14	dose	dose	NOUN
bjp-23953	72	15	of	of	ADP
bjp-23953	72	16	amrubicin	amrubicin	NOUN
bjp-23953	72	17	may	may	AUX
bjp-23953	72	18	be	be	AUX
bjp-23953	72	19	35	35	NUM
bjp-23953	72	20	mg	mg	NOUN
bjp-23953	72	21	/	/	SYM
bjp-23953	72	22	m2	m2	PROPN
bjp-23953	72	23	on	on	ADP
bjp-23953	72	24	the	the	DET
bjp-23953	72	25	first	first	ADJ
bjp-23953	72	26	,	,	PUNCT
bjp-23953	72	27	second	second	ADJ
bjp-23953	72	28	and	and	CCONJ
bjp-23953	72	29	third	third	ADJ
bjp-23953	72	30	days	day	NOUN
bjp-23953	72	31	,	,	PUNCT
bjp-23953	72	32	with	with	ADP
bjp-23953	72	33	the	the	DET
bjp-23953	72	34	repeat	repeat	NOUN
bjp-23953	72	35	of	of	ADP
bjp-23953	72	36	three	three	NUM
bjp-23953	72	37	weeks	week	NOUN
bjp-23953	72	38	(	(	PUNCT
bjp-23953	72	39	matsunaga	matsunaga	NOUN
bjp-23953	72	40	et	et	PROPN
bjp-23953	72	41	al	al	PROPN
bjp-23953	72	42	.	.	PROPN
bjp-23953	72	43	,	,	PUNCT
bjp-23953	72	44	2006	2006	NUM
bjp-23953	72	45	)	)	PUNCT
bjp-23953	72	46	.	.	PUNCT
bjp-23953	73	1	for	for	ADP
bjp-23953	73	2	the	the	DET
bjp-23953	73	3	second	second	ADJ
bjp-23953	73	4	-	-	PUNCT
bjp-23953	73	5	line	line	NOUN
bjp-23953	73	6	chemotherapy	chemotherapy	NOUN
bjp-23953	73	7	of	of	ADP
bjp-23953	73	8	small	small	ADJ
bjp-23953	73	9	-	-	PUNCT
bjp-23953	73	10	cell	cell	NOUN
bjp-23953	73	11	lung	lung	NOUN
bjp-23953	73	12	cancer	cancer	NOUN
bjp-23953	73	13	currently	currently	ADV
bjp-23953	73	14	,	,	PUNCT
bjp-23953	73	15	participation	participation	NOUN
bjp-23953	73	16	in	in	ADP
bjp-23953	73	17	clinical	clinical	ADJ
bjp-23953	73	18	trials	trial	NOUN
bjp-23953	73	19	was	be	AUX
bjp-23953	73	20	recommended	recommend	VERB
bjp-23953	73	21	in	in	ADP
bjp-23953	73	22	2010	2010	NUM
bjp-23953	73	23	by	by	ADP
bjp-23953	73	24	the	the	DET
bjp-23953	73	25	us	us	PROPN
bjp-23953	73	26	national	national	PROPN
bjp-23953	73	27	comprehensive	comprehensive	PROPN
bjp-23953	73	28	cancer	cancer	NOUN
bjp-23953	73	29	alliance	alliance	NOUN
bjp-23953	73	30	;	;	PUNCT
bjp-23953	73	31	the	the	DET
bjp-23953	73	32	patients	patient	NOUN
bjp-23953	73	33	with	with	ADP
bjp-23953	73	34	the	the	DET
bjp-23953	73	35	relapse	relapse	NOUN
bjp-23953	73	36	within	within	ADP
bjp-23953	73	37	2	2	NUM
bjp-23953	73	38	-	-	SYM
bjp-23953	73	39	3	3	NUM
bjp-23953	73	40	months	month	NOUN
bjp-23953	73	41	and	and	CCONJ
bjp-23953	73	42	ps	ps	PROPN
bjp-23953	73	43	table	table	PROPN
bjp-23953	73	44	ii	ii	PROPN
bjp-23953	73	45	response	response	NOUN
bjp-23953	73	46	to	to	ADP
bjp-23953	73	47	amrubicin	amrubicin	NOUN
bjp-23953	73	48	in	in	ADP
bjp-23953	73	49	intent	intent	NOUN
bjp-23953	73	50	-	-	PUNCT
bjp-23953	73	51	to	to	AUX
bjp-23953	73	52	-	-	PUNCT
bjp-23953	73	53	treat	treat	VERB
bjp-23953	73	54	population	population	NOUN
bjp-23953	73	55	response	response	NOUN
bjp-23953	73	56	number	number	NOUN
bjp-23953	73	57	of	of	ADP
bjp-23953	73	58	patients	patient	NOUN
bjp-23953	73	59	(	(	PUNCT
bjp-23953	73	60	n	n	NOUN
bjp-23953	73	61	=	=	SYM
bjp-23953	73	62	95	95	NUM
bjp-23953	73	63	)	)	PUNCT
bjp-23953	73	64	complete	complete	ADJ
bjp-23953	73	65	response	response	NOUN
bjp-23953	73	66	5	5	NUM
bjp-23953	73	67	5.3	5.3	NUM
bjp-23953	73	68	partial	partial	ADJ
bjp-23953	73	69	response	response	NOUN
bjp-23953	73	70	32	32	NUM
bjp-23953	73	71	33.7	33.7	NUM
bjp-23953	73	72	stable	stable	ADJ
bjp-23953	73	73	disease	disease	NOUN
bjp-23953	73	74	41	41	NUM
bjp-23953	73	75	43.2	43.2	NUM
bjp-23953	73	76	progressive	progressive	ADJ
bjp-23953	73	77	disease	disease	NOUN
bjp-23953	73	78	16	16	NUM
bjp-23953	73	79	16.8	16.8	NUM
bjp-23953	73	80	not	not	PART
bjp-23953	73	81	evaluable	evaluable	ADJ
bjp-23953	73	82	1	1	NUM
bjp-23953	73	83	1.0	1.0	NUM
bjp-23953	73	84	overall	overall	ADJ
bjp-23953	73	85	response	response	NOUN
bjp-23953	73	86	rate	rate	NOUN
bjp-23953	73	87	37	37	NUM
bjp-23953	73	88	39.0	39.0	NUM
bjp-23953	73	89	table	table	NOUN
bjp-23953	73	90	iii	iii	NUM
bjp-23953	73	91	adverse	adverse	ADJ
bjp-23953	73	92	events	event	NOUN
bjp-23953	73	93	of	of	ADP
bjp-23953	73	94	in	in	ADP
bjp-23953	73	95	grade	grade	NOUN
bjp-23953	73	96	3	3	NUM
bjp-23953	73	97	or	or	CCONJ
bjp-23953	73	98	4	4	NUM
bjp-23953	73	99	patients	patient	NOUN
bjp-23953	73	100	treated	treat	VERB
bjp-23953	73	101	with	with	ADP
bjp-23953	73	102	amrubicin	amrubicin	PROPN
bjp-23953	73	103	adverse	adverse	ADJ
bjp-23953	73	104	event	event	NOUN
bjp-23953	73	105	grade	grade	NOUN
bjp-23953	73	106	3	3	NUM
bjp-23953	73	107	grade	grade	NOUN
bjp-23953	73	108	4	4	NUM
bjp-23953	73	109	grade	grade	NOUN
bjp-23953	73	110	3	3	NUM
bjp-23953	73	111	+	+	SYM
bjp-23953	73	112	4	4	NUM
bjp-23953	73	113	n	n	NUM
bjp-23953	73	114	%	%	NOUN
bjp-23953	74	1	n	n	PRON
bjp-23953	74	2	%	%	NOUN
bjp-23953	75	1	n	n	PRON
bjp-23953	75	2	%	%	NOUN
bjp-23953	75	3	leukopenia	leukopenia	NOUN
bjp-23953	75	4	53	53	NUM
bjp-23953	75	5	55.8	55.8	NUM
bjp-23953	75	6	24	24	NUM
bjp-23953	75	7	25.3	25.3	NUM
bjp-23953	75	8	77	77	NUM
bjp-23953	75	9	81.1	81.1	NUM
bjp-23953	75	10	anemia	anemia	NOUN
bjp-23953	75	11	25	25	NUM
bjp-23953	75	12	26.3	26.3	NUM
bjp-23953	75	13	4	4	NUM
bjp-23953	75	14	4.2	4.2	NUM
bjp-23953	75	15	29	29	NUM
bjp-23953	75	16	30.5	30.5	NUM
bjp-23953	75	17	febrile	febrile	NOUN
bjp-23953	75	18	neutropenia	neutropenia	NOUN
bjp-23953	75	19	28	28	NUM
bjp-23953	75	20	29.5	29.5	NUM
bjp-23953	75	21	2	2	NUM
bjp-23953	75	22	2.1	2.1	NUM
bjp-23953	75	23	30	30	NUM
bjp-23953	75	24	31.6	31.6	NUM
bjp-23953	75	25	neutropenia	neutropenia	NOUN
bjp-23953	75	26	21	21	NUM
bjp-23953	75	27	22.1	22.1	NUM
bjp-23953	75	28	64	64	NUM
bjp-23953	75	29	67.4	67.4	NUM
bjp-23953	75	30	85	85	NUM
bjp-23953	75	31	89.5	89.5	NUM
bjp-23953	75	32	thrombocytopenia	thrombocytopenia	NOUN
bjp-23953	75	33	15	15	NUM
bjp-23953	75	34	15.8	15.8	NUM
bjp-23953	75	35	7	7	NUM
bjp-23953	75	36	7.4	7.4	NUM
bjp-23953	75	37	22	22	NUM
bjp-23953	75	38	23.2	23.2	NUM
bjp-23953	75	39	hyperglycemia	hyperglycemia	NOUN
bjp-23953	75	40	14	14	NUM
bjp-23953	75	41	14.7	14.7	NUM
bjp-23953	75	42	1	1	NUM
bjp-23953	75	43	1.1	1.1	NUM
bjp-23953	75	44	12	12	NUM
bjp-23953	75	45	12.6	12.6	NUM
bjp-23953	75	46	hyponatremia	hyponatremia	NOUN
bjp-23953	75	47	11	11	NUM
bjp-23953	75	48	11.6	11.6	NUM
bjp-23953	75	49	5	5	NUM
bjp-23953	75	50	5.3	5.3	NUM
bjp-23953	75	51	16	16	NUM
bjp-23953	75	52	16.8	16.8	NUM
bjp-23953	75	53	infection	infection	NOUN
bjp-23953	75	54	7	7	NUM
bjp-23953	75	55	7.4	7.4	NUM
bjp-23953	75	56	1	1	NUM
bjp-23953	75	57	1.1	1.1	NUM
bjp-23953	75	58	8	8	NUM
bjp-23953	75	59	8.4	8.4	NUM
bjp-23953	75	60	elevated	elevated	ADJ
bjp-23953	75	61	alanine	alanine	NOUN
bjp-23953	75	62	transaminase	transaminase	NOUN
bjp-23953	75	63	level	level	NOUN
bjp-23953	75	64	4	4	NUM
bjp-23953	75	65	4.2	4.2	NUM
bjp-23953	75	66	2	2	NUM
bjp-23953	75	67	2.1	2.1	NUM
bjp-23953	75	68	6	6	NUM
bjp-23953	75	69	6.3	6.3	NUM
bjp-23953	75	70	elevated	elevated	ADJ
bjp-23953	75	71	aspartate	aspartate	NOUN
bjp-23953	75	72	aminotransferase	aminotransferase	NOUN
bjp-23953	75	73	level	level	NOUN
bjp-23953	75	74	4	4	NUM
bjp-23953	75	75	4.2	4.2	NUM
bjp-23953	75	76	0	0	NUM
bjp-23953	75	77	0	0	NUM
bjp-23953	75	78	4	4	NUM
bjp-23953	75	79	4.2	4.2	NUM
bjp-23953	75	80	bangladesh	bangladesh	NOUN
bjp-23953	75	81	j	j	PROPN
bjp-23953	75	82	pharmacol	pharmacol	PROPN
bjp-23953	75	83	2016	2016	NUM
bjp-23953	75	84	;	;	PUNCT
bjp-23953	75	85	11	11	NUM
bjp-23953	75	86	:	:	SYM
bjp-23953	75	87	564	564	NUM
bjp-23953	75	88	-	-	SYM
bjp-23953	75	89	569	569	NUM
bjp-23953	75	90	567	567	NUM
bjp-23953	75	91	score	score	NOUN
bjp-23953	75	92	of	of	ADP
bjp-23953	75	93	0	0	NUM
bjp-23953	75	94	-	-	SYM
bjp-23953	75	95	2	2	NUM
bjp-23953	75	96	points	point	NOUN
bjp-23953	75	97	can	can	AUX
bjp-23953	75	98	consider	consider	VERB
bjp-23953	75	99	the	the	DET
bjp-23953	75	100	drugs	drug	NOUN
bjp-23953	75	101	:	:	PUNCT
bjp-23953	75	102	different	different	ADJ
bjp-23953	75	103	ring	ring	NOUN
bjp-23953	75	104	phosphoramidite	phosphoramidite	NOUN
bjp-23953	75	105	,	,	PUNCT
bjp-23953	75	106	paclitaxel	paclitaxel	NOUN
bjp-23953	75	107	,	,	PUNCT
bjp-23953	75	108	docetaxel	docetaxel	NOUN
bjp-23953	75	109	,	,	PUNCT
bjp-23953	75	110	gemcitabine	gemcitabine	NOUN
bjp-23953	75	111	,	,	PUNCT
bjp-23953	75	112	irinotecan	irinotecan	NOUN
bjp-23953	75	113	and	and	CCONJ
bjp-23953	75	114	topotecan	topotecan	NOUN
bjp-23953	75	115	;	;	PUNCT
bjp-23953	75	116	the	the	DET
bjp-23953	75	117	patients	patient	NOUN
bjp-23953	75	118	with	with	ADP
bjp-23953	75	119	the	the	DET
bjp-23953	75	120	relapse	relapse	NOUN
bjp-23953	75	121	between	between	ADP
bjp-23953	75	122	2	2	NUM
bjp-23953	75	123	-	-	SYM
bjp-23953	75	124	3	3	NUM
bjp-23953	75	125	months	month	NOUN
bjp-23953	75	126	and	and	CCONJ
bjp-23953	75	127	six	six	NUM
bjp-23953	75	128	months	month	NOUN
bjp-23953	75	129	can	can	AUX
bjp-23953	75	130	consider	consider	VERB
bjp-23953	75	131	the	the	DET
bjp-23953	75	132	application	application	NOUN
bjp-23953	75	133	of	of	ADP
bjp-23953	75	134	topotecan	topotecan	NOUN
bjp-23953	75	135	(	(	PUNCT
bjp-23953	75	136	level	level	NOUN
bjp-23953	75	137	1	1	NUM
bjp-23953	75	138	evidence	evidence	NOUN
bjp-23953	75	139	)	)	PUNCT
bjp-23953	75	140	,	,	PUNCT
bjp-23953	75	141	cav	cav	NOUN
bjp-23953	75	142	,	,	PUNCT
bjp-23953	75	143	gemcitabine	gemcitabine	NOUN
bjp-23953	75	144	,	,	PUNCT
bjp-23953	75	145	paclitaxel	paclitaxel	PROPN
bjp-23953	75	146	,	,	PUNCT
bjp-23953	75	147	docetaxel	docetaxel	NOUN
bjp-23953	75	148	,	,	PUNCT
bjp-23953	75	149	oral	oral	ADJ
bjp-23953	75	150	etoposide	etoposide	NOUN
bjp-23953	75	151	and	and	CCONJ
bjp-23953	75	152	vinorelbine	vinorelbine	NOUN
bjp-23953	75	153	;	;	PUNCT
bjp-23953	75	154	the	the	DET
bjp-23953	75	155	patients	patient	NOUN
bjp-23953	75	156	with	with	ADP
bjp-23953	75	157	the	the	DET
bjp-23953	75	158	relapse	relapse	NOUN
bjp-23953	75	159	after	after	ADP
bjp-23953	75	160	six	six	NUM
bjp-23953	75	161	months	month	NOUN
bjp-23953	75	162	can	can	AUX
bjp-23953	75	163	consider	consider	VERB
bjp-23953	75	164	the	the	DET
bjp-23953	75	165	original	original	ADJ
bjp-23953	75	166	proposal	proposal	NOUN
bjp-23953	75	167	(	(	PUNCT
bjp-23953	75	168	ettinger	ettinger	PROPN
bjp-23953	75	169	et	et	PROPN
bjp-23953	75	170	al	al	PROPN
bjp-23953	75	171	.	.	PROPN
bjp-23953	75	172	,	,	PUNCT
bjp-23953	75	173	2010	2010	NUM
bjp-23953	75	174	)	)	PUNCT
bjp-23953	75	175	.	.	PUNCT
bjp-23953	76	1	in	in	ADP
bjp-23953	76	2	practice	practice	NOUN
bjp-23953	76	3	,	,	PUNCT
bjp-23953	76	4	the	the	DET
bjp-23953	76	5	application	application	NOUN
bjp-23953	76	6	of	of	ADP
bjp-23953	76	7	second	second	ADJ
bjp-23953	76	8	-	-	PUNCT
bjp-23953	76	9	line	line	NOUN
bjp-23953	76	10	treatment	treatment	NOUN
bjp-23953	76	11	should	should	AUX
bjp-23953	76	12	be	be	AUX
bjp-23953	76	13	combined	combine	VERB
bjp-23953	76	14	with	with	ADP
bjp-23953	76	15	full	full	ADJ
bjp-23953	76	16	consideration	consideration	NOUN
bjp-23953	76	17	of	of	ADP
bjp-23953	76	18	the	the	DET
bjp-23953	76	19	general	general	ADJ
bjp-23953	76	20	condition	condition	NOUN
bjp-23953	76	21	of	of	ADP
bjp-23953	76	22	the	the	DET
bjp-23953	76	23	patient	patient	NOUN
bjp-23953	76	24	,	,	PUNCT
bjp-23953	76	25	the	the	DET
bjp-23953	76	26	situation	situation	NOUN
bjp-23953	76	27	of	of	ADP
bjp-23953	76	28	first	first	ADJ
bjp-23953	76	29	-	-	PUNCT
bjp-23953	76	30	line	line	NOUN
bjp-23953	76	31	chemotherapy	chemotherapy	NOUN
bjp-23953	76	32	and	and	CCONJ
bjp-23953	76	33	side	side	NOUN
bjp-23953	76	34	effects	effect	NOUN
bjp-23953	76	35	of	of	ADP
bjp-23953	76	36	selected	select	VERB
bjp-23953	76	37	drugs	drug	NOUN
bjp-23953	76	38	(	(	PUNCT
bjp-23953	76	39	shah	shah	NOUN
bjp-23953	76	40	,	,	PUNCT
bjp-23953	76	41	2009	2009	NUM
bjp-23953	76	42	)	)	PUNCT
bjp-23953	76	43	.	.	PUNCT
bjp-23953	77	1	in	in	ADP
bjp-23953	77	2	this	this	DET
bjp-23953	77	3	study	study	NOUN
bjp-23953	77	4	,	,	PUNCT
bjp-23953	77	5	we	we	PRON
bjp-23953	77	6	found	find	VERB
bjp-23953	77	7	that	that	SCONJ
bjp-23953	77	8	among	among	ADP
bjp-23953	77	9	overall	overall	ADJ
bjp-23953	77	10	response	response	NOUN
bjp-23953	77	11	rate	rate	NOUN
bjp-23953	77	12	was	be	AUX
bjp-23953	77	13	38.95	38.95	NUM
bjp-23953	77	14	%	%	NOUN
bjp-23953	77	15	,	,	PUNCT
bjp-23953	77	16	the	the	DET
bjp-23953	77	17	median	median	ADJ
bjp-23953	77	18	follow	follow	VERB
bjp-23953	77	19	-	-	PUNCT
bjp-23953	77	20	up	up	NOUN
bjp-23953	77	21	time	time	NOUN
bjp-23953	77	22	of	of	ADP
bjp-23953	77	23	all	all	DET
bjp-23953	77	24	registered	register	VERB
bjp-23953	77	25	patients	patient	NOUN
bjp-23953	77	26	was	be	AUX
bjp-23953	77	27	9.1	9.1	NUM
bjp-23953	77	28	months	month	NOUN
bjp-23953	77	29	(	(	PUNCT
bjp-23953	77	30	1.3	1.3	NUM
bjp-23953	77	31	-	-	SYM
bjp-23953	77	32	25.1	25.1	NUM
bjp-23953	77	33	months	month	NOUN
bjp-23953	77	34	)	)	PUNCT
bjp-23953	77	35	at	at	ADP
bjp-23953	77	36	the	the	DET
bjp-23953	77	37	cutoff	cutoff	NOUN
bjp-23953	77	38	date	date	NOUN
bjp-23953	77	39	for	for	ADP
bjp-23953	77	40	data	data	NOUN
bjp-23953	77	41	collection	collection	NOUN
bjp-23953	77	42	.	.	PUNCT
bjp-23953	78	1	the	the	DET
bjp-23953	78	2	median	median	ADJ
bjp-23953	78	3	overall	overall	ADJ
bjp-23953	78	4	survival	survival	NOUN
bjp-23953	78	5	of	of	ADP
bjp-23953	78	6	all	all	DET
bjp-23953	78	7	registered	register	VERB
bjp-23953	78	8	patients	patient	NOUN
bjp-23953	78	9	was	be	AUX
bjp-23953	78	10	9.2	9.2	NUM
bjp-23953	78	11	months	month	NOUN
bjp-23953	78	12	.	.	PUNCT
bjp-23953	79	1	murakami	murakami	PROPN
bjp-23953	79	2	et	et	PROPN
bjp-23953	79	3	al	al	PROPN
bjp-23953	79	4	,	,	PUNCT
bjp-23953	79	5	(	(	PUNCT
bjp-23953	79	6	2014	2014	NUM
bjp-23953	79	7	)	)	PUNCT
bjp-23953	79	8	reported	report	VERB
bjp-23953	79	9	that	that	SCONJ
bjp-23953	79	10	overall	overall	ADJ
bjp-23953	79	11	survival	survival	NOUN
bjp-23953	79	12	periods	period	NOUN
bjp-23953	79	13	were	be	AUX
bjp-23953	79	14	8.9	8.9	NUM
bjp-23953	79	15	months	month	NOUN
bjp-23953	79	16	and	and	CCONJ
bjp-23953	79	17	overall	overall	ADJ
bjp-23953	79	18	response	response	NOUN
bjp-23953	79	19	rate	rate	NOUN
bjp-23953	79	20	was	be	AUX
bjp-23953	79	21	32.9	32.9	NUM
bjp-23953	79	22	%	%	NOUN
bjp-23953	79	23	in	in	ADP
bjp-23953	79	24	japanese	japanese	ADJ
bjp-23953	79	25	patients	patient	NOUN
bjp-23953	79	26	.	.	PUNCT
bjp-23953	80	1	overall	overall	ADJ
bjp-23953	80	2	response	response	NOUN
bjp-23953	80	3	rate	rate	NOUN
bjp-23953	80	4	and	and	CCONJ
bjp-23953	80	5	overall	overall	ADJ
bjp-23953	80	6	survival	survival	NOUN
bjp-23953	80	7	of	of	ADP
bjp-23953	80	8	our	our	PRON
bjp-23953	80	9	results	result	NOUN
bjp-23953	80	10	were	be	AUX
bjp-23953	80	11	higher	high	ADJ
bjp-23953	80	12	than	than	ADP
bjp-23953	80	13	findings	finding	NOUN
bjp-23953	80	14	of	of	ADP
bjp-23953	80	15	murakami	murakami	NOUN
bjp-23953	80	16	et	et	PROPN
bjp-23953	80	17	al	al	PROPN
bjp-23953	80	18	,	,	PUNCT
bjp-23953	80	19	(	(	PUNCT
bjp-23953	80	20	2014	2014	NUM
bjp-23953	80	21	)	)	PUNCT
bjp-23953	80	22	.	.	PUNCT
bjp-23953	81	1	these	these	DET
bjp-23953	81	2	differences	difference	NOUN
bjp-23953	81	3	may	may	AUX
bjp-23953	81	4	be	be	AUX
bjp-23953	81	5	genetic	genetic	ADJ
bjp-23953	81	6	and	and	CCONJ
bjp-23953	81	7	species	specie	NOUN
bjp-23953	81	8	difference	difference	NOUN
bjp-23953	81	9	from	from	ADP
bjp-23953	81	10	chinese	chinese	ADJ
bjp-23953	81	11	patients	patient	NOUN
bjp-23953	81	12	and	and	CCONJ
bjp-23953	81	13	japanese	japanese	ADJ
bjp-23953	81	14	patients	patient	NOUN
bjp-23953	81	15	.	.	PUNCT
bjp-23953	82	1	amrubicin	amrubicin	PROPN
bjp-23953	82	2	has	have	VERB
bjp-23953	82	3	good	good	ADJ
bjp-23953	82	4	efficacy	efficacy	NOUN
bjp-23953	82	5	in	in	ADP
bjp-23953	82	6	the	the	DET
bjp-23953	82	7	first	first	ADJ
bjp-23953	82	8	and	and	CCONJ
bjp-23953	82	9	second	second	ADJ
bjp-23953	82	10	line	line	NOUN
bjp-23953	82	11	treatment	treatment	NOUN
bjp-23953	82	12	of	of	ADP
bjp-23953	82	13	small	small	ADJ
bjp-23953	82	14	-	-	PUNCT
bjp-23953	82	15	cell	cell	NOUN
bjp-23953	82	16	lung	lung	NOUN
bjp-23953	82	17	cancer	cancer	NOUN
bjp-23953	82	18	,	,	PUNCT
bjp-23953	82	19	the	the	DET
bjp-23953	82	20	median	median	ADJ
bjp-23953	82	21	survival	survival	NOUN
bjp-23953	82	22	time	time	NOUN
bjp-23953	82	23	of	of	ADP
bjp-23953	82	24	the	the	DET
bjp-23953	82	25	patients	patient	NOUN
bjp-23953	82	26	treated	treat	VERB
bjp-23953	82	27	by	by	ADP
bjp-23953	82	28	the	the	DET
bjp-23953	82	29	combination	combination	NOUN
bjp-23953	82	30	of	of	ADP
bjp-23953	82	31	amrubicin	amrubicin	NOUN
bjp-23953	82	32	and	and	CCONJ
bjp-23953	82	33	cisplatin	cisplatin	NOUN
bjp-23953	82	34	in	in	ADP
bjp-23953	82	35	the	the	DET
bjp-23953	82	36	treatment	treatment	NOUN
bjp-23953	82	37	of	of	ADP
bjp-23953	82	38	previously	previously	ADV
bjp-23953	82	39	untreated	untreate	VERB
bjp-23953	82	40	extensive	extensive	ADJ
bjp-23953	82	41	-	-	PUNCT
bjp-23953	82	42	stage	stage	NOUN
bjp-23953	82	43	small	small	ADJ
bjp-23953	82	44	-	-	PUNCT
bjp-23953	82	45	cell	cell	NOUN
bjp-23953	82	46	lung	lung	NOUN
bjp-23953	82	47	cancer	cancer	NOUN
bjp-23953	82	48	,	,	PUNCT
bjp-23953	82	49	is	be	AUX
bjp-23953	82	50	more	more	ADJ
bjp-23953	82	51	than	than	ADP
bjp-23953	82	52	that	that	PRON
bjp-23953	82	53	of	of	ADP
bjp-23953	82	54	12.8	12.8	NUM
bjp-23953	82	55	months	month	NOUN
bjp-23953	82	56	in	in	ADP
bjp-23953	82	57	the	the	DET
bjp-23953	82	58	ip	ip	NOUN
bjp-23953	82	59	program	program	NOUN
bjp-23953	82	60	group	group	NOUN
bjp-23953	82	61	reported	report	VERB
bjp-23953	82	62	in	in	ADP
bjp-23953	82	63	the	the	DET
bjp-23953	82	64	jcog	jcog	PROPN
bjp-23953	82	65	9511	9511	NUM
bjp-23953	82	66	research	research	NOUN
bjp-23953	82	67	from	from	ADP
bjp-23953	82	68	japan	japan	PROPN
bjp-23953	82	69	(	(	PUNCT
bjp-23953	82	70	kobayashi	kobayashi	PROPN
bjp-23953	82	71	et	et	PROPN
bjp-23953	82	72	al	al	PROPN
bjp-23953	82	73	.	.	PROPN
bjp-23953	82	74	,	,	PUNCT
bjp-23953	82	75	2010	2010	NUM
bjp-23953	82	76	)	)	PUNCT
bjp-23953	82	77	.	.	PUNCT
bjp-23953	83	1	the	the	DET
bjp-23953	83	2	combination	combination	NOUN
bjp-23953	83	3	of	of	ADP
bjp-23953	83	4	amrubicin	amrubicin	NOUN
bjp-23953	83	5	and	and	CCONJ
bjp-23953	83	6	carboplatin	carboplatin	NOUN
bjp-23953	83	7	can	can	AUX
bjp-23953	83	8	also	also	ADV
bjp-23953	83	9	realize	realize	VERB
bjp-23953	83	10	good	good	ADJ
bjp-23953	83	11	efficacy	efficacy	NOUN
bjp-23953	83	12	in	in	ADP
bjp-23953	83	13	the	the	DET
bjp-23953	83	14	treatment	treatment	NOUN
bjp-23953	83	15	of	of	ADP
bjp-23953	83	16	elderly	elderly	ADJ
bjp-23953	83	17	small	small	ADJ
bjp-23953	83	18	-	-	PUNCT
bjp-23953	83	19	cell	cell	NOUN
bjp-23953	83	20	lung	lung	NOUN
bjp-23953	83	21	cancer	cancer	NOUN
bjp-23953	83	22	,	,	PUNCT
bjp-23953	83	23	with	with	ADP
bjp-23953	83	24	the	the	DET
bjp-23953	83	25	recommended	recommend	VERB
bjp-23953	83	26	dose	dose	NOUN
bjp-23953	83	27	of	of	ADP
bjp-23953	83	28	amrubicin	amrubicin	PROPN
bjp-23953	83	29	35	35	NUM
bjp-23953	83	30	mg	mg	NUM
bjp-23953	83	31	/	/	SYM
bjp-23953	83	32	m2	m2	PROPN
bjp-23953	83	33	on	on	ADP
bjp-23953	83	34	the	the	DET
bjp-23953	83	35	first	first	ADJ
bjp-23953	83	36	,	,	PUNCT
bjp-23953	83	37	second	second	ADJ
bjp-23953	83	38	and	and	CCONJ
bjp-23953	83	39	third	third	ADJ
bjp-23953	83	40	days	day	NOUN
bjp-23953	83	41	,	,	PUNCT
bjp-23953	83	42	and	and	CCONJ
bjp-23953	83	43	carboplatin	carboplatin	NOUN
bjp-23953	83	44	is	be	AUX
bjp-23953	83	45	calculated	calculate	VERB
bjp-23953	83	46	according	accord	VERB
bjp-23953	83	47	to	to	ADP
bjp-23953	83	48	auc	auc	NOUN
bjp-23953	83	49	4	4	NUM
bjp-23953	83	50	,	,	PUNCT
bjp-23953	83	51	and	and	CCONJ
bjp-23953	83	52	used	use	VERB
bjp-23953	83	53	on	on	ADP
bjp-23953	83	54	the	the	DET
bjp-23953	83	55	first	first	ADJ
bjp-23953	83	56	day	day	NOUN
bjp-23953	83	57	,	,	PUNCT
bjp-23953	83	58	with	with	ADP
bjp-23953	83	59	the	the	DET
bjp-23953	83	60	repeat	repeat	NOUN
bjp-23953	83	61	of	of	ADP
bjp-23953	83	62	three	three	NUM
bjp-23953	83	63	weeks	week	NOUN
bjp-23953	83	64	(	(	PUNCT
bjp-23953	83	65	igawa	igawa	PROPN
bjp-23953	83	66	et	et	PROPN
bjp-23953	83	67	al	al	PROPN
bjp-23953	83	68	.	.	PROPN
bjp-23953	83	69	,	,	PUNCT
bjp-23953	83	70	2013	2013	NUM
bjp-23953	83	71	)	)	PUNCT
bjp-23953	83	72	.	.	PUNCT
bjp-23953	84	1	amrubicin	amrubicin	PROPN
bjp-23953	84	2	second	second	ADJ
bjp-23953	84	3	-	-	PUNCT
bjp-23953	84	4	line	line	NOUN
bjp-23953	84	5	treatment	treatment	NOUN
bjp-23953	84	6	has	have	VERB
bjp-23953	84	7	a	a	DET
bjp-23953	84	8	good	good	ADJ
bjp-23953	84	9	effect	effect	NOUN
bjp-23953	84	10	of	of	ADP
bjp-23953	84	11	refractory	refractory	NOUN
bjp-23953	84	12	or	or	CCONJ
bjp-23953	84	13	relapsed	relapse	VERB
bjp-23953	84	14	sensitive	sensitive	ADJ
bjp-23953	84	15	small	small	ADJ
bjp-23953	84	16	-	-	PUNCT
bjp-23953	84	17	cell	cell	NOUN
bjp-23953	84	18	lung	lung	NOUN
bjp-23953	84	19	cancer	cancer	NOUN
bjp-23953	84	20	,	,	PUNCT
bjp-23953	84	21	and	and	CCONJ
bjp-23953	84	22	phase	phase	NOUN
bjp-23953	84	23	ii	ii	NOUN
bjp-23953	84	24	clinical	clinical	ADJ
bjp-23953	84	25	trials	trial	NOUN
bjp-23953	84	26	have	have	AUX
bjp-23953	84	27	shown	show	VERB
bjp-23953	84	28	superior	superior	ADJ
bjp-23953	84	29	efficacy	efficacy	NOUN
bjp-23953	84	30	to	to	ADP
bjp-23953	84	31	that	that	PRON
bjp-23953	84	32	of	of	ADP
bjp-23953	84	33	tinto	tinto	PROPN
bjp-23953	84	34	topotecan	topotecan	ADJ
bjp-23953	84	35	.	.	PUNCT
bjp-23953	85	1	european	european	ADJ
bjp-23953	85	2	countries	country	NOUN
bjp-23953	85	3	are	be	AUX
bjp-23953	85	4	also	also	ADV
bjp-23953	85	5	conducting	conduct	VERB
bjp-23953	85	6	clinical	clinical	ADJ
bjp-23953	85	7	trials	trial	NOUN
bjp-23953	85	8	of	of	ADP
bjp-23953	85	9	the	the	DET
bjp-23953	85	10	treatment	treatment	NOUN
bjp-23953	85	11	of	of	ADP
bjp-23953	85	12	small	small	ADJ
bjp-23953	85	13	-	-	PUNCT
bjp-23953	85	14	cell	cell	NOUN
bjp-23953	85	15	lung	lung	NOUN
bjp-23953	85	16	cancer	cancer	NOUN
bjp-23953	85	17	by	by	ADP
bjp-23953	85	18	amrubicin	amrubicin	PROPN
bjp-23953	85	19	,	,	PUNCT
bjp-23953	85	20	the	the	DET
bjp-23953	85	21	phase	phase	NOUN
bjp-23953	85	22	iii	iii	NUM
bjp-23953	85	23	clinical	clinical	ADJ
bjp-23953	85	24	trials	trial	NOUN
bjp-23953	85	25	of	of	ADP
bjp-23953	85	26	firstor	firstor	NOUN
bjp-23953	85	27	second	second	ADJ
bjp-23953	85	28	-	-	PUNCT
bjp-23953	85	29	line	line	NOUN
bjp-23953	85	30	treatment	treatment	NOUN
bjp-23953	85	31	of	of	ADP
bjp-23953	85	32	small	small	ADJ
bjp-23953	85	33	-	-	PUNCT
bjp-23953	85	34	cell	cell	NOUN
bjp-23953	85	35	lung	lung	NOUN
bjp-23953	85	36	cancer	cancer	NOUN
bjp-23953	85	37	abroad	abroad	ADV
bjp-23953	85	38	by	by	ADP
bjp-23953	85	39	amrubicin	amrubicin	NOUN
bjp-23953	85	40	are	be	AUX
bjp-23953	85	41	underway	underway	ADJ
bjp-23953	85	42	,	,	PUNCT
bjp-23953	85	43	of	of	ADP
bjp-23953	85	44	which	which	PRON
bjp-23953	85	45	the	the	DET
bjp-23953	85	46	final	final	ADJ
bjp-23953	85	47	results	result	NOUN
bjp-23953	85	48	report	report	NOUN
bjp-23953	85	49	is	be	AUX
bjp-23953	85	50	expected	expect	VERB
bjp-23953	85	51	.	.	PUNCT
bjp-23953	86	1	amrubicin	amrubicin	PROPN
bjp-23953	86	2	has	have	VERB
bjp-23953	86	3	better	well	ADJ
bjp-23953	86	4	cardiac	cardiac	ADJ
bjp-23953	86	5	safety	safety	NOUN
bjp-23953	86	6	,	,	PUNCT
bjp-23953	86	7	which	which	PRON
bjp-23953	86	8	may	may	AUX
bjp-23953	86	9	also	also	ADV
bjp-23953	86	10	be	be	AUX
bjp-23953	86	11	a	a	DET
bjp-23953	86	12	good	good	ADJ
bjp-23953	86	13	choice	choice	NOUN
bjp-23953	86	14	for	for	ADP
bjp-23953	86	15	patients	patient	NOUN
bjp-23953	86	16	with	with	ADP
bjp-23953	86	17	poor	poor	ADJ
bjp-23953	86	18	kidney	kidney	NOUN
bjp-23953	86	19	function	function	NOUN
bjp-23953	86	20	,	,	PUNCT
bjp-23953	86	21	and	and	CCONJ
bjp-23953	86	22	the	the	DET
bjp-23953	86	23	main	main	ADJ
bjp-23953	86	24	side	side	NOUN
bjp-23953	86	25	effect	effect	NOUN
bjp-23953	86	26	is	be	AUX
bjp-23953	86	27	hematologic	hematologic	ADJ
bjp-23953	86	28	toxicity	toxicity	NOUN
bjp-23953	86	29	,	,	PUNCT
bjp-23953	86	30	deserving	deserve	VERB
bjp-23953	86	31	our	our	PRON
bjp-23953	86	32	attention	attention	NOUN
bjp-23953	86	33	(	(	PUNCT
bjp-23953	86	34	ohe	ohe	NOUN
bjp-23953	86	35	et	et	PROPN
bjp-23953	86	36	al	al	PROPN
bjp-23953	86	37	.	.	PROPN
bjp-23953	86	38	,	,	PUNCT
bjp-23953	86	39	2005	2005	NUM
bjp-23953	86	40	;	;	PUNCT
bjp-23953	87	1	onoda	onoda	INTJ
bjp-23953	87	2	et	et	PROPN
bjp-23953	87	3	al	al	PROPN
bjp-23953	87	4	.	.	PROPN
bjp-23953	87	5	,	,	PUNCT
bjp-23953	87	6	2006	2006	NUM
bjp-23953	87	7	;	;	PUNCT
bjp-23953	87	8	hanada	hanada	PROPN
bjp-23953	87	9	et	et	PROPN
bjp-23953	87	10	al	al	PROPN
bjp-23953	87	11	.	.	PROPN
bjp-23953	87	12	,	,	PUNCT
bjp-23953	87	13	2007	2007	NUM
bjp-23953	87	14	;	;	PUNCT
bjp-23953	87	15	hira	hira	PROPN
bjp-23953	87	16	et	et	PROPN
bjp-23953	87	17	al	al	PROPN
bjp-23953	87	18	.	.	PROPN
bjp-23953	87	19	,	,	PUNCT
bjp-23953	87	20	2008	2008	NUM
bjp-23953	87	21	)	)	PUNCT
bjp-23953	87	22	.	.	PUNCT
bjp-23953	88	1	in	in	ADP
bjp-23953	88	2	the	the	DET
bjp-23953	88	3	present	present	ADJ
bjp-23953	88	4	study	study	NOUN
bjp-23953	88	5	,	,	PUNCT
bjp-23953	88	6	53	53	NUM
bjp-23953	88	7	patients	patient	NOUN
bjp-23953	88	8	(	(	PUNCT
bjp-23953	88	9	55.8	55.8	NUM
bjp-23953	88	10	%	%	NOUN
bjp-23953	88	11	)	)	PUNCT
bjp-23953	88	12	were	be	AUX
bjp-23953	88	13	observed	observe	VERB
bjp-23953	88	14	grade	grade	NOUN
bjp-23953	88	15	3	3	NUM
bjp-23953	88	16	leukopenia	leukopenia	NOUN
bjp-23953	88	17	,	,	PUNCT
bjp-23953	88	18	24	24	NUM
bjp-23953	88	19	patients	patient	NOUN
bjp-23953	88	20	(	(	PUNCT
bjp-23953	88	21	25.3	25.3	NUM
bjp-23953	88	22	%	%	NOUN
bjp-23953	88	23	)	)	PUNCT
bjp-23953	88	24	were	be	AUX
bjp-23953	88	25	observed	observe	VERB
bjp-23953	88	26	grade	grade	NOUN
bjp-23953	88	27	4	4	NUM
bjp-23953	88	28	leukopenia	leukopenia	NOUN
bjp-23953	88	29	,	,	PUNCT
bjp-23953	88	30	and	and	CCONJ
bjp-23953	88	31	77	77	NUM
bjp-23953	88	32	patients	patient	NOUN
bjp-23953	88	33	(	(	PUNCT
bjp-23953	88	34	81.1	81.1	NUM
bjp-23953	88	35	%	%	NOUN
bjp-23953	88	36	)	)	PUNCT
bjp-23953	88	37	were	be	AUX
bjp-23953	88	38	observed	observe	VERB
bjp-23953	88	39	grade	grade	NOUN
bjp-23953	88	40	3	3	NUM
bjp-23953	88	41	+	+	SYM
bjp-23953	88	42	4	4	NUM
bjp-23953	88	43	leukopenia	leukopenia	NOUN
bjp-23953	88	44	.	.	PUNCT
bjp-23953	89	1	anemia	anemia	NOUN
bjp-23953	89	2	,	,	PUNCT
bjp-23953	89	3	febrile	febrile	NOUN
bjp-23953	89	4	neutropenia	neutropenia	NOUN
bjp-23953	89	5	,	,	PUNCT
bjp-23953	89	6	thrombocytopenia	thrombocytopenia	PROPN
bjp-23953	89	7	,	,	PUNCT
bjp-23953	89	8	hyperglycemia	hyperglycemia	NOUN
bjp-23953	89	9	,	,	PUNCT
bjp-23953	89	10	hyponatremia	hyponatremia	NOUN
bjp-23953	89	11	,	,	PUNCT
bjp-23953	89	12	infection	infection	NOUN
bjp-23953	89	13	,	,	PUNCT
bjp-23953	89	14	elevated	elevated	ADJ
bjp-23953	89	15	alt	alt	ADJ
bjp-23953	89	16	and	and	CCONJ
bjp-23953	89	17	ast	ast	NOUN
bjp-23953	89	18	level	level	NOUN
bjp-23953	89	19	were	be	AUX
bjp-23953	89	20	also	also	ADV
bjp-23953	89	21	appeared	appear	VERB
bjp-23953	89	22	,	,	PUNCT
bjp-23953	89	23	but	but	CCONJ
bjp-23953	89	24	quantity	quantity	NOUN
bjp-23953	89	25	of	of	ADP
bjp-23953	89	26	these	these	DET
bjp-23953	89	27	adverse	adverse	ADJ
bjp-23953	89	28	events	event	NOUN
bjp-23953	89	29	were	be	AUX
bjp-23953	89	30	very	very	ADV
bjp-23953	89	31	few	few	ADJ
bjp-23953	89	32	.	.	PUNCT
bjp-23953	90	1	however	however	ADV
bjp-23953	90	2	,	,	PUNCT
bjp-23953	90	3	21	21	NUM
bjp-23953	90	4	patients	patient	NOUN
bjp-23953	90	5	(	(	PUNCT
bjp-23953	90	6	22.1	22.1	NUM
bjp-23953	90	7	%	%	NOUN
bjp-23953	90	8	)	)	PUNCT
bjp-23953	90	9	were	be	AUX
bjp-23953	90	10	observed	observe	VERB
bjp-23953	90	11	grade	grade	NOUN
bjp-23953	90	12	3	3	NUM
bjp-23953	90	13	neutropenia	neutropenia	NOUN
bjp-23953	90	14	,	,	PUNCT
bjp-23953	90	15	64	64	NUM
bjp-23953	90	16	patients	patient	NOUN
bjp-23953	90	17	(	(	PUNCT
bjp-23953	90	18	67.4	67.4	NUM
bjp-23953	90	19	%	%	NOUN
bjp-23953	90	20	)	)	PUNCT
bjp-23953	90	21	were	be	AUX
bjp-23953	90	22	observed	observe	VERB
bjp-23953	90	23	grade	grade	NOUN
bjp-23953	90	24	4	4	NUM
bjp-23953	90	25	neutropenia	neutropenia	NOUN
bjp-23953	90	26	,	,	PUNCT
bjp-23953	90	27	and	and	CCONJ
bjp-23953	90	28	85	85	NUM
bjp-23953	90	29	patients	patient	NOUN
bjp-23953	90	30	(	(	PUNCT
bjp-23953	90	31	89.5	89.5	NUM
bjp-23953	90	32	%	%	NOUN
bjp-23953	90	33	)	)	PUNCT
bjp-23953	90	34	were	be	AUX
bjp-23953	90	35	observed	observe	VERB
bjp-23953	90	36	grade	grade	NOUN
bjp-23953	90	37	3	3	NUM
bjp-23953	90	38	+	+	SYM
bjp-23953	90	39	4	4	NUM
bjp-23953	90	40	neutropenia	neutropenia	NOUN
bjp-23953	90	41	.	.	PUNCT
bjp-23953	91	1	conclusion	conclusion	NOUN
bjp-23953	91	2	amrubicin	amrubicin	NOUN
bjp-23953	91	3	therapy	therapy	NOUN
bjp-23953	91	4	improves	improve	VERB
bjp-23953	91	5	patients	patient	NOUN
bjp-23953	91	6	with	with	ADP
bjp-23953	91	7	refractory	refractory	NOUN
bjp-23953	91	8	small	small	ADJ
bjp-23953	91	9	-	-	PUNCT
bjp-23953	91	10	cell	cell	NOUN
bjp-23953	91	11	lung	lung	NOUN
bjp-23953	91	12	cancer	cancer	NOUN
bjp-23953	91	13	,	,	PUNCT
bjp-23953	91	14	which	which	PRON
bjp-23953	91	15	showed	show	VERB
bjp-23953	91	16	a	a	DET
bjp-23953	91	17	favorable	favorable	ADJ
bjp-23953	91	18	tumor	tumor	NOUN
bjp-23953	91	19	response	response	NOUN
bjp-23953	91	20	,	,	PUNCT
bjp-23953	91	21	prolonged	prolonged	ADJ
bjp-23953	91	22	survival	survival	NOUN
bjp-23953	91	23	,	,	PUNCT
bjp-23953	91	24	and	and	CCONJ
bjp-23953	91	25	acceptable	acceptable	ADJ
bjp-23953	91	26	toxicity	toxicity	NOUN
bjp-23953	91	27	.	.	PUNCT
bjp-23953	92	1	therefore	therefore	ADV
bjp-23953	92	2	,	,	PUNCT
bjp-23953	92	3	amrubicin	amrubicin	NOUN
bjp-23953	92	4	therapy	therapy	NOUN
bjp-23953	92	5	emerges	emerge	VERB
bjp-23953	92	6	a	a	DET
bjp-23953	92	7	standard	standard	ADJ
bjp-23953	92	8	treatment	treatment	NOUN
bjp-23953	92	9	for	for	ADP
bjp-23953	92	10	refractory	refractory	NOUN
bjp-23953	92	11	small	small	ADJ
bjp-23953	92	12	-	-	PUNCT
bjp-23953	92	13	cell	cell	NOUN
bjp-23953	92	14	lung	lung	NOUN
bjp-23953	92	15	cancer	cancer	NOUN
bjp-23953	92	16	.	.	PUNCT
bjp-23953	93	1	references	reference	NOUN
bjp-23953	93	2	asai	asai	PROPN
bjp-23953	93	3	n	n	CCONJ
bjp-23953	93	4	,	,	PUNCT
bjp-23953	93	5	ohkuni	ohkuni	PROPN
bjp-23953	93	6	y	y	PROPN
bjp-23953	93	7	,	,	PUNCT
bjp-23953	93	8	matsunuma	matsunuma	ADJ
bjp-23953	93	9	r	r	PROPN
bjp-23953	93	10	,	,	PUNCT
bjp-23953	93	11	nakashima	nakashima	PROPN
bjp-23953	93	12	k	k	PROPN
bjp-23953	93	13	,	,	PUNCT
bjp-23953	93	14	iwasaki	iwasaki	PROPN
bjp-23953	93	15	t	t	PROPN
bjp-23953	93	16	,	,	PUNCT
bjp-23953	93	17	kaneko	kaneko	PROPN
bjp-23953	93	18	n.	n.	PROPN
bjp-23953	93	19	efficacy	efficacy	PROPN
bjp-23953	93	20	and	and	CCONJ
bjp-23953	93	21	safety	safety	NOUN
bjp-23953	93	22	of	of	ADP
bjp-23953	93	23	amurubicin	amurubicin	NOUN
bjp-23953	93	24	for	for	ADP
bjp-23953	93	25	the	the	DET
bjp-23953	93	26	elderly	elderly	ADJ
bjp-23953	93	27	patients	patient	NOUN
bjp-23953	93	28	with	with	ADP
bjp-23953	93	29	refractory	refractory	NOUN
bjp-23953	93	30	relapsed	relapse	VERB
bjp-23953	93	31	small	small	ADJ
bjp-23953	93	32	cell	cell	NOUN
bjp-23953	93	33	lung	lung	NOUN
bjp-23953	93	34	cancer	cancer	NOUN
bjp-23953	93	35	as	as	ADP
bjp-23953	93	36	third	third	ADJ
bjp-23953	93	37	-	-	PUNCT
bjp-23953	93	38	line	line	NOUN
bjp-23953	93	39	chemotherapy	chemotherapy	NOUN
bjp-23953	93	40	.	.	PUNCT
bjp-23953	94	1	j	j	PROPN
bjp-23953	94	2	cancer	cancer	NOUN
bjp-23953	94	3	res	re	VERB
bjp-23953	94	4	ther	ther	ADV
bjp-23953	94	5	.	.	PUNCT
bjp-23953	95	1	2012	2012	NUM
bjp-23953	95	2	;	;	PUNCT
bjp-23953	95	3	8	8	NUM
bjp-23953	95	4	:	:	SYM
bjp-23953	95	5	266	266	NUM
bjp-23953	95	6	-	-	SYM
bjp-23953	95	7	71	71	NUM
bjp-23953	95	8	.	.	PUNCT
bjp-23953	96	1	bosch	bosch	PROPN
bjp-23953	96	2	x.	x.	PROPN
bjp-23953	96	3	small	small	ADJ
bjp-23953	96	4	-	-	PUNCT
bjp-23953	96	5	cell	cell	NOUN
bjp-23953	96	6	lung	lung	NOUN
bjp-23953	96	7	cancer	cancer	NOUN
bjp-23953	96	8	responds	respond	VERB
bjp-23953	96	9	to	to	ADP
bjp-23953	96	10	amrubicin	amrubicin	PROPN
bjp-23953	96	11	.	.	PUNCT
bjp-23953	97	1	lancet	lancet	PROPN
bjp-23953	97	2	oncol	oncol	PROPN
bjp-23953	97	3	.	.	PUNCT
bjp-23953	98	1	2007	2007	NUM
bjp-23953	98	2	;	;	PUNCT
bjp-23953	98	3	8	8	NUM
bjp-23953	98	4	:	:	SYM
bjp-23953	98	5	13	13	NUM
bjp-23953	98	6	.	.	PUNCT
bjp-23953	99	1	cheng	cheng	PROPN
bjp-23953	99	2	cy	cy	PROPN
bjp-23953	99	3	,	,	PUNCT
bjp-23953	99	4	su	su	PROPN
bjp-23953	99	5	cc	cc	PROPN
bjp-23953	99	6	.	.	PROPN
bjp-23953	99	7	tanshinone	tanshinone	PROPN
bjp-23953	99	8	iia	iia	PROPN
bjp-23953	99	9	may	may	AUX
bjp-23953	99	10	inhibit	inhibit	VERB
bjp-23953	99	11	the	the	DET
bjp-23953	99	12	growth	growth	NOUN
bjp-23953	99	13	of	of	ADP
bjp-23953	99	14	small	small	ADJ
bjp-23953	99	15	cell	cell	NOUN
bjp-23953	99	16	lung	lung	NOUN
bjp-23953	99	17	cancer	cancer	NOUN
bjp-23953	99	18	h146	h146	PROPN
bjp-23953	99	19	cells	cell	NOUN
bjp-23953	99	20	by	by	ADP
bjp-23953	99	21	up	up	ADV
bjp-23953	99	22	-	-	PUNCT
bjp-23953	99	23	regulating	regulate	VERB
bjp-23953	99	24	the	the	DET
bjp-23953	99	25	bax/	bax/	NOUN
bjp-23953	99	26	bcl-2	bcl-2	PUNCT
bjp-23953	99	27	ratio	ratio	NOUN
bjp-23953	99	28	and	and	CCONJ
bjp-23953	99	29	decreasing	decrease	VERB
bjp-23953	99	30	mitochondrial	mitochondrial	ADJ
bjp-23953	99	31	membrane	membrane	NOUN
bjp-23953	99	32	potential	potential	NOUN
bjp-23953	99	33	.	.	PUNCT
bjp-23953	100	1	mol	mol	ADP
bjp-23953	100	2	med	med	PROPN
bjp-23953	100	3	rep	rep	PROPN
bjp-23953	100	4	.	.	PROPN
bjp-23953	100	5	2010	2010	NUM
bjp-23953	100	6	;	;	PUNCT
bjp-23953	100	7	3	3	NUM
bjp-23953	100	8	:	:	PUNCT
bjp-23953	100	9	645	645	NUM
bjp-23953	100	10	-	-	SYM
bjp-23953	100	11	50	50	NUM
bjp-23953	100	12	.	.	PUNCT
bjp-23953	101	1	chotenimitkhun	chotenimitkhun	PROPN
bjp-23953	101	2	r	r	PROPN
bjp-23953	101	3	,	,	PUNCT
bjp-23953	101	4	d'agostino	d'agostino	PROPN
bjp-23953	101	5	r	r	NOUN
bjp-23953	101	6	jr	jr	PROPN
bjp-23953	101	7	.	.	PROPN
bjp-23953	101	8	,	,	PUNCT
bjp-23953	101	9	lawrence	lawrence	PROPN
bjp-23953	101	10	ja	ja	PROPN
bjp-23953	101	11	,	,	PUNCT
bjp-23953	101	12	hamilton	hamilton	PROPN
bjp-23953	101	13	ca	ca	PROPN
bjp-23953	101	14	,	,	PUNCT
bjp-23953	101	15	jordan	jordan	PROPN
bjp-23953	101	16	jh	jh	PROPN
bjp-23953	101	17	,	,	PUNCT
bjp-23953	101	18	vasu	vasu	PROPN
bjp-23953	101	19	s	s	PROPN
bjp-23953	101	20	,	,	PUNCT
bjp-23953	101	21	lash	lash	VERB
bjp-23953	101	22	tl	tl	PROPN
bjp-23953	101	23	,	,	PUNCT
bjp-23953	101	24	yeboah	yeboah	PROPN
bjp-23953	101	25	j	j	PROPN
bjp-23953	101	26	,	,	PUNCT
bjp-23953	101	27	herrington	herrington	PROPN
bjp-23953	101	28	dm	dm	PROPN
bjp-23953	101	29	,	,	PUNCT
bjp-23953	101	30	hundley	hundley	PROPN
bjp-23953	101	31	wg	wg	PROPN
bjp-23953	101	32	.	.	PUNCT
bjp-23953	102	1	chronic	chronic	PROPN
bjp-23953	102	2	statin	statin	PROPN
bjp-23953	102	3	administration	administration	PROPN
bjp-23953	102	4	may	may	AUX
bjp-23953	102	5	attenuate	attenuate	VERB
bjp-23953	102	6	early	early	ADJ
bjp-23953	102	7	anthracycline	anthracycline	NOUN
bjp-23953	102	8	-	-	PUNCT
bjp-23953	102	9	associated	associate	VERB
bjp-23953	102	10	declines	decline	NOUN
bjp-23953	102	11	in	in	ADP
bjp-23953	102	12	left	left	ADJ
bjp-23953	102	13	ventricular	ventricular	ADJ
bjp-23953	102	14	ejection	ejection	NOUN
bjp-23953	102	15	function	function	NOUN
bjp-23953	102	16	.	.	PUNCT
bjp-23953	103	1	can	can	AUX
bjp-23953	103	2	j	j	PROPN
bjp-23953	103	3	cardiol	cardiol	VERB
bjp-23953	103	4	.	.	PUNCT
bjp-23953	104	1	2015	2015	NUM
bjp-23953	104	2	;	;	PUNCT
bjp-23953	104	3	31	31	NUM
bjp-23953	104	4	:	:	SYM
bjp-23953	104	5	302	302	NUM
bjp-23953	104	6	-	-	SYM
bjp-23953	104	7	07	07	NUM
bjp-23953	104	8	.	.	PUNCT
bjp-23953	105	1	ding	de	VERB
bjp-23953	105	2	c	c	PROPN
bjp-23953	105	3	,	,	PUNCT
bjp-23953	105	4	li	li	PROPN
bjp-23953	105	5	r	r	PROPN
bjp-23953	105	6	,	,	PUNCT
bjp-23953	105	7	peng	peng	PROPN
bjp-23953	105	8	j	j	PROPN
bjp-23953	105	9	,	,	PUNCT
bjp-23953	105	10	li	li	PROPN
bjp-23953	105	11	s	s	PROPN
bjp-23953	105	12	,	,	PUNCT
bjp-23953	105	13	guo	guo	PROPN
bjp-23953	105	14	z.	z.	PROPN
bjp-23953	105	15	a	a	DET
bjp-23953	105	16	polymorphism	polymorphism	NOUN
bjp-23953	105	17	at	at	ADP
bjp-23953	105	18	the	the	DET
bjp-23953	105	19	mir502	mir502	PROPN
bjp-23953	105	20	binding	bind	VERB
bjp-23953	105	21	site	site	NOUN
bjp-23953	105	22	in	in	ADP
bjp-23953	105	23	the	the	DET
bjp-23953	105	24	3	3	NUM
bjp-23953	105	25	'	'	PART
bjp-23953	105	26	untranslated	untranslated	ADJ
bjp-23953	105	27	region	region	NOUN
bjp-23953	105	28	of	of	ADP
bjp-23953	105	29	the	the	DET
bjp-23953	105	30	set8	set8	PROPN
bjp-23953	105	31	gene	gene	NOUN
bjp-23953	105	32	is	be	AUX
bjp-23953	105	33	associated	associate	VERB
bjp-23953	105	34	with	with	ADP
bjp-23953	105	35	the	the	DET
bjp-23953	105	36	outcome	outcome	NOUN
bjp-23953	105	37	of	of	ADP
bjp-23953	105	38	small	small	ADJ
bjp-23953	105	39	-	-	PUNCT
bjp-23953	105	40	cell	cell	NOUN
bjp-23953	105	41	lung	lung	NOUN
bjp-23953	105	42	cancer	cancer	NOUN
bjp-23953	105	43	.	.	PUNCT
bjp-23953	106	1	exp	exp	NOUN
bjp-23953	106	2	ther	ther	PROPN
bjp-23953	106	3	med	med	PROPN
bjp-23953	106	4	.	.	PUNCT
bjp-23953	106	5	2012	2012	NUM
bjp-23953	106	6	;	;	PUNCT
bjp-23953	106	7	3	3	NUM
bjp-23953	106	8	:	:	PUNCT
bjp-23953	106	9	689	689	NUM
bjp-23953	106	10	-	-	SYM
bjp-23953	106	11	92	92	NUM
bjp-23953	106	12	.	.	PUNCT
bjp-23953	107	1	ding	de	VERB
bjp-23953	107	2	q	q	PROPN
bjp-23953	107	3	,	,	PUNCT
bjp-23953	107	4	zhan	zhan	PROPN
bjp-23953	107	5	j.	j.	PROPN
bjp-23953	107	6	amrubicin	amrubicin	PROPN
bjp-23953	107	7	:	:	PUNCT
bjp-23953	107	8	potential	potential	NOUN
bjp-23953	107	9	in	in	ADP
bjp-23953	107	10	combination	combination	NOUN
bjp-23953	107	11	with	with	ADP
bjp-23953	107	12	cisplatin	cisplatin	NOUN
bjp-23953	107	13	or	or	CCONJ
bjp-23953	107	14	carboplatin	carboplatin	NOUN
bjp-23953	107	15	to	to	PART
bjp-23953	107	16	treat	treat	VERB
bjp-23953	107	17	small	small	ADJ
bjp-23953	107	18	-	-	PUNCT
bjp-23953	107	19	cell	cell	NOUN
bjp-23953	107	20	lung	lung	NOUN
bjp-23953	107	21	cancer	cancer	NOUN
bjp-23953	107	22	.	.	PUNCT
bjp-23953	108	1	drug	drug	NOUN
bjp-23953	108	2	des	des	PROPN
bjp-23953	108	3	devel	devel	NOUN
bjp-23953	108	4	ther	ther	ADV
bjp-23953	108	5	.	.	PUNCT
bjp-23953	109	1	2013	2013	NUM
bjp-23953	109	2	;	;	PUNCT
bjp-23953	109	3	7	7	NUM
bjp-23953	109	4	:	:	SYM
bjp-23953	109	5	681	681	NUM
bjp-23953	109	6	-	-	SYM
bjp-23953	109	7	89	89	NUM
bjp-23953	109	8	.	.	PUNCT
bjp-23953	110	1	ettinger	ettinger	PROPN
bjp-23953	110	2	ds	ds	PROPN
bjp-23953	110	3	,	,	PUNCT
bjp-23953	110	4	jotte	jotte	NOUN
bjp-23953	110	5	r	r	PROPN
bjp-23953	110	6	,	,	PUNCT
bjp-23953	110	7	lorigan	lorigan	VERB
bjp-23953	110	8	p	p	NOUN
bjp-23953	110	9	,	,	PUNCT
bjp-23953	110	10	gupta	gupta	PROPN
bjp-23953	110	11	v	v	NOUN
bjp-23953	110	12	,	,	PUNCT
bjp-23953	110	13	garbo	garbo	PROPN
bjp-23953	110	14	l	l	PROPN
bjp-23953	110	15	,	,	PUNCT
bjp-23953	110	16	alemany	alemany	NOUN
bjp-23953	110	17	c	c	NOUN
bjp-23953	110	18	,	,	PUNCT
bjp-23953	110	19	conkling	conkle	VERB
bjp-23953	110	20	p	p	PRON
bjp-23953	110	21	,	,	PUNCT
bjp-23953	110	22	spigel	spigel	NOUN
bjp-23953	110	23	dr	dr	PROPN
bjp-23953	110	24	,	,	PUNCT
bjp-23953	110	25	dudek	dudek	PROPN
bjp-23953	110	26	az	az	PROPN
bjp-23953	110	27	,	,	PUNCT
bjp-23953	110	28	shah	shah	PROPN
bjp-23953	110	29	c	c	PROPN
bjp-23953	110	30	,	,	PUNCT
bjp-23953	110	31	salgia	salgia	ADJ
bjp-23953	110	32	r	r	NOUN
bjp-23953	110	33	,	,	PUNCT
bjp-23953	110	34	mcnally	mcnally	PROPN
bjp-23953	110	35	r	r	PROPN
bjp-23953	110	36	,	,	PUNCT
bjp-23953	110	37	renschler	renschler	NOUN
bjp-23953	110	38	mf	mf	PROPN
bjp-23953	110	39	,	,	PUNCT
bjp-23953	110	40	oliver	oliver	PROPN
bjp-23953	110	41	jw	jw	PROPN
bjp-23953	110	42	.	.	PROPN
bjp-23953	110	43	phase	phase	PROPN
bjp-23953	110	44	ii	ii	PROPN
bjp-23953	110	45	study	study	NOUN
bjp-23953	110	46	of	of	ADP
bjp-23953	110	47	amrubicin	amrubicin	NOUN
bjp-23953	110	48	as	as	ADP
bjp-23953	110	49	second	second	ADJ
bjp-23953	110	50	-	-	PUNCT
bjp-23953	110	51	line	line	NOUN
bjp-23953	110	52	therapy	therapy	NOUN
bjp-23953	110	53	in	in	ADP
bjp-23953	110	54	patients	patient	NOUN
bjp-23953	110	55	with	with	ADP
bjp-23953	110	56	platinumrefractory	platinumrefractory	NOUN
bjp-23953	110	57	small	small	ADJ
bjp-23953	110	58	-	-	PUNCT
bjp-23953	110	59	cell	cell	NOUN
bjp-23953	110	60	lung	lung	NOUN
bjp-23953	110	61	cancer	cancer	NOUN
bjp-23953	110	62	.	.	PUNCT
bjp-23953	111	1	j	j	PROPN
bjp-23953	111	2	clin	clin	PROPN
bjp-23953	111	3	oncol	oncol	PROPN
bjp-23953	111	4	.	.	PUNCT
bjp-23953	112	1	2010	2010	NUM
bjp-23953	112	2	;	;	PUNCT
bjp-23953	112	3	28	28	NUM
bjp-23953	112	4	:	:	SYM
bjp-23953	112	5	2598603	2598603	NUM
bjp-23953	112	6	.	.	PUNCT
bjp-23953	113	1	gervais	gervais	PROPN
bjp-23953	113	2	r	r	PROPN
bjp-23953	113	3	,	,	PUNCT
bjp-23953	113	4	le	le	X
bjp-23953	113	5	caer	caer	PROPN
bjp-23953	113	6	h	h	PROPN
bjp-23953	113	7	,	,	PUNCT
bjp-23953	113	8	monnet	monnet	VERB
bjp-23953	113	9	i	i	PRON
bjp-23953	113	10	,	,	PUNCT
bjp-23953	113	11	falchero	falchero	PROPN
bjp-23953	113	12	l	l	NOUN
bjp-23953	113	13	,	,	PUNCT
bjp-23953	113	14	baize	baize	NOUN
bjp-23953	113	15	n	n	CCONJ
bjp-23953	113	16	,	,	PUNCT
bjp-23953	113	17	olivero	olivero	PROPN
bjp-23953	113	18	g	g	PROPN
bjp-23953	113	19	,	,	PUNCT
bjp-23953	113	20	thomas	thomas	PROPN
bjp-23953	113	21	p	p	PROPN
bjp-23953	113	22	,	,	PUNCT
bjp-23953	113	23	berard	berard	PROPN
bjp-23953	113	24	h	h	PROPN
bjp-23953	113	25	,	,	PUNCT
bjp-23953	113	26	auliac	auliac	PROPN
bjp-23953	113	27	jb	jb	PROPN
bjp-23953	113	28	,	,	PUNCT
bjp-23953	113	29	chouaid	chouaid	VERB
bjp-23953	113	30	c.	c.	PROPN
bjp-23953	113	31	second	second	ADJ
bjp-23953	113	32	-	-	PUNCT
bjp-23953	113	33	line	line	NOUN
bjp-23953	113	34	oral	oral	ADJ
bjp-23953	113	35	chemotherapy	chemotherapy	NOUN
bjp-23953	113	36	(	(	PUNCT
bjp-23953	113	37	lomustine	lomustine	NOUN
bjp-23953	113	38	,	,	PUNCT
bjp-23953	113	39	cyclophosphamide	cyclophosphamide	NOUN
bjp-23953	113	40	,	,	PUNCT
bjp-23953	113	41	etoposide	etoposide	NOUN
bjp-23953	113	42	)	)	PUNCT
bjp-23953	113	43	versus	versus	ADP
bjp-23953	113	44	intravenous	intravenous	ADJ
bjp-23953	113	45	therapy	therapy	NOUN
bjp-23953	113	46	(	(	PUNCT
bjp-23953	113	47	cyclophosphamide	cyclophosphamide	PROPN
bjp-23953	113	48	,	,	PUNCT
bjp-23953	113	49	doxorubicin	doxorubicin	PROPN
bjp-23953	113	50	,	,	PUNCT
bjp-23953	113	51	and	and	CCONJ
bjp-23953	113	52	vincristine	vincristine	NOUN
bjp-23953	113	53	)	)	PUNCT
bjp-23953	113	54	in	in	ADP
bjp-23953	113	55	patients	patient	NOUN
bjp-23953	113	56	with	with	ADP
bjp-23953	113	57	relapsed	relapse	VERB
bjp-23953	113	58	small	small	ADJ
bjp-23953	113	59	cell	cell	NOUN
bjp-23953	113	60	lung	lung	NOUN
bjp-23953	113	61	cancer	cancer	NOUN
bjp-23953	113	62	:	:	PUNCT
bjp-23953	113	63	a	a	DET
bjp-23953	113	64	randomized	randomized	ADJ
bjp-23953	113	65	phase	phase	NOUN
bjp-23953	113	66	ii	ii	PROPN
bjp-23953	113	67	study	study	NOUN
bjp-23953	113	68	of	of	ADP
bjp-23953	113	69	gfpc	gfpc	PROPN
bjp-23953	113	70	0501	0501	NUM
bjp-23953	113	71	.	.	PUNCT
bjp-23953	114	1	clin	clin	PROPN
bjp-23953	114	2	lung	lung	NOUN
bjp-23953	114	3	cancer	cancer	NOUN
bjp-23953	114	4	.	.	PUNCT
bjp-23953	115	1	2015	2015	NUM
bjp-23953	115	2	;	;	PUNCT
bjp-23953	115	3	16	16	NUM
bjp-23953	115	4	:	:	SYM
bjp-23953	115	5	100	100	NUM
bjp-23953	115	6	-	-	SYM
bjp-23953	115	7	05	05	NUM
bjp-23953	115	8	.	.	PUNCT
bjp-23953	116	1	hanada	hanada	PROPN
bjp-23953	116	2	m	m	PROPN
bjp-23953	116	3	,	,	PUNCT
bjp-23953	116	4	noguchi	noguchi	PROPN
bjp-23953	116	5	t	t	PROPN
bjp-23953	116	6	,	,	PUNCT
bjp-23953	116	7	yamaoka	yamaoka	PROPN
bjp-23953	116	8	t.	t.	PROPN
bjp-23953	116	9	amrubicin	amrubicin	PROPN
bjp-23953	116	10	,	,	PUNCT
bjp-23953	116	11	a	a	DET
bjp-23953	116	12	novel	novel	ADJ
bjp-23953	116	13	9aminoanthracycline	9aminoanthracycline	NUM
bjp-23953	116	14	,	,	PUNCT
bjp-23953	116	15	enhances	enhance	VERB
bjp-23953	116	16	the	the	DET
bjp-23953	116	17	antitumor	antitumor	PROPN
bjp-23953	116	18	activity	activity	NOUN
bjp-23953	116	19	of	of	ADP
bjp-23953	116	20	568	568	NUM
bjp-23953	116	21	bangladesh	bangladesh	NOUN
bjp-23953	116	22	j	j	PROPN
bjp-23953	116	23	pharmacol	pharmacol	PROPN
bjp-23953	116	24	2016	2016	NUM
bjp-23953	116	25	;	;	PUNCT
bjp-23953	116	26	11	11	NUM
bjp-23953	116	27	:	:	SYM
bjp-23953	116	28	564	564	NUM
bjp-23953	116	29	-	-	SYM
bjp-23953	116	30	569	569	NUM
bjp-23953	116	31	author	author	NOUN
bjp-23953	116	32	info	info	NOUN
bjp-23953	116	33	naikang	naikang	PROPN
bjp-23953	116	34	zhou	zhou	PROPN
bjp-23953	116	35	(	(	PUNCT
bjp-23953	116	36	principal	principal	ADJ
bjp-23953	116	37	contact	contact	NOUN
bjp-23953	116	38	)	)	PUNCT
bjp-23953	116	39	e	e	NOUN
bjp-23953	116	40	-	-	NOUN
bjp-23953	116	41	mail	mail	NOUN
bjp-23953	116	42	:	:	PUNCT
bjp-23953	116	43	zhounk2005@163.com	zhounk2005@163.com	NUM
bjp-23953	116	44	chemotherapeutic	chemotherapeutic	ADJ
bjp-23953	116	45	agents	agent	NOUN
bjp-23953	116	46	against	against	ADP
bjp-23953	116	47	human	human	ADJ
bjp-23953	116	48	cancer	cancer	NOUN
bjp-23953	116	49	cells	cell	NOUN
bjp-23953	116	50	in	in	ADP
bjp-23953	116	51	vitro	vitro	X
bjp-23953	116	52	and	and	CCONJ
bjp-23953	116	53	in	in	ADP
bjp-23953	116	54	vivo	vivo	NOUN
bjp-23953	116	55	.	.	PUNCT
bjp-23953	117	1	cancer	cancer	PROPN
bjp-23953	117	2	sci	sci	PROPN
bjp-23953	117	3	.	.	PROPN
bjp-23953	117	4	2007	2007	NUM
bjp-23953	117	5	;	;	PUNCT
bjp-23953	117	6	98	98	NUM
bjp-23953	117	7	:	:	SYM
bjp-23953	117	8	447	447	NUM
bjp-23953	117	9	-	-	SYM
bjp-23953	117	10	54	54	NUM
bjp-23953	117	11	.	.	PUNCT
bjp-23953	118	1	hira	hira	PROPN
bjp-23953	118	2	a	a	PROPN
bjp-23953	118	3	,	,	PUNCT
bjp-23953	118	4	watanabe	watanabe	PROPN
bjp-23953	118	5	h	h	PROPN
bjp-23953	118	6	,	,	PUNCT
bjp-23953	118	7	maeda	maeda	PROPN
bjp-23953	118	8	y	y	PROPN
bjp-23953	118	9	,	,	PUNCT
bjp-23953	118	10	yokoo	yokoo	PROPN
bjp-23953	118	11	k	k	PROPN
bjp-23953	118	12	,	,	PUNCT
bjp-23953	118	13	sanematsu	sanematsu	PROPN
bjp-23953	118	14	e	e	NOUN
bjp-23953	118	15	,	,	PUNCT
bjp-23953	118	16	fujii	fujii	PROPN
bjp-23953	118	17	j	j	PROPN
bjp-23953	118	18	,	,	PUNCT
bjp-23953	118	19	sasaki	sasaki	PROPN
bjp-23953	118	20	j	j	PROPN
bjp-23953	118	21	,	,	PUNCT
bjp-23953	118	22	hamada	hamada	PROPN
bjp-23953	118	23	a	a	PROPN
bjp-23953	118	24	,	,	PUNCT
bjp-23953	118	25	saito	saito	PROPN
bjp-23953	118	26	h.	h.	PROPN
bjp-23953	118	27	role	role	NOUN
bjp-23953	118	28	of	of	ADP
bjp-23953	118	29	p	p	NOUN
bjp-23953	118	30	-	-	PUNCT
bjp-23953	118	31	glycoprotein	glycoprotein	NOUN
bjp-23953	118	32	in	in	ADP
bjp-23953	118	33	accumulation	accumulation	NOUN
bjp-23953	118	34	and	and	CCONJ
bjp-23953	118	35	cytotoxicity	cytotoxicity	NOUN
bjp-23953	118	36	of	of	ADP
bjp-23953	118	37	amrubicin	amrubicin	NOUN
bjp-23953	118	38	and	and	CCONJ
bjp-23953	118	39	amrubicinol	amrubicinol	NOUN
bjp-23953	118	40	in	in	ADP
bjp-23953	118	41	mdr1	mdr1	PROPN
bjp-23953	118	42	gene	gene	NOUN
bjp-23953	118	43	-	-	PUNCT
bjp-23953	118	44	transfected	transfecte	VERB
bjp-23953	118	45	llc	llc	PROPN
bjp-23953	118	46	-	-	PUNCT
bjp-23953	118	47	pk1	pk1	NOUN
bjp-23953	118	48	cells	cell	NOUN
bjp-23953	118	49	and	and	CCONJ
bjp-23953	118	50	human	human	ADJ
bjp-23953	118	51	a549	a549	PROPN
bjp-23953	118	52	lung	lung	NOUN
bjp-23953	118	53	adenocarcinoma	adenocarcinoma	NOUN
bjp-23953	118	54	cells	cell	NOUN
bjp-23953	118	55	.	.	PUNCT
bjp-23953	119	1	biochem	biochem	PROPN
bjp-23953	119	2	pharmacol	pharmacol	PROPN
bjp-23953	119	3	.	.	PROPN
bjp-23953	119	4	2008	2008	NUM
bjp-23953	119	5	;	;	PUNCT
bjp-23953	119	6	75	75	NUM
bjp-23953	119	7	:	:	PUNCT
bjp-23953	119	8	973	973	NUM
bjp-23953	119	9	-	-	SYM
bjp-23953	119	10	80	80	NUM
bjp-23953	119	11	.	.	PUNCT
bjp-23953	120	1	igawa	igawa	PROPN
bjp-23953	120	2	s	s	PROPN
bjp-23953	120	3	,	,	PUNCT
bjp-23953	120	4	sasaki	sasaki	PROPN
bjp-23953	120	5	j	j	PROPN
bjp-23953	120	6	,	,	PUNCT
bjp-23953	120	7	ishihara	ishihara	PROPN
bjp-23953	120	8	m	m	PROPN
bjp-23953	120	9	,	,	PUNCT
bjp-23953	120	10	otani	otani	PROPN
bjp-23953	120	11	s	s	PROPN
bjp-23953	120	12	,	,	PUNCT
bjp-23953	120	13	maki	maki	PROPN
bjp-23953	120	14	s	s	PROPN
bjp-23953	120	15	,	,	PUNCT
bjp-23953	120	16	hiyoshi	hiyoshi	PROPN
bjp-23953	120	17	y	y	PROPN
bjp-23953	120	18	,	,	PUNCT
bjp-23953	120	19	kasajima	kasajima	PROPN
bjp-23953	120	20	m	m	PROPN
bjp-23953	120	21	,	,	PUNCT
bjp-23953	120	22	katono	katono	PROPN
bjp-23953	120	23	k	k	PROPN
bjp-23953	120	24	,	,	PUNCT
bjp-23953	120	25	takakura	takakura	PROPN
bjp-23953	120	26	a	a	PROPN
bjp-23953	120	27	,	,	PUNCT
bjp-23953	120	28	masuda	masuda	PROPN
bjp-23953	120	29	n.	n.	PROPN
bjp-23953	120	30	evaluation	evaluation	NOUN
bjp-23953	120	31	of	of	ADP
bjp-23953	120	32	amrubicin	amrubicin	NOUN
bjp-23953	120	33	as	as	ADP
bjp-23953	120	34	a	a	DET
bjp-23953	120	35	third	third	ADJ
bjp-23953	120	36	or	or	CCONJ
bjp-23953	120	37	later	late	ADJ
bjp-23953	120	38	line	line	NOUN
bjp-23953	120	39	of	of	ADP
bjp-23953	120	40	chemotherapy	chemotherapy	NOUN
bjp-23953	120	41	for	for	ADP
bjp-23953	120	42	advanced	advanced	ADJ
bjp-23953	120	43	non	non	ADJ
bjp-23953	120	44	-	-	ADJ
bjp-23953	120	45	small	small	ADJ
bjp-23953	120	46	cell	cell	NOUN
bjp-23953	120	47	lung	lung	NOUN
bjp-23953	120	48	cancer	cancer	NOUN
bjp-23953	120	49	.	.	PUNCT
bjp-23953	121	1	chemotherapy	chemotherapy	NOUN
bjp-23953	121	2	2013	2013	NUM
bjp-23953	121	3	;	;	PUNCT
bjp-23953	121	4	59	59	NUM
bjp-23953	121	5	:	:	SYM
bjp-23953	121	6	99	99	NUM
bjp-23953	121	7	-	-	SYM
bjp-23953	121	8	105	105	NUM
bjp-23953	121	9	.	.	PUNCT
bjp-23953	122	1	ikeda	ikeda	PROPN
bjp-23953	122	2	t	t	PROPN
bjp-23953	122	3	,	,	PUNCT
bjp-23953	122	4	fukuda	fukuda	PROPN
bjp-23953	122	5	m	m	PROPN
bjp-23953	122	6	,	,	PUNCT
bjp-23953	122	7	nakamura	nakamura	PROPN
bjp-23953	122	8	y	y	PROPN
bjp-23953	122	9	,	,	PUNCT
bjp-23953	122	10	kinoshita	kinoshita	VERB
bjp-23953	122	11	a	a	PRON
bjp-23953	122	12	,	,	PUNCT
bjp-23953	122	13	senju	senju	PROPN
bjp-23953	122	14	h	h	NOUN
bjp-23953	122	15	,	,	PUNCT
bjp-23953	122	16	nakano	nakano	PROPN
bjp-23953	122	17	h	h	PROPN
bjp-23953	122	18	,	,	PUNCT
bjp-23953	122	19	kitazaki	kitazaki	PROPN
bjp-23953	122	20	t	t	PROPN
bjp-23953	122	21	,	,	PUNCT
bjp-23953	122	22	ogawara	ogawara	ADJ
bjp-23953	122	23	d	d	PROPN
bjp-23953	122	24	,	,	PUNCT
bjp-23953	122	25	taniguchi	taniguchi	PROPN
bjp-23953	122	26	h	h	PROPN
bjp-23953	122	27	,	,	PUNCT
bjp-23953	122	28	motoshima	motoshima	PROPN
bjp-23953	122	29	k	k	PROPN
bjp-23953	122	30	,	,	PUNCT
bjp-23953	122	31	yamaguchi	yamaguchi	PROPN
bjp-23953	122	32	h	h	PROPN
bjp-23953	122	33	,	,	PUNCT
bjp-23953	122	34	nakatomi	nakatomi	PROPN
bjp-23953	122	35	k	k	PROPN
bjp-23953	122	36	,	,	PUNCT
bjp-23953	122	37	shimada	shimada	PROPN
bjp-23953	122	38	m	m	PROPN
bjp-23953	122	39	,	,	PUNCT
bjp-23953	122	40	nagashima	nagashima	PROPN
bjp-23953	122	41	s	s	PROPN
bjp-23953	122	42	,	,	PUNCT
bjp-23953	122	43	tsukamoto	tsukamoto	PROPN
bjp-23953	122	44	k	k	PROPN
bjp-23953	122	45	,	,	PUNCT
bjp-23953	122	46	kohno	kohno	PROPN
bjp-23953	122	47	s.	s.	PROPN
bjp-23953	122	48	a	a	DET
bjp-23953	122	49	phase	phase	NOUN
bjp-23953	122	50	ii	ii	PROPN
bjp-23953	122	51	study	study	NOUN
bjp-23953	122	52	of	of	ADP
bjp-23953	122	53	amrubicin	amrubicin	NOUN
bjp-23953	122	54	and	and	CCONJ
bjp-23953	122	55	carboplatin	carboplatin	NOUN
bjp-23953	122	56	for	for	ADP
bjp-23953	122	57	previously	previously	ADV
bjp-23953	122	58	untreated	untreated	ADJ
bjp-23953	122	59	patients	patient	NOUN
bjp-23953	122	60	with	with	ADP
bjp-23953	122	61	extensivedisease	extensivedisease	X
bjp-23953	122	62	small	small	ADJ
bjp-23953	122	63	cell	cell	NOUN
bjp-23953	122	64	lung	lung	NOUN
bjp-23953	122	65	cancer	cancer	NOUN
bjp-23953	122	66	.	.	PUNCT
bjp-23953	123	1	cancer	cancer	NOUN
bjp-23953	123	2	chemother	chemother	PROPN
bjp-23953	123	3	pharmacol	pharmacol	PROPN
bjp-23953	123	4	.	.	PROPN
bjp-23953	124	1	2014	2014	NUM
bjp-23953	124	2	;	;	PUNCT
bjp-23953	124	3	74	74	NUM
bjp-23953	124	4	:	:	SYM
bjp-23953	124	5	497	497	NUM
bjp-23953	124	6	-	-	SYM
bjp-23953	124	7	502	502	NUM
bjp-23953	124	8	.	.	PUNCT
bjp-23953	125	1	kobayashi	kobayashi	PROPN
bjp-23953	125	2	m	m	PROPN
bjp-23953	125	3	,	,	PUNCT
bjp-23953	125	4	matsui	matsui	PROPN
bjp-23953	125	5	k	k	PROPN
bjp-23953	125	6	,	,	PUNCT
bjp-23953	125	7	iwamoto	iwamoto	PROPN
bjp-23953	125	8	y	y	PROPN
bjp-23953	125	9	,	,	PUNCT
bjp-23953	125	10	ebi	ebi	X
bjp-23953	125	11	n	n	PART
bjp-23953	125	12	,	,	PUNCT
bjp-23953	125	13	oizumi	oizumi	PROPN
bjp-23953	125	14	s	s	PROPN
bjp-23953	125	15	,	,	PUNCT
bjp-23953	125	16	takeda	takeda	X
bjp-23953	125	17	k	k	PROPN
bjp-23953	125	18	,	,	PUNCT
bjp-23953	125	19	sawa	sawa	PROPN
bjp-23953	125	20	t	t	PROPN
bjp-23953	125	21	,	,	PUNCT
bjp-23953	125	22	shibata	shibata	PROPN
bjp-23953	125	23	k	k	PROPN
bjp-23953	125	24	,	,	PUNCT
bjp-23953	125	25	saka	saka	PROPN
bjp-23953	125	26	h	h	PROPN
bjp-23953	125	27	,	,	PUNCT
bjp-23953	125	28	imamura	imamura	PROPN
bjp-23953	125	29	f	f	PROPN
bjp-23953	125	30	,	,	PUNCT
bjp-23953	125	31	seki	seki	PROPN
bjp-23953	125	32	n	n	PROPN
bjp-23953	125	33	,	,	PUNCT
bjp-23953	125	34	saito	saito	PROPN
bjp-23953	125	35	h	h	PROPN
bjp-23953	125	36	,	,	PUNCT
bjp-23953	125	37	goto	goto	PROPN
bjp-23953	125	38	i	i	PROPN
bjp-23953	125	39	,	,	PUNCT
bjp-23953	125	40	nakagawa	nakagawa	PROPN
bjp-23953	125	41	k.	k.	PROPN
bjp-23953	125	42	phase	phase	PROPN
bjp-23953	125	43	ii	ii	PROPN
bjp-23953	125	44	study	study	NOUN
bjp-23953	125	45	of	of	ADP
bjp-23953	125	46	sequential	sequential	ADJ
bjp-23953	125	47	triplet	triplet	NOUN
bjp-23953	125	48	chemotherapy	chemotherapy	NOUN
bjp-23953	125	49	,	,	PUNCT
bjp-23953	125	50	irinotecan	irinotecan	NOUN
bjp-23953	125	51	and	and	CCONJ
bjp-23953	125	52	cisplatin	cisplatin	NOUN
bjp-23953	125	53	followed	follow	VERB
bjp-23953	125	54	by	by	ADP
bjp-23953	125	55	amrubicin	amrubicin	NOUN
bjp-23953	125	56	,	,	PUNCT
bjp-23953	125	57	in	in	ADP
bjp-23953	125	58	patients	patient	NOUN
bjp-23953	125	59	with	with	ADP
bjp-23953	125	60	extensive	extensive	ADJ
bjp-23953	125	61	-	-	PUNCT
bjp-23953	125	62	stage	stage	NOUN
bjp-23953	125	63	small	small	ADJ
bjp-23953	125	64	cell	cell	NOUN
bjp-23953	125	65	lung	lung	NOUN
bjp-23953	125	66	cancer	cancer	NOUN
bjp-23953	125	67	:	:	PUNCT
bjp-23953	125	68	west	west	PROPN
bjp-23953	125	69	japan	japan	PROPN
bjp-23953	125	70	thoracic	thoracic	PROPN
bjp-23953	125	71	oncology	oncology	NOUN
bjp-23953	125	72	group	group	PROPN
bjp-23953	125	73	study	study	NOUN
bjp-23953	125	74	0301	0301	NUM
bjp-23953	125	75	.	.	PUNCT
bjp-23953	126	1	j	j	PROPN
bjp-23953	126	2	thorac	thorac	PROPN
bjp-23953	126	3	oncol	oncol	ADJ
bjp-23953	126	4	.	.	PUNCT
bjp-23953	127	1	2010	2010	NUM
bjp-23953	127	2	;	;	PUNCT
bjp-23953	127	3	5	5	NUM
bjp-23953	127	4	:	:	PUNCT
bjp-23953	127	5	1075	1075	NUM
bjp-23953	127	6	-	-	SYM
bjp-23953	127	7	80	80	NUM
bjp-23953	127	8	.	.	PUNCT
bjp-23953	128	1	matsunaga	matsunaga	PROPN
bjp-23953	128	2	y	y	PROPN
bjp-23953	128	3	,	,	PUNCT
bjp-23953	128	4	hamada	hamada	PROPN
bjp-23953	128	5	a	a	PROPN
bjp-23953	128	6	,	,	PUNCT
bjp-23953	128	7	okamoto	okamoto	PROPN
bjp-23953	128	8	i	i	PROPN
bjp-23953	128	9	,	,	PUNCT
bjp-23953	128	10	sasaki	sasaki	PROPN
bjp-23953	128	11	j	j	PROPN
bjp-23953	128	12	,	,	PUNCT
bjp-23953	128	13	moriyama	moriyama	PROPN
bjp-23953	128	14	e	e	PROPN
bjp-23953	128	15	,	,	PUNCT
bjp-23953	128	16	kishi	kishi	PROPN
bjp-23953	128	17	h	h	PROPN
bjp-23953	128	18	,	,	PUNCT
bjp-23953	128	19	matsumoto	matsumoto	PROPN
bjp-23953	128	20	m	m	PROPN
bjp-23953	128	21	,	,	PUNCT
bjp-23953	128	22	hira	hira	PROPN
bjp-23953	128	23	a	a	PROPN
bjp-23953	128	24	,	,	PUNCT
bjp-23953	128	25	watanabe	watanabe	PROPN
bjp-23953	128	26	h	h	PROPN
bjp-23953	128	27	,	,	PUNCT
bjp-23953	128	28	saito	saito	PROPN
bjp-23953	128	29	h.	h.	PROPN
bjp-23953	128	30	pharmacokinetics	pharmacokinetic	NOUN
bjp-23953	128	31	of	of	ADP
bjp-23953	128	32	amrubicin	amrubicin	NOUN
bjp-23953	128	33	and	and	CCONJ
bjp-23953	128	34	its	its	PRON
bjp-23953	128	35	active	active	ADJ
bjp-23953	128	36	metabolite	metabolite	NOUN
bjp-23953	128	37	amrubicinol	amrubicinol	NOUN
bjp-23953	128	38	in	in	ADP
bjp-23953	128	39	lung	lung	NOUN
bjp-23953	128	40	cancer	cancer	NOUN
bjp-23953	128	41	patients	patient	NOUN
bjp-23953	128	42	.	.	PUNCT
bjp-23953	129	1	ther	ther	PROPN
bjp-23953	129	2	drug	drug	PROPN
bjp-23953	129	3	monit	monit	PROPN
bjp-23953	129	4	.	.	PUNCT
bjp-23953	130	1	2006	2006	NUM
bjp-23953	130	2	;	;	PUNCT
bjp-23953	130	3	28	28	NUM
bjp-23953	130	4	:	:	SYM
bjp-23953	130	5	76	76	NUM
bjp-23953	130	6	-	-	SYM
bjp-23953	130	7	82	82	NUM
bjp-23953	130	8	.	.	PUNCT
bjp-23953	131	1	ohe	ohe	PROPN
bjp-23953	131	2	y	y	PROPN
bjp-23953	131	3	,	,	PUNCT
bjp-23953	131	4	negoro	negoro	PROPN
bjp-23953	131	5	s	s	PART
bjp-23953	131	6	,	,	PUNCT
bjp-23953	131	7	matsui	matsui	PROPN
bjp-23953	131	8	k	k	PROPN
bjp-23953	131	9	,	,	PUNCT
bjp-23953	131	10	nakagawa	nakagawa	PROPN
bjp-23953	131	11	k	k	PROPN
bjp-23953	131	12	,	,	PUNCT
bjp-23953	131	13	sugiura	sugiura	PROPN
bjp-23953	131	14	t	t	PROPN
bjp-23953	131	15	,	,	PUNCT
bjp-23953	131	16	takada	takada	PROPN
bjp-23953	131	17	y	y	PROPN
bjp-23953	131	18	,	,	PUNCT
bjp-23953	131	19	nishiwaki	nishiwaki	PROPN
bjp-23953	131	20	y	y	PROPN
bjp-23953	131	21	,	,	PUNCT
bjp-23953	131	22	yokota	yokota	PROPN
bjp-23953	131	23	s	s	PROPN
bjp-23953	131	24	,	,	PUNCT
bjp-23953	131	25	kawahara	kawahara	PROPN
bjp-23953	131	26	m	m	PROPN
bjp-23953	131	27	,	,	PUNCT
bjp-23953	131	28	saijo	saijo	PROPN
bjp-23953	131	29	n	n	CCONJ
bjp-23953	131	30	,	,	PUNCT
bjp-23953	131	31	fukuoka	fukuoka	PROPN
bjp-23953	131	32	m	m	PROPN
bjp-23953	131	33	,	,	PUNCT
bjp-23953	131	34	ariyoshi	ariyoshi	PROPN
bjp-23953	131	35	y.	y.	PROPN
bjp-23953	131	36	phase	phase	PROPN
bjp-23953	131	37	i	i	PROPN
bjp-23953	131	38	-	-	PUNCT
bjp-23953	131	39	ii	ii	PROPN
bjp-23953	131	40	study	study	NOUN
bjp-23953	131	41	of	of	ADP
bjp-23953	131	42	amrubicin	amrubicin	NOUN
bjp-23953	131	43	and	and	CCONJ
bjp-23953	131	44	cisplatin	cisplatin	NOUN
bjp-23953	131	45	in	in	ADP
bjp-23953	131	46	previously	previously	ADV
bjp-23953	131	47	untreated	untreated	ADJ
bjp-23953	131	48	patients	patient	NOUN
bjp-23953	131	49	with	with	ADP
bjp-23953	131	50	extensive	extensive	ADJ
bjp-23953	131	51	-	-	PUNCT
bjp-23953	131	52	stage	stage	NOUN
bjp-23953	131	53	small	small	ADJ
bjp-23953	131	54	-	-	PUNCT
bjp-23953	131	55	cell	cell	NOUN
bjp-23953	131	56	lung	lung	NOUN
bjp-23953	131	57	cancer	cancer	NOUN
bjp-23953	131	58	.	.	PUNCT
bjp-23953	132	1	ann	ann	PROPN
bjp-23953	132	2	oncol	oncol	PROPN
bjp-23953	132	3	.	.	PUNCT
bjp-23953	133	1	2005	2005	NUM
bjp-23953	133	2	;	;	PUNCT
bjp-23953	133	3	16	16	NUM
bjp-23953	133	4	:	:	SYM
bjp-23953	133	5	430	430	NUM
bjp-23953	133	6	-	-	SYM
bjp-23953	133	7	36	36	NUM
bjp-23953	133	8	.	.	PUNCT
bjp-23953	134	1	onoda	onoda	PRON
bjp-23953	134	2	s	s	PROPN
bjp-23953	134	3	,	,	PUNCT
bjp-23953	134	4	masuda	masuda	PROPN
bjp-23953	134	5	n	n	CCONJ
bjp-23953	134	6	,	,	PUNCT
bjp-23953	134	7	seto	seto	PROPN
bjp-23953	134	8	t	t	PROPN
bjp-23953	134	9	,	,	PUNCT
bjp-23953	134	10	eguchi	eguchi	X
bjp-23953	134	11	k	k	PROPN
bjp-23953	134	12	,	,	PUNCT
bjp-23953	134	13	takiguchi	takiguchi	PROPN
bjp-23953	134	14	y	y	PROPN
bjp-23953	134	15	,	,	PUNCT
bjp-23953	134	16	isobe	isobe	PROPN
bjp-23953	134	17	h	h	PROPN
bjp-23953	134	18	,	,	PUNCT
bjp-23953	134	19	okamoto	okamoto	PROPN
bjp-23953	134	20	h	h	PROPN
bjp-23953	134	21	,	,	PUNCT
bjp-23953	134	22	ogura	ogura	PROPN
bjp-23953	134	23	t	t	PROPN
bjp-23953	134	24	,	,	PUNCT
bjp-23953	134	25	yokoyama	yokoyama	PROPN
bjp-23953	134	26	a	a	PROPN
bjp-23953	134	27	,	,	PUNCT
bjp-23953	134	28	seki	seki	PROPN
bjp-23953	134	29	n	n	CCONJ
bjp-23953	134	30	,	,	PUNCT
bjp-23953	134	31	asaka	asaka	X
bjp-23953	134	32	-	-	PUNCT
bjp-23953	134	33	amano	amano	PROPN
bjp-23953	134	34	y	y	PROPN
bjp-23953	134	35	,	,	PUNCT
bjp-23953	134	36	harada	harada	PROPN
bjp-23953	134	37	m	m	PROPN
bjp-23953	134	38	,	,	PUNCT
bjp-23953	134	39	tagawa	tagawa	PROPN
bjp-23953	134	40	a	a	PRON
bjp-23953	134	41	,	,	PUNCT
bjp-23953	134	42	kunikane	kunikane	PROPN
bjp-23953	134	43	h	h	NOUN
bjp-23953	134	44	,	,	PUNCT
bjp-23953	134	45	yokoba	yokoba	PROPN
bjp-23953	134	46	m	m	PROPN
bjp-23953	134	47	,	,	PUNCT
bjp-23953	134	48	uematsu	uematsu	PROPN
bjp-23953	134	49	k	k	PROPN
bjp-23953	134	50	,	,	PUNCT
bjp-23953	134	51	kuriyama	kuriyama	PROPN
bjp-23953	134	52	t	t	PROPN
bjp-23953	134	53	,	,	PUNCT
bjp-23953	134	54	kuroiwa	kuroiwa	VERB
bjp-23953	134	55	y	y	PROPN
bjp-23953	134	56	,	,	PUNCT
bjp-23953	134	57	watanabe	watanabe	PROPN
bjp-23953	134	58	k.	k.	PROPN
bjp-23953	134	59	phase	phase	PROPN
bjp-23953	134	60	ii	ii	PROPN
bjp-23953	134	61	trial	trial	NOUN
bjp-23953	134	62	of	of	ADP
bjp-23953	134	63	amrubicin	amrubicin	NOUN
bjp-23953	134	64	for	for	ADP
bjp-23953	134	65	treatment	treatment	NOUN
bjp-23953	134	66	of	of	ADP
bjp-23953	134	67	refractory	refractory	NOUN
bjp-23953	134	68	or	or	CCONJ
bjp-23953	134	69	relapsed	relapse	VERB
bjp-23953	134	70	small	small	ADJ
bjp-23953	134	71	-	-	PUNCT
bjp-23953	134	72	cell	cell	NOUN
bjp-23953	134	73	lung	lung	NOUN
bjp-23953	134	74	cancer	cancer	NOUN
bjp-23953	134	75	:	:	PUNCT
bjp-23953	134	76	thoracic	thoracic	NOUN
bjp-23953	134	77	oncology	oncology	NOUN
bjp-23953	134	78	research	research	NOUN
bjp-23953	134	79	group	group	NOUN
bjp-23953	134	80	study	study	NOUN
bjp-23953	134	81	0301	0301	NUM
bjp-23953	134	82	.	.	PUNCT
bjp-23953	135	1	j	j	PROPN
bjp-23953	135	2	clin	clin	PROPN
bjp-23953	135	3	oncol	oncol	PROPN
bjp-23953	135	4	.	.	PUNCT
bjp-23953	136	1	2006	2006	NUM
bjp-23953	136	2	;	;	PUNCT
bjp-23953	136	3	24	24	NUM
bjp-23953	136	4	:	:	PUNCT
bjp-23953	136	5	5448	5448	NUM
bjp-23953	136	6	-	-	SYM
bjp-23953	136	7	53	53	NUM
bjp-23953	136	8	.	.	PUNCT
bjp-23953	137	1	sekine	sekine	PROPN
bjp-23953	137	2	i	i	PROPN
bjp-23953	137	3	,	,	PUNCT
bjp-23953	137	4	okamoto	okamoto	PROPN
bjp-23953	137	5	h	h	PROPN
bjp-23953	137	6	,	,	PUNCT
bjp-23953	137	7	horai	horai	PROPN
bjp-23953	137	8	t	t	PROPN
bjp-23953	137	9	,	,	PUNCT
bjp-23953	137	10	nakagawa	nakagawa	PROPN
bjp-23953	137	11	k	k	PROPN
bjp-23953	137	12	,	,	PUNCT
bjp-23953	137	13	ohmatsu	ohmatsu	PROPN
bjp-23953	137	14	h	h	PROPN
bjp-23953	137	15	,	,	PUNCT
bjp-23953	137	16	yokoyama	yokoyama	PROPN
bjp-23953	137	17	a	a	PROPN
bjp-23953	137	18	,	,	PUNCT
bjp-23953	137	19	katakami	katakami	NOUN
bjp-23953	137	20	n	n	CCONJ
bjp-23953	137	21	,	,	PUNCT
bjp-23953	137	22	shibuya	shibuya	PROPN
bjp-23953	137	23	m	m	PROPN
bjp-23953	137	24	,	,	PUNCT
bjp-23953	137	25	saijo	saijo	PROPN
bjp-23953	137	26	n	n	CCONJ
bjp-23953	137	27	,	,	PUNCT
bjp-23953	137	28	fukuoka	fukuoka	PROPN
bjp-23953	137	29	m.	m.	NOUN
bjp-23953	137	30	a	a	DET
bjp-23953	137	31	randomized	randomized	ADJ
bjp-23953	137	32	phase	phase	NOUN
bjp-23953	137	33	iii	iii	NUM
bjp-23953	137	34	study	study	NOUN
bjp-23953	137	35	of	of	ADP
bjp-23953	137	36	single	single	ADJ
bjp-23953	137	37	-	-	PUNCT
bjp-23953	137	38	agent	agent	NOUN
bjp-23953	137	39	amrubicin	amrubicin	NOUN
bjp-23953	137	40	vs.	vs.	ADP
bjp-23953	137	41	carboplatin	carboplatin	NOUN
bjp-23953	137	42	/	/	SYM
bjp-23953	137	43	etoposide	etoposide	NOUN
bjp-23953	137	44	in	in	ADP
bjp-23953	137	45	elderly	elderly	ADJ
bjp-23953	137	46	patients	patient	NOUN
bjp-23953	137	47	with	with	ADP
bjp-23953	137	48	extensivedisease	extensivedisease	NOUN
bjp-23953	137	49	small	small	ADJ
bjp-23953	137	50	-	-	PUNCT
bjp-23953	137	51	cell	cell	NOUN
bjp-23953	137	52	lung	lung	NOUN
bjp-23953	137	53	cancer	cancer	NOUN
bjp-23953	137	54	.	.	PUNCT
bjp-23953	138	1	clin	clin	PROPN
bjp-23953	138	2	lung	lung	PROPN
bjp-23953	138	3	cancer	cancer	NOUN
bjp-23953	138	4	.	.	PUNCT
bjp-23953	139	1	2014	2014	NUM
bjp-23953	139	2	;	;	PUNCT
bjp-23953	139	3	15	15	NUM
bjp-23953	139	4	:	:	SYM
bjp-23953	139	5	96	96	NUM
bjp-23953	139	6	-102	-102	X
bjp-23953	139	7	.	.	PUNCT
bjp-23953	140	1	shah	shah	PROPN
bjp-23953	140	2	cm	cm	PROPN
bjp-23953	140	3	.	.	PUNCT
bjp-23953	141	1	amrubicin	amrubicin	PROPN
bjp-23953	141	2	:	:	PUNCT
bjp-23953	141	3	a	a	DET
bjp-23953	141	4	synthetic	synthetic	ADJ
bjp-23953	141	5	anthracyclin	anthracyclin	NOUN
bjp-23953	141	6	analogue	analogue	NOUN
bjp-23953	141	7	in	in	ADP
bjp-23953	141	8	the	the	DET
bjp-23953	141	9	treatment	treatment	NOUN
bjp-23953	141	10	of	of	ADP
bjp-23953	141	11	extensive	extensive	ADJ
bjp-23953	141	12	stage	stage	NOUN
bjp-23953	141	13	small	small	ADJ
bjp-23953	141	14	cell	cell	NOUN
bjp-23953	141	15	lung	lung	NOUN
bjp-23953	141	16	cancer	cancer	NOUN
bjp-23953	141	17	.	.	PUNCT
bjp-23953	142	1	recent	recent	ADJ
bjp-23953	142	2	pat	pat	NOUN
bjp-23953	142	3	anticancer	anticancer	NOUN
bjp-23953	142	4	drug	drug	NOUN
bjp-23953	142	5	discov	discov	NOUN
bjp-23953	142	6	.	.	PUNCT
bjp-23953	143	1	2009	2009	NUM
bjp-23953	143	2	;	;	PUNCT
bjp-23953	143	3	4	4	NUM
bjp-23953	143	4	:	:	PUNCT
bjp-23953	143	5	241	241	NUM
bjp-23953	143	6	-	-	SYM
bjp-23953	143	7	45	45	NUM
bjp-23953	143	8	.	.	PUNCT
bjp-23953	144	1	wang	wang	PROPN
bjp-23953	144	2	l	l	PROPN
bjp-23953	144	3	,	,	PUNCT
bjp-23953	144	4	tan	tan	PROPN
bjp-23953	144	5	tc	tc	NOUN
bjp-23953	144	6	,	,	PUNCT
bjp-23953	144	7	halpern	halpern	PROPN
bjp-23953	144	8	ef	ef	PROPN
bjp-23953	144	9	,	,	PUNCT
bjp-23953	144	10	neilan	neilan	NOUN
bjp-23953	144	11	tg	tg	PROPN
bjp-23953	144	12	,	,	PUNCT
bjp-23953	144	13	francis	francis	PROPN
bjp-23953	144	14	sa	sa	PROPN
bjp-23953	144	15	,	,	PUNCT
bjp-23953	144	16	picard	picard	PROPN
bjp-23953	144	17	mh	mh	PROPN
bjp-23953	144	18	,	,	PUNCT
bjp-23953	144	19	fei	fei	PROPN
bjp-23953	144	20	h	h	PROPN
bjp-23953	144	21	,	,	PUNCT
bjp-23953	144	22	hochberg	hochberg	PROPN
bjp-23953	144	23	ep	ep	PROPN
bjp-23953	144	24	,	,	PUNCT
bjp-23953	144	25	abramson	abramson	PROPN
bjp-23953	144	26	js	js	PROPN
bjp-23953	144	27	,	,	PUNCT
bjp-23953	144	28	weyman	weyman	PROPN
bjp-23953	144	29	ae	ae	PROPN
bjp-23953	144	30	,	,	PUNCT
bjp-23953	144	31	kuter	kuter	PROPN
bjp-23953	144	32	i	i	PRON
bjp-23953	144	33	,	,	PUNCT
bjp-23953	144	34	scherrer	scherrer	ADJ
bjp-23953	144	35	-	-	PUNCT
bjp-23953	144	36	crosbie	crosbie	NOUN
bjp-23953	144	37	m.	m.	NOUN
bjp-23953	144	38	major	major	ADJ
bjp-23953	144	39	cardiac	cardiac	ADJ
bjp-23953	144	40	events	event	NOUN
bjp-23953	144	41	and	and	CCONJ
bjp-23953	144	42	the	the	DET
bjp-23953	144	43	value	value	NOUN
bjp-23953	144	44	of	of	ADP
bjp-23953	144	45	echocardiographic	echocardiographic	ADJ
bjp-23953	144	46	evaluation	evaluation	NOUN
bjp-23953	144	47	in	in	ADP
bjp-23953	144	48	patients	patient	NOUN
bjp-23953	144	49	receiving	receive	VERB
bjp-23953	144	50	anthracycline	anthracycline	NOUN
bjp-23953	144	51	-	-	PUNCT
bjp-23953	144	52	based	base	VERB
bjp-23953	144	53	chemotherapy	chemotherapy	NOUN
bjp-23953	144	54	.	.	PUNCT
bjp-23953	144	55	am	be	AUX
bjp-23953	144	56	j	j	PROPN
bjp-23953	144	57	cardiol	cardiol	NOUN
bjp-23953	144	58	.	.	PUNCT
bjp-23953	145	1	2015	2015	NUM
bjp-23953	145	2	;	;	PUNCT
bjp-23953	145	3	116	116	NUM
bjp-23953	145	4	:	:	PUNCT
bjp-23953	145	5	442	442	NUM
bjp-23953	145	6	-	-	SYM
bjp-23953	145	7	46	46	NUM
bjp-23953	145	8	.	.	PUNCT
bjp-23953	146	1	yamaoka	yamaoka	PROPN
bjp-23953	146	2	t	t	PROPN
bjp-23953	146	3	,	,	PUNCT
bjp-23953	146	4	hanada	hanada	PROPN
bjp-23953	146	5	m	m	PROPN
bjp-23953	146	6	,	,	PUNCT
bjp-23953	146	7	ichii	ichii	PROPN
bjp-23953	146	8	s	s	PROPN
bjp-23953	146	9	,	,	PUNCT
bjp-23953	146	10	morisada	morisada	PROPN
bjp-23953	146	11	s	s	PROPN
bjp-23953	146	12	,	,	PUNCT
bjp-23953	146	13	noguchi	noguchi	PROPN
bjp-23953	146	14	t	t	PROPN
bjp-23953	146	15	,	,	PUNCT
bjp-23953	146	16	yanagi	yanagi	PROPN
bjp-23953	146	17	y.	y.	PROPN
bjp-23953	146	18	uptake	uptake	VERB
bjp-23953	146	19	and	and	CCONJ
bjp-23953	146	20	intracellular	intracellular	ADJ
bjp-23953	146	21	distribution	distribution	NOUN
bjp-23953	146	22	of	of	ADP
bjp-23953	146	23	amrubicin	amrubicin	NOUN
bjp-23953	146	24	,	,	PUNCT
bjp-23953	146	25	a	a	DET
bjp-23953	146	26	novel	novel	ADJ
bjp-23953	146	27	9	9	NUM
bjp-23953	146	28	-	-	PUNCT
bjp-23953	146	29	amino	amino	NOUN
bjp-23953	146	30	-	-	PUNCT
bjp-23953	146	31	anthracycline	anthracycline	NOUN
bjp-23953	146	32	,	,	PUNCT
bjp-23953	146	33	and	and	CCONJ
bjp-23953	146	34	its	its	PRON
bjp-23953	146	35	active	active	ADJ
bjp-23953	146	36	metabolite	metabolite	NOUN
bjp-23953	146	37	amrubicinol	amrubicinol	NOUN
bjp-23953	146	38	in	in	ADP
bjp-23953	146	39	p388	p388	PROPN
bjp-23953	146	40	murine	murine	ADJ
bjp-23953	146	41	leukemia	leukemia	NOUN
bjp-23953	146	42	cells	cell	NOUN
bjp-23953	146	43	.	.	PUNCT
bjp-23953	147	1	jpn	jpn	PROPN
bjp-23953	147	2	j	j	PROPN
bjp-23953	147	3	cancer	cancer	NOUN
bjp-23953	147	4	res	re	NOUN
bjp-23953	147	5	.	.	PUNCT
bjp-23953	147	6	1999	1999	NUM
bjp-23953	147	7	;	;	PUNCT
bjp-23953	147	8	90	90	NUM
bjp-23953	147	9	:	:	SYM
bjp-23953	147	10	685	685	NUM
bjp-23953	147	11	-	-	SYM
bjp-23953	147	12	90	90	NUM
bjp-23953	147	13	.	.	PUNCT
bjp-23953	148	1	zhang	zhang	PROPN
bjp-23953	148	2	f	f	PROPN
bjp-23953	148	3	,	,	PUNCT
bjp-23953	148	4	wang	wang	PROPN
bjp-23953	148	5	y	y	PROPN
bjp-23953	148	6	,	,	PUNCT
bjp-23953	148	7	xu	xu	PROPN
bjp-23953	148	8	m	m	PROPN
bjp-23953	148	9	,	,	PUNCT
bjp-23953	148	10	dong	dong	PROPN
bjp-23953	148	11	h	h	PROPN
bjp-23953	148	12	,	,	PUNCT
bjp-23953	148	13	liu	liu	PROPN
bjp-23953	148	14	n	n	PROPN
bjp-23953	148	15	,	,	PUNCT
bjp-23953	148	16	zhou	zhou	PROPN
bjp-23953	148	17	j	j	PROPN
bjp-23953	148	18	,	,	PUNCT
bjp-23953	148	19	pang	pang	PROPN
bjp-23953	148	20	h	h	PROPN
bjp-23953	148	21	,	,	PUNCT
bjp-23953	148	22	ma	ma	PROPN
bjp-23953	148	23	n	n	PROPN
bjp-23953	148	24	,	,	PUNCT
bjp-23953	148	25	zhang	zhang	PROPN
bjp-23953	148	26	n	n	CCONJ
bjp-23953	148	27	,	,	PUNCT
bjp-23953	148	28	pei	pei	PROPN
bjp-23953	148	29	y	y	PROPN
bjp-23953	148	30	,	,	PUNCT
bjp-23953	148	31	zhang	zhang	PROPN
bjp-23953	148	32	h	h	PROPN
bjp-23953	148	33	,	,	PUNCT
bjp-23953	148	34	liu	liu	PROPN
bjp-23953	148	35	l.	l.	PROPN
bjp-23953	148	36	mgr1	mgr1	PROPN
bjp-23953	148	37	-	-	PUNCT
bjp-23953	148	38	ag	ag	PROPN
bjp-23953	148	39	promotes	promote	VERB
bjp-23953	148	40	invasion	invasion	NOUN
bjp-23953	148	41	and	and	CCONJ
bjp-23953	148	42	bone	bone	NOUN
bjp-23953	148	43	metastasis	metastasis	NOUN
bjp-23953	148	44	of	of	ADP
bjp-23953	148	45	small	small	ADJ
bjp-23953	148	46	-	-	PUNCT
bjp-23953	148	47	cell	cell	NOUN
bjp-23953	148	48	lung	lung	NOUN
bjp-23953	148	49	cancer	cancer	NOUN
bjp-23953	148	50	in	in	ADP
bjp-23953	148	51	vitro	vitro	X
bjp-23953	148	52	and	and	CCONJ
bjp-23953	148	53	in	in	ADP
bjp-23953	148	54	vivo	vivo	NOUN
bjp-23953	148	55	.	.	PUNCT
bjp-23953	149	1	oncol	oncol	PROPN
bjp-23953	149	2	rep	rep	PROPN
bjp-23953	149	3	.	.	PROPN
bjp-23953	149	4	2013	2013	NUM
bjp-23953	149	5	;	;	PUNCT
bjp-23953	149	6	29	29	NUM
bjp-23953	149	7	:	:	PUNCT
bjp-23953	149	8	2283	2283	NUM
bjp-23953	149	9	-	-	SYM
bjp-23953	149	10	90	90	NUM
bjp-23953	149	11	.	.	PUNCT
bjp-23953	150	1	bangladesh	bangladesh	PROPN
bjp-23953	150	2	j	j	PROPN
bjp-23953	150	3	pharmacol	pharmacol	PROPN
bjp-23953	150	4	2016	2016	NUM
bjp-23953	150	5	;	;	PUNCT
bjp-23953	150	6	11	11	NUM
bjp-23953	150	7	:	:	SYM
bjp-23953	150	8	564	564	NUM
bjp-23953	150	9	-	-	SYM
bjp-23953	150	10	569	569	NUM
bjp-23953	150	11	569	569	NUM
bjp-23953	150	12	murakami	murakami	NOUN
bjp-23953	150	13	h	h	NOUN
bjp-23953	150	14	et	et	PROPN
bjp-23953	150	15	al	al	PROPN
bjp-23953	150	16	.	.	PUNCT
bjp-23953	151	1	a	a	DET
bjp-23953	151	2	single	single	ADJ
bjp-23953	151	3	-	-	PUNCT
bjp-23953	151	4	arm	arm	NOUN
bjp-23953	151	5	confirmatory	confirmatory	NOUN
bjp-23953	151	6	study	study	NOUN
bjp-23953	151	7	of	of	ADP
bjp-23953	151	8	amrubicin	amrubicin	PROPN
bjp-23953	151	9	therapy	therapy	NOUN
bjp-23953	151	10	in	in	ADP
bjp-23953	151	11	patients	patient	NOUN
bjp-23953	151	12	with	with	ADP
bjp-23953	151	13	refractory	refractory	NOUN
bjp-23953	151	14	small	small	ADJ
bjp-23953	151	15	-	-	PUNCT
bjp-23953	151	16	cell	cell	NOUN
bjp-23953	151	17	lung	lung	NOUN
bjp-23953	151	18	cancer	cancer	NOUN
bjp-23953	151	19	:	:	PUNCT
bjp-23953	151	20	japan	japan	PROPN
bjp-23953	151	21	clinical	clinical	ADJ
bjp-23953	151	22	oncology	oncology	NOUN
bjp-23953	151	23	group	group	NOUN
bjp-23953	151	24	study	study	NOUN
bjp-23953	151	25	(	(	PUNCT
bjp-23953	151	26	jcog0901	jcog0901	PROPN
bjp-23953	151	27	)	)	PUNCT
bjp-23953	151	28	.	.	PUNCT
bjp-23953	152	1	lung	lung	NOUN
bjp-23953	152	2	cancer	cancer	NOUN
bjp-23953	152	3	.	.	PUNCT
bjp-23953	153	1	2014	2014	NUM
bjp-23953	153	2	;	;	PUNCT
bjp-23953	153	3	84	84	NUM
bjp-23953	153	4	:	:	SYM
bjp-23953	153	5	67	67	NUM
bjp-23953	153	6	-	-	SYM
bjp-23953	153	7	72	72	NUM
bjp-23953	153	8	..	..	PUNCT
bjp-23953	153	9	your	your	PRON
bjp-23953	153	10	feedback	feedback	NOUN
bjp-23953	153	11	about	about	ADP
bjp-23953	153	12	this	this	DET
bjp-23953	153	13	paper	paper	NOUN
bjp-23953	153	14	1	1	NUM
bjp-23953	153	15	.	.	PUNCT
bjp-23953	153	16	number	number	NOUN
bjp-23953	153	17	of	of	ADP
bjp-23953	153	18	times	time	NOUN
bjp-23953	153	19	you	you	PRON
bjp-23953	153	20	have	have	AUX
bjp-23953	153	21	read	read	VERB
bjp-23953	153	22	this	this	DET
bjp-23953	153	23	paper	paper	NOUN
bjp-23953	153	24	2	2	NUM
bjp-23953	153	25	.	.	PUNCT
bjp-23953	153	26	quality	quality	NOUN
bjp-23953	153	27	of	of	ADP
bjp-23953	153	28	paper	paper	NOUN
bjp-23953	153	29	3	3	X
bjp-23953	153	30	.	.	PUNCT
bjp-23953	154	1	your	your	PRON
bjp-23953	154	2	comments	comment	NOUN
bjp-23953	154	3	introduction	introduction	NOUN
bjp-23953	154	4	:	:	PUNCT
bjp-23953	154	5	materials	material	NOUN
bjp-23953	154	6	and	and	CCONJ
bjp-23953	154	7	methods	method	NOUN
bjp-23953	154	8	:	:	PUNCT
bjp-23953	154	9	discussion	discussion	NOUN
bjp-23953	154	10	:	:	PUNCT
bjp-23953	154	11	adverse	adverse	ADJ
bjp-23953	154	12	event	event	NOUN
bjp-23953	154	13	grade	grade	NOUN
bjp-23953	154	14	3	3	NUM
bjp-23953	154	15	grade	grade	NOUN
bjp-23953	154	16	4	4	NUM
bjp-23953	154	17	grade	grade	NOUN
bjp-23953	154	18	3	3	NUM
bjp-23953	154	19	4	4	NUM
bjp-23953	154	20	:	:	PUNCT
bjp-23953	154	21	conclusion	conclusion	NOUN
bjp-23953	154	22	:	:	PUNCT
bjp-23953	154	23	references	reference	NOUN
bjp-23953	154	24	:	:	PUNCT
bjp-23953	154	25	text1	text1	X
bjp-23953	154	26	:	:	PUNCT
bjp-23953	154	27	dropdown2	dropdown2	PROPN
bjp-23953	154	28	:	:	PUNCT
bjp-23953	155	1	[	[	X
bjp-23953	155	2	click	click	VERB
bjp-23953	155	3	]	]	PUNCT
bjp-23953	155	4	dropdown3	dropdown3	PROPN
bjp-23953	155	5	:	:	PUNCT
bjp-23953	156	1	[	[	X
bjp-23953	156	2	0	0	X
bjp-23953	156	3	]	]	PUNCT
bjp-23953	156	4	dateprinted	dateprinte	VERB
bjp-23953	156	5	:	:	PUNCT
bjp-23953	156	6	this	this	DET
bjp-23953	156	7	article	article	NOUN
bjp-23953	156	8	was	be	AUX
bjp-23953	156	9	downloaded	download	VERB
bjp-23953	156	10	by	by	ADP
bjp-23953	156	11	you	you	PRON
bjp-23953	156	12	on	on	ADP
bjp-23953	156	13	:	:	PUNCT
bjp-23953	156	14	jun	jun	PROPN
bjp-23953	156	15	01	01	NUM
bjp-23953	156	16	,	,	PUNCT
bjp-23953	156	17	2016	2016	NUM